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Cardiovascular disease (CVD) is the leading cause of death and morbidity worldwide. In 
Norway there are approximately 13,000 heart attacks and 12,000 strokes each year. Despite 
the fact that preventive and acute treatment have improved significantly over the last 30 years, 
CVD rates are expected to increase globally. The traditional risk factors (age, sex, blood 
pressure, cholesterol, diabetes and smoking) have limited ability to single out individuals at 
increased risk of CVD. It is therefore important to identify novel markers of disease activity 
in the preclinical phase which may improve identification of individuals at risk and refine 
individualized preventive treatment. Atherosclerosis is the underlying cause of most CVD 
events. Deposits of lipids and inflammation (plaques) in the arteries may rupture and initiate 
blood clot formation which subsequently occludes arteries and compromises blood flow to 
organs such as the heart and brain. The degree of atherosclerosis can be measured by 
ultrasound of the carotid arteries. Previous research indicates that plaques which increase in 
size pose a higher risk of CVD than atherosclerosis that remains stable over time. The aim of 
this study was to investigate the relationship between the inflammatory marker C-reactive 
protein (CRP) and other markers in blood with the progression of atherosclerosis, as well as 
clinical events such as myocardial infarction (MI) and ischemic stroke (IS). 
The Tromsø Study is a population-based cohort study where participants have been invited to 
repeated health surveys. Repeated assessments of traditional risk factors, blood samples and 
ultrasound of the right carotid artery have been performed in the period 1994-2008. In 
addition, clinical events such as MI and IS have been recorded. This has given us a unique 
opportunity to investigate the association between blood markers and the progression of 
carotid atherosclerosis over time, as well as the association to clinical events. 
We found that CRP was associated with the presence of carotid plaque and total plaque area 
in cross sectional examinations. The associations were strongest in men. CRP did not predict 
future plaque formation or plaque progression adjusted for traditional risk factors. Both CRP 
and carotid total plaque area were associated with higher risk of future MI and IS. Individuals 
who had both elevated CRP and large carotid plaques had highest risk of MI and IS. Carotid 
ultrasound examination and determination of CRP levels in the blood added predictive value 
beyond traditional risk factors for identification of individuals with increased CVD risk. The 
inflammatory cytokine interleukin-6 was associated with plaque progression after six years of 
follow-up, suggesting that interleukin-6 may be a useful marker to identify patients with 





Hjerte- og karsykdom er ledende årsak til død og sykelighet på verdensbasis. I Norge er det 
årlig ca. 13 000 hjerteinfarkt og 12 000 hjerneslag. Til tross for at den forebyggende og 
akuttmedisinske behandlingen er betydelig forbedret i løpet av de siste 30 år, forventes en 
fortsatt økning i hjerte- og karsykdommer på verdensbasis. De tradisjonelle risikofaktorene 
(alder, kjønn, blodtrykk, kolesterol, diabetes og røyking) har begrenset evne til å forutsi 
hvilke individer som har økt risiko for hjerte- og karsykdom. Det er derfor viktig å 
identifisere nye markører som er assosiert med økt risiko for sykdom, for å kunne tilby 
personer med økt risiko en bedre tilpasset forebyggende behandling. Aterosklerose er 
bakenforliggende årsak til de fleste kliniske hendelser og er en sykdomsprosess som fører til 
avleiring (plakk) av fett, kalk og betennelsesceller i arterier. Aterosklerotiske plakk som 
sprekker kan føre til at det dannes blodpropper som tetter til pulsårer og hemmer 
blodtilførselen til viktige organer som hjerte og hjerne. Grad av aterosklerose kan måles med 
ultralyd av halskar. Mye tyder på at plakk som øker i størrelse utgjør en høyere risiko for 
hjerte- og karsykdom enn aterosklerose som forblir stabil over tid. Målet med denne studien 
var å undersøke sammenhengen mellom betennelsesmarkøren C-reaktivt protein (CRP) og 
andre markører i blod med utvikling av aterosklerose, samt kliniske hendelser som 
hjerteinfarkt og hjerneslag. 
Tromsøundersøkelsen er en pågående helseundersøkelse av befolkningen i Tromsø hvor 
deltakerne har blitt invitert til gjentatte undersøkelser. Denne avhandlingen bygger på 
repeterte målinger av tradisjonelle risikofaktorer, blodprøver samt ultralyd av halskar hos 
deltakerne i perioden 1994-2008. I tillegg er det registrert kliniske hendelser som hjerteinfarkt 
og hjerneslag til og med 2013. Dette har gitt oss en unik mulighet til å undersøke 
sammenhengen mellom markører i blodet og utviklingen av aterosklerose i halskar, samt 
kliniske hendelser.  
Vi fant at nivå av CRP i blodet var assosiert med tilstedeværelse av plakk i halskar og totalt 
plakkareal i tverrsnittsundersøkelse. Sammenhengen var sterkest hos menn. CRP kunne ikke 
forutsi fremtidig utvikling av plakk eller økning av plakkstørrelse i analyser justert for 
tradisjonelle risikofaktorer. Både CRP i blod og plakkstørrelse i halskar var assosiert med 
høyere risiko for fremtidig hjerteinfarkt og hjerneslag. De som hadde både forhøyet CRP og 
store plakk hadde den høyeste risiko for hjerteinfarkt og hjerneinfarkt. Ultralydundersøkelse 
av halskar og nivå av CRP i blodet ga tilleggseffekt utover tradisjonelle risikofaktorer når det 
gjaldt å identifisere individer med økt risiko for hjerte- og karsykdom. Nivå av 
betennelsesmarkøren interleukin-6 var forbundet med plakkvekst seks år senere. Dette tyder 
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1.1 Cardiovascular disease  
Cardiovascular disease (CVD) is an umbrella term for a number of pathologies, commonly 
defined as coronary heart disease (CHD), cerebrovascular disease, peripheral arterial disease, 
rheumatic and congenital heart disease, and venous thromboembolism.
1
 CVD is the most 
common cause of mortality in developed countries and an important cause of disability leading 
to major health and economic burdens globally.
2
 In 2013, CVD was the most frequent 
underlying cause of death in the world, accounting for an estimated 17.3 million of the 54 
million total deaths (31.5%).
3
 Ischemic CVD more specifically refers to diseases where the blood 
supply and thereby oxygen delivery is insufficient due to an occluded or stenotic artery, 
potentially leading to tissue damage in the affected organs. Ischemic cardiovascular disease 
includes coronary artery diseases (myocardial infarction and angina pectoris), ischemic cerebral 
stroke, transient ischemic attack and peripheral artery disease. In the remaining part of this 
thesis, CVD refers to myocardial infarction and ischemic stroke. 
Myocardial infarction (MI) is myocardial cell death due to prolonged ischemia. The universal 
definition of MI includes “symptoms suggestive of myocardial ischemia, accompanied by new 
ST elevation, or new left bundle-branch block, and/or evidence of fresh thrombus by coronary 
angiography and/or at autopsy,” all of which imply a focal arterial occlusion.
4, 5
 Myocardial 
injury is detected when blood levels of sensitive and specific biomarkers, such as cardiac 
troponin or the MB fraction of creatine kinase (CKMB), are increased. Cardiac troponin I and T 
are components of the contractile apparatus of myocardial cells and are expressed almost 
exclusively in the heart, showing high myocardial tissue specificity as well as high clinical 
sensitivity. To establish the diagnosis of MI, a rise and/or fall in troponin values with at least 1 
value above the decision level is required, coupled with a strong pre-test likelihood.
5
 Acute or 
evolving changes in the ST–T waveforms and Q waves of the electrocardiogram (ECG), aid 
clinicians in timing the event, identifying the infarct-related artery, estimating amount of 
myocardium at risk and determining therapeutic strategy. The pathophysiological mechanism 
leading to MI is typically an intraluminal thrombus in one or more coronary arteries causing 






The World Health Organization (WHO) introduced in 1970 the definition of stroke that is still in 
use; “rapidly developing clinical signs of focal (or global) disturbance of cerebral function, 
lasting more than 24 hours or leading to death, with no apparent cause other than that of vascular 
origin”.
4
 Ischemic stroke (IS) is an episode of neurological dysfunction caused by focal cerebral 
infarction. IS is confirmed by brain imaging (computer tomography (CT) or magnetic resonance 
imaging (MRI)) or by pathological findings at autopsy.
4
 IS accounts for 80-85% of stroke cases, 
in addition stroke comprises intracerebral hemorrhage (10-15%), and subarachnoid hemorrhage 
(3-5%). During the last two decades, CT and MRI have become increasingly available in the 
diagnosis of stroke and can differentiate between stroke types and localize the regions of brain 
infarction and hemorrhage. Occlusion of cerebral arteries leading to brain infarction can be 
caused by several mechanisms including atherothrombosis (extra- or intracranial), embolism 
(cardiogenic typically due to atrial fibrillation or artery-to-artery embolism), primary occlusive 
disease of the small penetrating arteries, and non-atherosclerotic abnormalities (dissections, 
vasculitis and coagulopathies). No specific cause can be identified in about 30% of patients 
(“cryptogenic stroke”).   
Globally, there were 7.4 million deaths due to ischemic heart disease and 6.7 million stroke 
deaths in 2015.
3, 6
 In Norway, there are approximately 13 000 MIs and 12 000 strokes annually. 
Men are on average 7-10 years younger than women when they experience their first CVD 
event.
3
 Population based, epidemiologic studies have played an important role in identifying 
CVD risk factors, i.e., observable characteristics in the preclinical phase associated with 
increased risk of future CVD events. Several non-modifiable (age, sex and race) and modifiable 
risk factors have been identified, highlighting opportunities for prevention.
2
 Therapeutic and life-
style interventions aimed at improving modifiable risk factors such as dyslipidemia, 
hypertension, diabetes, smoking, and abdominal obesity have been developed and implemented 
in clinical practice. In addition, new treatment options have evolved, including thrombolytic 
drugs aimed at dissolving clots and intravascular catheter-based methods for opening stenotic 
and occluded arteries. Preventive strategies associated with declining incidence and improved 
treatments with subsequently decreased case fatality, have led to reduced global age-
standardized death rates of ischemic heart disease and ischemic stroke by 19.5% and 26.6% 
respectively since 1990.
7
 Still these diseases remain the top two causes of death worldwide, with 
increasing incidence in many low and middle-income countries.
7
 Globally, 80% of CVD deaths 
take place in low- and middle-income countries,
3




new treatments are limited. The rate of CVD worldwide is predicted to increase due to the global 
epidemic of obesity and insulin resistance, aging populations and rising prevalence of CVD risk 
factors in previously low-risk countries.
1
 The WHO estimates that 80% of premature heart 
disease and stroke are preventable and that risk factor improvement can help reduce the growing 




Atherosclerosis is a slowly progressing systemic disease in large and medium sized arteries 
which represents the underlying cause of the majority of clinical CVD events.
3
 The artery wall 
consists of three layers. The intima is the layer closest to the lumen and consists of endothelial 
cells (ECs) and the internal basement membrane. The middle layer, tunica media, consists of 
smooth muscle cells (SMCs) and extracellular matrix. The adventitia is the external layer and 
mainly consists of loose connective tissue with nerve fibers, small vessels and an external elastic 
layer. Atherosclerosis is a process where the arterial wall thickens when fatty deposits, 
inflammation, cells, and scar tissue build up and form atheromas (atherosclerotic plaques) within 
the sub-intimal layer. In Greek, athere means gruel, and skleros means hard. Among the first to 
describe atherosclerosis was Leonardo da Vinci (1452-1519), who stated that “Vessels in the 
elderly restrict the transit of blood through thickening of the tunics”. In 1799, the British 
physician Caleb Hillier Parry discovered a plaster-like substance within the coronary arteries 
when performing autopsy on a sheep and he was the first to suggest the correct mechanism of 
ischemic heart disease.
8
 Atheroma rupture was reported for the first time during the autopsy of 
the Danish artist and sculptor, Bertel Thorvaldsen, who died a sudden cardiac death in the Royal 
Theatre in Copenhagen in 1844. It was recognized that the vessel wall contained “several 
atheromatous plaques, one of which quite clearly had ulcerated, pouring the atheromatous mass 




As shown in Figure 1, atherosclerosis occurs as an indolent disease progressing throughout adult 
life. Most individuals with atherosclerosis will never experience clear clinical symptoms related 








Figure 1 - Development of atherosclerosis throughout life from fatty streak to complicated lesion with potential to 
cause clinical cardiovascular events. Reproduced in accordance with license CC BY_SA 3.0 
(https://creativecommons.org/licenses/by-sa/3.0), via Wikimedia Commons. 
 
1.3 Inflammation in atherosclerosis 
Celsus described inflammation in the 1
st
 century AD as a localized protective reaction of tissue 
to irritation, injury or infection. Inflammation is characterized by rubor (redness due to 
hyperaemia), tumor (swelling, caused by increased permeability of micro-vessels and leakage of 
proteins to the interstitial space), calor (heat, associated with increased blood flow and metabolic 
activity), dolor (pain, due to changes in the perivasculature and associated nerve endings) and 
loss of function.
10, 11
 By the end of the 18th century, Rudolf Virchow argued that an 
inflammatory process with reactive fibrosis induced by proliferating connective tissue cells 
within the intima caused development of atherosclerotic plaques. He suggested that mechanical 
forces represented an irritative initiating stimulus and that atherosclerosis was part of a repair 
mechanism.
12
 Virchow’s hypothesis gave basis for the popular “response to injury” hypothesis of 




focal injury to arterial endothelium, followed by adherence, aggregation and release of 
platelets”.
8
 Atherosclerosis proceeds from intima-media thickening to fatty streaks, intermediate 
lesions and raised plaques to complicated plaques prone for rupture with ability to cause clinical 
events through thromboembolism. Inflammation is now acknowledged to play an important role 
at all stages of the disease.  
The innate immune response is a rapid response to tissue injury, which detects a broad number of 
patterns that are commonly found in pathogens, but are foreign to mammals; so-called pathogen 
associated molecular patterns (PAMPs). Macrophages express a set of pattern recognition 
receptors including scavenger receptors and toll-like receptors, whose ligands include PAMPs 
such as lipopolysaccharides on the surface of pathogens, but also low-density lipoprotein 
cholesterol (LDL-C) modified by oxidation and glycation. Ligation of scavenger receptors can 
lead to endocytosis and lysosomal degradation of bound ligands. On the other hand, ligation of 
toll-like receptors results in activation of the transcription factor nuclear factor-kappa B (NF-kB) 
and mitogen-activated protein kinase pathways, increasing phagocytosis, production of reactive 
oxygen species and release of cytokines that amplify the inflammatory response.
11, 13
 
The adaptive immune response is a slow and more focused defence mechanism depending on the 
recognition of specific molecular structures and generation of a large number antigen receptors 
i.e., T-cell receptors and immunoglobulins. When T-cells recognize foreign antigens presented to 
them, they initiate responses that target precisely that antigen, including direct attack against the 
specific antigen by cytotoxic T-cells, stimulation of antibody production by B-cells and 
induction of local inflammatory responses. T-cells differentiate into T-helper cells (TH1 and 
TH2). TH1 cells produce a number of cytokines (including gamma interferon) coordinating 
crosstalk with the innate immune system, stimulating macrophages to increase production of 
mediators including reactive oxygen species (ROS) and pro-inflammatory cytokines. TH2 cells 
stimulate maturation of B-cells into anti-body producing plasma cells and may also mute the 




In chronic diseases, the innate and adaptive immune systems interact and approach epithelial 
cells and mesenchymal cells. Selective and sequential migration of blood cells into tissues and 
interaction between these blood-based cells with resident tissue cells lead to extracellular matrix 




organ. A persistent stimulus may preclude resolution of the inflammatory response leading to a 
chronic inflammatory condition such as atherosclerosis.
11
 Pathophysiological processes involved 
in the development of  atherosclerosis are described below and illustrated in Figure 2. 
 Mechanisms of atherosclerosis initiation 1.3.1
Atherosclerosis occurs as focal lesions located within the intima at specific susceptible sites in 
the arterial tree. Typical sites are branch points, the outer wall of bifurcations, the inner wall of 
curvatures and cardiac valves, associated with variations in shear stress and flow disturbances. In 
their normal state, vascular ECs resist contact with leucocytes, maintain a non-thrombotic 
interface, and regulate vessel permeability and contractility.
14
 The initial step in atherosclerosis 
involves EC activation. Low shear stress associated with non-laminar flow reduces nitric oxide 
(NO)-dependent athero-protection and leads to increased uptake and permeability of 
apolipoprotein-B100 (ApoB100) containing LDL-C. High levels of LDL-C cause augmented 
transcytosis at lesion-susceptible areas. Plasma derived LDL-C is then trapped within the 
subintimal space and becomes oxidative modified (oxLDL).
15
 When exposed to activating 
stimuli such as changes in plasma homeostasis including hypercholesterolemia, hyperglycaemia, 
hypertension, microbial constitutes or pro-inflammatory cytokines, ECs shift to a secretory 
phenotype. This leads to proliferation of the extracellular matrix and development of a 
hyperplastic multilayered basal lamina,
14
 and to expression of vascular cell adhesion molecule-1 
(VCAM-1), intercellular adhesion molecule 1 (ICAM-1) and members of the selectin family 
which binds circulating white blood cells (WBC) including monocytes, T-lymphocytes and 
neutrophils.
11
  After adhesion to the ECs, monocytes undergo directed migration into the artery 
wall, mediated by chemokines such as monocyte chemoattractant protein-1 (MCP-1). 
Procalcitonin (PCT), a marker of sepsis and pro-hormone of calcitonin, is suggested to act as a 
chemoattractant during monocyte adhesion and migration. PCT is produced in response to 
various stimuli, such as lipopolysaccharides or pro-inflammatory cytokines (IL-1β and IL-6).
16
 
In the intima, mediators such as macrophage colony stimulating factor (M-CSF) promotes 
proliferation of recruited monocytes and differentiation into macrophages.
11
 These macrophages 
over-express scavenger receptors and engulf modified lipoprotein particles through endocytosis. 
Cholesterol esters then accumulate in cytoplasmic droplets in the macrophages, transforming 
them to lipid-loaded macrophage derived foam cells, which are characteristic for fatty streaks.
14
 
Cholesterol can crystallize and activate a multimolecular signaling complex known as 






 Activation of the NLRP3 inflammasome results in caspase-1 mediated 
processing of the precursors of inflammatory cytokines IL-1β and IL-18 to their active forms, 
which subsequently leads to release of IL-6 and amplification of  the inflammatory cascade.
17, 18
 
 Mechanisms of atherosclerosis progression 1.3.2
Once present in the arterial wall, cells of the innate immune system produce ROS, cytokines and 
pro-coagulants that amplify and sustain the inflammatory response. Both ECs and SMCs respond 
to these signals and are activated to propagate the inflammation by generating a spectrum of 
mediators (IL-1α, IL-1β, IL-6, IL-18, tumor necrosis factor α (TNFα), M-CSF, MCP-1, ICAM-1 
and pro-coagulant tissue factor).
11
 Locally expressed cytokines (IL-2 and IL-18) induce a TH1 
dominated response. TH1-cytokines promote development and progression of disease, whereas 
TH2 and T-regulatory cytokines exert anti-atherogenic activities.
14
 TH1 cells secrete 
inflammatory cytokines, which induce monocyte polarization towards classical activated 
macrophages (M1), which in turn produce pro-inflammatory cytokines, metalloproteinases 
(MMPs) and tissue factor. Neopterin is a marker of monocyte activation, and mirrors elevated 
inflammatory states and vascular oxidative stress. SMCs located in the intima and medial layer 
of the vessel switch from a contractile to a synthetic phenotype which migrates and proliferates 
rapidly, synthesizes collagen and expresses increased number of receptors involved in lipid 
uptake leading to SMC-derived foam cells. MMPs (especially MMP-2 and MMP-9) promote 
SMC migration from the media to the intima, contributing to fibrous cap formation. OxLDL may 
also induce trans-differentiation of SMC toward an osteoblastic-like phenotype through the 
expression of S100 calcium binding proteins.
19
 This process represents a key feature in atheroma 
calcification.
19
 Advanced atherosclerotic plaques contain macrophages, SMC- and macrophage-
derived foam cells, extracellular lipid droplets and calcified cores. Collagen rich, fibrous plaques 
are encapsulated by a robust SMC-rich fibrous tissue cap, have smaller lipid cores, less 
inflammation, more calcification and are considered stable. Plaques that are characterized by 





Figure 2 - Pathogenesis of atherosclerosis. (a) In the first stage, LDL-C is deposited in the endothelium and 
undergoes oxidative modification, resulting in oxidized LDL-C (oxLDL). OxLDL stimulates endothelial cells to 
express adhesion molecules (VCAM-1, P-Selectin) and various chemokines (MCP-1, IL-8). This leads to 
recruitment of monocytes, which transmigrate into the intima and differentiate to pro-atherogenic macrophages; (b) 
Macrophages harvest residual oxLDL via their scavenger receptors and add to the endothelial activation and, 
subsequently, leukocyte recruitment with the secretion of tumor necrosis factor α (TNFα) and IL-6; (c) The 
increasing plaque volume promotes neovascularization. Proliferating smooth muscle cells (SMCs) stabilize the 
nascent fibrous plaque. With deposition of fibrin and activated platelets on the dysfunctional endothelium that 
expresses tissue factor, a pro-thrombotic milieu is formed; (d) Foam cells can undergo apoptosis and release cell 
debris and lipids, which will result in the formation of a necrotic core. In addition, proteases secreted from foam 
cells can destabilize the plaque. This can lead to plaque rupture, in which case extracellular matrix molecules (e.g., 
collagens, elastin and tissue factor) catalyze thrombotic events. (Reproduced with permission in accordance to 
Creative Commons Attribution License 4.0 from Steinl DC, Kaufmann BA. Ultrasound Imaging for Risk Assessment 
in Atherosclerosis. International Journal of Molecular Sciences. 2015; 16(5):9749-976. Figure legend is modified) 
 
 Mechanisms of acute thromboembolic complications  1.3.3
Chronic stable and asymptomatic atherosclerosis does not usually progress to chronic flow-
limiting lesions. Thromboembolic complications most commonly result from fibrous cap rupture 
or superficial erosion of the endothelial monolayer of the atherosclerotic plaque. This initiates 
local thrombus formation and may cause occlusion at the site of plaque rupture or clots that 
dislodge from the surface of atherosclerotic lesions and occlude more distal arteries 
(thromboembolism).
20
 Thinning of the fibrous cap, excess of inflammatory cytokines and 
proteases (inducing digestion of extracellular matrix), decreased collagen synthesis, 




may result in plaque rupture.
14
 Plaque enlargement leads to intraplaque hypoxia, which triggers 
local neovascularization. The presence of neovessels within atherosclerotic lesions does not only 
promote plaque growth, but also contributes to its vulnerability.
21
 As the atheroma increases in 
size, neovessels may leak causing intra-plaque hemorrhage and induction of additional ROS 
formation, inflammation and proteolytic degradation related to angiogenetic factors.  
Inflammation in the intima is associated with decreased synthesis and increased breakdown of 
collagen, preventing repair and stability of the fibrous cap. Gamma interferon produced by TH1 
cells in the atheroma inhibits the production of new collagen by SMCs. Cleavage and 
degradation of interstitial collagen are dependent of collagenases mostly belonging to the family 
of MMPs. Active collagenases are not present in normal arteries, but are produced by ECs, 
SMCs and macrophages in atherosclerotic plaques. MMP-9 is a potent matrix-degrading enzyme 
and may be involved in arterial remodelling including compensatory artery enlargement at 
plaque sites and in aneurysm formation. Ubiquitous tissue inhibitors of matrix 
metalloproteinases (TIMPs) regulate the actions of MMPs and are also present in plaques.
20
 
Death of SMCs, macrophages and other types of vascular cells are found in advanced lesions and 
lead to decreased lesion cellularity, weakening of the fibrous cap, necrotic core formation and 
lesion instability. Pyroptosis is a pro-inflammatory form of cell death, uniquely dependent on 
caspase-1 and suspected to play an important role in atherosclerosis.
22
 In pyroptosis, the dying 
cells undergo loss of plasma membrane integrity and DNA fragmentation and release their 
cytoplasmic content into the extracellular space.
22
  Dying cells thus release growth factors, pro-
inflammatory cytokines, proteases and intracellular lipid into the extracellular spaces which in 
turn initiate inflammation, promote plaque disruption and arterial thrombosis.
23
 Ruptured 




Polymorph nuclear cells may play a role in plaque destabilization and rupture through release of 
ROS and pro-inflammatory mediators in the blood and on the endothelial surface. 
Myeloperoxidase (MPO) is released by activated granulocytes during the respiratory burst and 
suspected to be involved in plaque rupture.
20
 MPO binds to extracellular matrix and converts 
chloride ions plus hydrogen peroxide to hypochlorus acid, a potent oxidant and chlorinating 
species. Hypochlorus acid provokes programmed cell death of ECs, linking oxidative stress 






Fracture of the cap exposes blood to pro-coagulants in the lipid core and triggers thrombosis. 
Pathological studies indicate that plaque disruption often occurs subclinically.
24
 The interaction 
between plaque and blood determines the consequences of plaque disruption and hence the 
composition of the blood is crucial.
20
 Platelets activate upon contact with subendothelial 
extracellular matrix, and aggregate to form a thrombus.
14
 Tissue factor is expressed in 
macrophages upon signals from inflammatory mediators. When exposed to blood, tissue factor 
activates the coagulation cascade, which generates thrombin and subsequent conversion of 
fibrinogen to fibrin resulting in blood clotting. Tissue factor is synthesized in the adventitia of 
normal blood vessels, where it functions to maintain haemostasis after vascular trauma. Tissue 
factor is not present in the intima of normal arteries, but is found in the lipid-rich cores of 
atherosclerotic plaques.
25
 Blood levels of fibrinogen and the endogenous fibrinolysis inhibitor 
plasminogen activator inhibitor-1 (PAI-1) regulate coagulation and fibrinolysis. D-dimer is a 
fibrin degradation product. Levels of these substances may determine formation and stability of a 
thrombus. Inflammatory signalling alters the synthesis of acute phase reactants such as 
fibrinogen and CRP in the liver. In this regard, inflammation is involved in both regulating the 
stability of the plaque and in determining the consequences of plaque rupture; microscopic 
subclinical mural thrombus or occlusive arterial thrombus with clinical manifestation.
20
  
1.4 Traditional risk factors, chronic inflammation and atherosclerosis 
Epidemiological data show consistent associations between traditional risk factors (TRFs) and 
increased levels of inflammatory markers such as IL-6, TNFα and CRP.
26, 27
 In the body, free 
radicals are continuously formed because of oxidative chemical reactions. Experimental and 
clinical studies have demonstrated that TRFs such as hypercholesterolemia, hypertension, 
diabetes, and smoking are associated with an increased production of ROS.
28
 Superoxide 
dismutases (SODs), including Cu/Zn SOD, represent the major antioxidant defence systems 
against ROS in vivo. High dose or inadequate removal of ROS results in oxidative stress.
29
 ROS 
have been implicated in key processes of atherosclerosis including oxidative modification of 
LDL-C, EC activation and regulation of pro-inflammatory cytokines.
30
  
High density lipoprotein cholesterol (HDL-C) is inversely correlated to CVD and plaque 
progression.
31
 Cholesterol cannot be degraded within the vessel wall but may be removed by 
HDL-C containing apolipoprotein-A1 (ApoA1) lipoproteins and transported to the liver for 
degradation. In addition, HDL-C exerts anti-inflammatory properties. Activation of innate 








Chronic activation of the renin-angiotensin-system (RAS) may result in constantly enhanced 
blood pressure and volume overload of the vasculature, causing pathological mechanical 
vascular wall stress, enhancing the vascular production of ROS and pro-inflammatory 
cytokines.
30
 Vasoactive peptides or their more stable precursors, such as midregional pro-
adrenomedullin (MR-proADM), midregional pro-atrial natriuretic peptide (MR-proANP), B-type 
natriuretic peptide (BNP), copeptin, the C-terminal part of the arginine vasopressin prohormone 
(CT-proAVP), reflect vascular function and neuro-humoral activity and also play a role in 
hypertension. Vascular tone and plasma volume is effectively controlled by the active form of 
MR-proADM and the natriuretic peptides, MR-proANP and BNP. The antidiuretic hypothalamic 
hormone vasopressin regulates osmotic homeostasis through water retention in the kidneys and 
acts directly on vascular SMCs. Adrenomedullin has vasodilating effects and is produced by ECs 
and SMCs. MR-proADM expression is induced by shear stress, ischemia, hypoxia and pro-
inflammatory factors such as IL-1β and raised levels are found in hypertension.
32
 
Levels of inflammatory markers in blood have shown ability to predict CVD independent of 
TRFs.
26, 27
 Evidence that suggests inflammation as a driver of atherosclerosis is supported by the 
fact that conditions of chronic inflammatory states, such as rheumatoid arthritis, inflammatory 
bowel disease, chronic renal failure and obesity, are associated with accelerated atherosclerosis 
and higher incidence of CVD. Adipose tissue is not only a fat depot, but also an endocrine organ. 
Macrophages accumulate in visceral adipose tissue, act as scavengers for apoptotic adipocytes 
and express pro-inflammatory proteins, such as TNFα, IL-1 and IL-6. These cytokines stimulate 
hepatic inflammation inducing a chronic systemic inflammatory response.
33
 Transplanted 
visceral adipose tissue from obese mice into atherosclerosis-prone Apo-E deficient mice has 
shown ability to increase atherosclerosis in the recipient animals, suggesting that inflamed 
adipose tissue exert pro-atherogenic effects.
34
 Adiponectin is a protein hormone secreted by 
adipocytes that modulates a number of metabolic processes, including glucose regulation and 
fatty acid oxidation and is inversely correlated with body mass and insulin resistance. 
Adiponectin exerts beneficial effects on endothelial vasorelaxation, supresses generation of ROS 
and leads to down-regulation of adhesion molecules and pro-inflammatory cytokines. On the 
other hand, leptin has been related to vascular disorders in human cohorts. Leptin is a hormone 




concentrations are often high in obese subjects. Leptin is associated with EC proliferation, 
angiogenesis, ROS generation, expression of tissue factor and adhesion molecules.
33
 
In patients with chronic kidney disease, accelerated atherosclerosis has been observed. Reasons 
for this may be increased prevalence of TRFs, such as hypertension, hypercholesterolemia and 
diabetes. A chronic inflammatory state, calcium phosphate metabolism disturbances, oxidative 
stress, fluid overload and disturbances in the coagulation system related to kidney disease 
represent other possible links. Cystatin C and creatinine are reliable markers of renal function. In 




1.5 C-reactive protein (CRP) 
A wide array of inflammatory biomarkers has been studied in relation to cardiovascular disease. 
C-reactive protein (CRP) is the most extensively studied marker. Properties such as relative 
stability in frozen samples, long plasma half-life (19h) and ease of testing with standardized 
assays have facilitated its use.
36
 The term “high sensitive CRP” or “hs-CRP” is often used and 
refers to CRP measured by high-sensitivity assays with lower detection limits of approximately 
0.03 mg/L. In comparison, the assays which are regularly used in the clinical setting of 
diagnosing infection are less sensitive with typical detection limits of 5-8 mg/L.  
In the 1990s, studies revealed that increased CRP values were associated with future coronary 
events. Since then, CRP has shown ability to predict CVD in more than 40 large epidemiological 
studies.
37
 Increase in relative risk estimates for CVD ranges from 1.45 to approximately 2-fold, 
when comparing the highest with the lowest CRP tertile.
38, 39
 This is comparable to the effect of 
TRFs such as blood cholesterol and blood pressure.
39
 A meta-analysis comprising individual 
participant records from 54 long-term prospective studies
27
 showed 1.37 (95% confidence 
interval (CI) 1.27, 1.48) relative risk increase for CHD and 1.27 (95% CI 1.15, 1.40) for IS per 
standard deviation (SD) increase in log-transformed CRP after adjustment for TRFs. In most 
studies, the magnitude of CRP’s association with CVD was smaller in women than in men. CRP 
concentrations are dependent on genetic polymorphisms and show heterogeneity between racial 
groups and sexes.
40
 In addition, raised levels are associated with the presence of TRFs, such as 
BMI, metabolic syndrome, diabetes mellitus, hypertension, smoking and age. CRP is also related 
to alcohol consumption, contraceptive drug use, physical exercise, periodontal disease, 
environmental pollution and chronic inflammatory conditions.
27, 40




the absence of infections, the intra-individual variability in CRP measured by high sensitivity 
assays on a year-to year basis corresponds to that of systolic blood pressure and cholesterol.
36
 
The American Heart Association recommended CRP cut-off points of low CVD risk (<1.0 
mg/L), average CVD risk (1.0 to 3.0 mg/L), and high CVD risk (>3.0 mg/L), corresponding to 
approximate tertiles of CRP in the adult population.
38
 
Treatment with statin therapy reduces both LDL–C and CRP levels and leads to reduction in 
CVD events.
41
 A potential role of CRP in the guidance of statin therapy has been proposed. 
Statin-induced CRP lowering is suggested to derive from both lipoprotein-mediated effects, and 
from pleiotropic effects of statins related to direct anti-inflammatory actions.
41, 42
 In animal 
models, statins showed ability to limit inflammation, increase collagen content, reduce tissue 
factor expression and CRP levels in plaques.
43
 JUPITER (Justification for the Use of Statin in 
Prevention: An Intervention Trial Evaluating Rosuvastatin) randomized 17 802 individuals of 
low to intermediate CVD risk with LDL-C <3.4 mmol/L and CRP >2 mg/L to 20 mg 
rosuvastatin daily or placebo.
41
 The lowest number of CVD events was seen in those treated with 
rosuvastatin who achieved low levels of both LDL and CRP. However, as a control group with 
low CRP levels at baseline was missing, the trial could not conclude whether CRP reduction was 
responsible for the observed benefits. A meta-analysis including 82 000 participants compared 
clinical outcomes of LDL-C levels in 10 statin trials versus nine non-statin trials. This study 
questions whether pleiotropic and anti-inflammatory effects of statins contributes to CVD risk 
reduction beyond LDL-lowering.
42
 The REVERSAL (Reversing atherosclerosis with aggressive 
lipid lowering) trial showed that aggressive lipid lowering with 80 mg compared to 40 mg 
pravastatin achieved greater reductions in both CRP and LDL-C levels, and was associated with 
reduced rate of progression of coronary atherosclerosis.
44
 The evidence that reducing CRP levels 
prevents CVD is so far inconclusive. 
CRP belongs to the pentraxin family of plasma proteins and circulates in the blood as a pentamer 
of identical subunits.
36
 It is produced in the liver as a response to acute infections, trauma and 
inflammation and its synthesis is controlled by several cytokines, IL-6 being the most potent 
driver.
10
 CRP binds to phosphocholine residues in bacterial cell membranes, thereby playing an 
important role in the innate immune response by facilitating the recognition and clearance of 
bacteria. CRP also binds phosphocholine residues in apoptotic eukaryotic cells, ox-LDL and 
several mammalian proteins. Aggregated or ligand-bound CRP activates the complement 
cascade.
10




CRP is produced locally and not just deposited from blood.
45, 46
 Macrophages and SMCs within 
plaques also produce CRP.
47
 Exposure of cultured vascular endothelial cells to CRP inhibits 
nitric oxide synthase expression, impairing vasoreactivity, and leads to up-regulation of ICAM-1 
and VCAM-1, facilitating monocyte adhesion and transmigration.
46
 A pro-thrombotic role of 
CRP has also been suggested. CRP may play an important role in regulating the function of 
platelets, the extrinsic coagulation system and the fibrinolytic system, thus enhancing the 
thrombotic response to vascular injury.
10
 However, the mechanistic way in which CRP links to 
CVD is not clearly understood. Whether CRP plays a causal role in atherosclerosis and its 
complications or is merely a clinical marker of inflammation and cardiovascular risk is 
continually debated. Plasma CRP levels are weakly correlated to atherosclerosis in humans
48
 and 
CRP’s ability to prospectively predict plaque formation and progression has been sparsely 
studied. 
1.6 Atherosclerosis imaging 
Since 1958, angiography has been considered the gold standard in the assessment of 
atherosclerosis. This technique requires percutaneous placement of an access needle with 
catheters over guide wires and contrast dye is injected into the artery of interest.
8
 However, 
angiography depicts only the contrast-filled lumen, and does not provide information about the 
vessel wall itself. Along with advances in imaging technology, the ability to detect and quantify 




Ultrasonography (US), magnetic resonance imaging (MRI) and computer tomography (CT) are 
now the most widely applied imaging modalities for studying the vessel wall. The use of multi-
slice CT angiography and MRI permit accurate evaluation of lumen diameter, plaque size and 
composition. However, radiation and nephrotoxic iodine-based contrast agents are drawbacks of 
CT, and MRI is a time-consuming and expensive examination with frequent contraindications 
and poor availability, limiting the use of these modalities in large population-based studies.  
US is used for visualization of carotid and peripheral arteries located at a depth in tissue which 
can be reached with ultrasound. Coronary artery imaging is challenging because high temporal 
resolution is needed to eliminate cardiac motion, and a high spatial resolution is needed to 
adequately visualize small coronary arteries.
8
 Coronary artery calcium (CAC) score by CT, 




limited to the cardiac region with quantification of calcium identified as areas of hyper-
attenuation. In this setting, CT is performed without the use of intravenous contrast and at low 
radiation doses and this technique has been applied in population studies.
3
 
Two-dimensional B-mode US imaging is a well-acknowledged method for evaluation of 
atherosclerotic disease in the carotid arteries. It is used to assess degree of stenosis with blood-
velocity profiles, carotid intima media thickness (IMT), the presence of plaque and plaque 
characteristics. US is non-invasive, reliable and reproducible.
49
 It is a low cost, low risk and 
accessible imaging modality that is well tolerated by patients and suitable for population studies 
and repeated measurements. An estimated 20% of ischemic strokes are caused by carotid 
atherosclerotic disease.
49
 A strong association between the extent of carotid atherosclerosis and 
coronary atherosclerosis as well as atherosclerosis elsewhere in the arterial tree has been 
confirmed.
50
 Plaques in the carotid artery may therefore serve as a measure of atherosclerotic 
burden in the individual. The main disadvantages of two-dimensional B-mode US imaging is 
that it is dependent on the examiners skills and image quality, resulting in observer variability. 
Invasive catheter-based intravascular ultrasonography provides more detailed information on 
plaque morphology, and size and depicts the arterial lumen. Contrast-enhanced US with micro 
bubble contrast depicts wall irregularities, ulcerations and intraplaque contrast enhancement 
suggestive of neovascularization.
49
 FDG-PET and SPECT represents promising imaging 
modalities for detection of plaque inflammation.   
 Ultrasound assessed atherosclerosis and association with CVD 1.6.1
Different ultrasonographic measures are used to assess different aspects of the atherosclerotic 
process; degree of stenosis, intima-media thickness (IMT), presence or absence of atherosclerotic 




The degree of luminal stenosis has been serving as the primary criterion for risk stratification of 
patients and treatment decision-making. Patients who have experienced a recent ischemic stroke, 
TIA or amaurosis fugax and have extracranial internal carotid artery disease may profit from 
surgical carotid endarterectomy when internal carotid artery luminal stenosis is >50%.
52
 
However, stenosis severity is a poor predictor of fatal and non-fatal stroke in asymptomatic 




need for further risk stratification and other preventive strategies.
49
 Measurement of stenosis is 
also limited by the phenomenon of compensatory vessel enlargement. The artery accommodates 
to the plaque and stenosis is considered a late stadium of atherosclerosis, likely resulting from 





Figure 3 - Ultrasonographic measures of carotid atherosclerosis. (A) Intima media thickness (IMT) in the near and 
far walls of the common catorid artery.(B) Plaque of low echogenicity in the far wall of the common carotid artery. 
(C) Plaque of high echogenicity in the far wall of the carotid bulb.  
 
IMT is the marker of subclinical atherosclerosis, which has been most commonly assessed in 
population studies. As depicted in Figure 3, IMT represents the thickness of two layers (the 
intima and media) of the vessel wall. Carotid intima-media thickening is thought to be an early 
manifestation of atherosclerosis, because thickening precedes the development of atherosclerotic 
plaque. However, epidemiological studies have been incoherent with regard to which part of the 




included in the measurements. IMT is most often assessed in the common carotid artery (cIMT), 
a site where atherosclerotic plaques rarely develop. cIMT probably largely represents medial 
SMC hypertrophy related to hypertension, rather than subintimal changes indicative of 
atherosclerosis.
53
 Assessment of cIMT has been widely used to predict cardiovascular risk but 
may not be useful for risk stratification in a general population.
54
 In addition, it is not feasible to 
measure progression of IMT within individuals over time, and in large cohorts IMT progression 
did not predict events.
55
 
Quantification of plaque burden by assessment of plaque prevalence (Figure 3) and total plaque 
area (TPA) in carotid arteries is superior to IMT, as it is a stronger predictor of cardiovascular 
events.
56, 57
 The presence of plaques increases the risk of stroke by 1.5-fold,
58
 whereas being in 
the highest TPA quartile was associated with 1.7-fold increased risk of stroke compared to no 
plaque.
56
 Also, being in the highest TPA tertile was associated with a 1.7-fold increased risk of 
MI compared to no plaque.
59
 In addition, plaque progression can be reliably evaluated within 
individuals within months.
60
 Progression of carotid atherosclerosis is related to higher risk of 
vascular events compared to atherosclerosis that remain stable or regress over time.
53, 60, 61
 
Measurement of plaque volume by 3D ultrasound may be even more sensitive to changes than 
TPA, for instance when evaluating the effect of therapy.
62
  
Vulnerable, rupture-prone plaques tend to have large lipid cores (cross-sectional plaque area of 
at least 25%), thin fibrous caps (<200µm thick) or intraplaque hemorrhage and thus appear 
echolucent with irregular surface and ulcerations detected by colour-Doppler ultrasound
49
 
(Figure 3). Grey-scale median (GSM) is an objective computerized measurement of 
echogenicity.
49
 However, evidence regarding the value of assessing plaque echogenicity in CVD 
prediction is diverging 
63-65
. In spite of major advances in imaging technology with potential to 
identify vulnerable plaque characteristics, this has not led to improved ability for risk 
prediction.
24
 Still, the complex exchange of cellular, molecular and biomechanical factors 
indicative of symptomatic plaque disruption and its sequelae cannot be accurately foreseen by 
any of the available imaging techniques.
9
 Studies with repeated assessments have shown that 
plaque morphology may change over a few months gaining or losing vulnerable characteristics, 
presumably secondary to subclinical rupture and healing.
20, 24
 In this way, atherosclerosis is a 
systemic condition which remains unpredictable concerning which particular lesion may cause a 
clinical event. Thus, some argue in favour of a greater focus on the atherosclerotic disease 




vulnerability represented by widespread atherosclerosis and inflammation may be more 
important that detecting individual vulnerable sites.
24
 
1.7 Risk stratification and novel therapeutic targets in CVD prevention 
The Framingham Heart Study was initiated in 1947 in Massachusetts to study CVD events in a 
stable population, and in 1960 the concept of risk factors was introduced. Risk factors are 
observable in the preclinical phase and have also been defined as factors that are “associated 
with a disease by virtue of its participation in the causal pathway leading to the disease”.
38
 Risk-
multiplying effects were acknowledged when several risk factors were present at the same time, 
and led to the development of 10-year absolute cardiovascular risk equations. The first was the 
Framingham Risk Score in 1998.
66
 TRFs are incorporated in these risk equations, which 
calculate an individual’s risk of experiencing a CVD event within the next 10 years. Issues 
regarding applicability of the Framingham Risk Score to other populations have led to the 
development of various risk calculators, most of them include variations of the original TRFs 
age, sex, hypercholesterolemia, hypertension, and smoking, which account for most of the risk in 
ischemic CVD. Such risk assessment equations are used as guiding tools for preventive 
strategies in the primary prevention setting. Some CVD prevention strategies are beneficial 
nearly for all and generally recommended, e.g., healthy diet, exercise and smoking cessation. 
Others are associated with considerable costs and risks for adverse effects, e.g., preventive 
medications such as aspirin, antihypertensive and lipid lowering drugs, and are reserved for use 
in persons for whom the benefits of interventions are expected to be large enough to outweigh 
the costs and risks.
66
 Subjects who score high on risk calculators, usually >20% risk of CVD in 
the next 10 years, are candidates for more intensive risk reduction interventions, including blood 
pressure and lipid lowering medications (statins) in addition to lifestyle interventions. 
Nonetheless, approximately 1/3 of individuals who subsequently experience CVD events are 
erroneously classified to be at low risk by TRFs, and CVD events also occur in subjects treated 
with prophylactic medications.
67
 Therefore, a wide array of blood biomarkers and imaging of 
subclinical atherosclerosis are being investigated for detection of subclinical disease, refinement 
of risk assessment and guidance in preventive strategies.  
In 1998, the National Institutes of Health Biomarkers Definitions Working Group defined a 
biomarker as “a characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic 




differences in subjects with and without disease. For a biomarker to be capable of discriminating 
individuals at risk independent of TRFs, it would require a robust association with CVD events 
in prospective studies and absence of collinearity with TRFs.
36
 Methods for evaluation of novel 
risk markers have evolved during the last decades. Initially the focus was on detecting an 
association between the novel marker and CVD events after multivariable adjustment for TRFs. 
Subsequently, focus shifted to the use of C-statistic i.e., area under the receiver operator 
characteristic curve (AUC), as a metric of improved discrimination between subjects who did 
and did not develop CVD.
66
 To significantly improve C-statistic or AUC the odds ratio between 
high and low risk categories needs to be more than 7, which has been deemed hard to achieve.
36
 
A biomarker is considered valuable if it has ability to change clinical management in health and 
cost-efficient ways. In the setting of CVD, this implies ability to correctly reclassify subjects 
who remain event-free into lower risk categories, and those who will suffer events into higher-
risk categories supporting a more aggressive treatment approach. Hence, statistical methods have 
been developed to assess whether adding information from a novel marker to standard risk 
assessment with TRFs improves reclassification across a treatment decision threshold.
68
 
Many of the investigated serological markers, such as CRP, are unspecific markers of 
inflammation which may be upregulated due to different biological processes. The studied 
markers are often correlated with each other and with TRFs. On the other hand, atherosclerosis is 
common and increases by age. The prevalence of plaque in the carotid arteries in a general 
population rises from <3 % in the age-group 25-35 years, to 50-60 % in men aged 55-70 years 
and 40-50 % in women aged 55-70 years.
69, 70
 Even higher prevalence of up to 80 % has been 
reported in Icelandic and Finnish populations.
71
  This implies that less than 10% of the 
population who test positive for atherosclerosis will experience a near-term CVD event.
67
 For 
both CRP and atherosclerosis imaging measures, the associations with CVD are partly explained 
by strong correlations with TRFs, and conflicting findings regarding added incremental value in 
risk prediction exist. The assessment of multiple markers simultaneously may increase 
sensitivity and specificity for detection of unstable atherosclerosis. Identification of reliable 
imaging and serological markers of disease activity may thus be essential to single out 
vulnerable patients and improve the cost-effectiveness of screening for carotid atherosclerosis in 
the primary prevention setting. 
In addition to a role in risk assessment, linking novel serological markers to different stages of 




mechanisms involved in disease progression. The knowledge gathered from epidemiological 
studies, in addition to experimental, genetic and gene expression studies represents valuable 
contributions in the search for novel therapeutic targets in CVD prevention. The attributable 
vascular risk associated with inflammation is substantial and targeted anti-inflammatory 
therapies in animal models have shown promise, but it remains unknown whether inhibition of 
inflammatory pathways in humans will lower vascular event rates.
72
 It is also uncertain whether 
the risk of serious adverse events, such as infection and cancer, might outweigh a potential effect 





2 Aims of the thesis  
 
The objectives of this thesis was 
1. -    To assess cross-sectional associations between CRP and carotid plaque presence    
      and plaque burden measured as total plaque area (TPA).   
- To explore whether CRP predicts novel plaque formation and plaque progression, 
independent of traditional risk factors. (Paper I) 
  
2. -    To investigate the associations between CRP and carotid atherosclerosis, alone and 
in combination, with incident IS and MI. 
- To assess whether CRP mediates the risk of IS and MI in subjects with subclinical 
carotid atherosclerosis.  
- To assess whether CRP and carotid atherosclerosis, alone and in combination, add 
incremental value beyond that obtained from traditional risk factors in risk prediction 
for IS and MI. (Paper II) 
 
3. -    To assess the association between 28 circulating protein biomarkers measured at  
      baseline and formation and progression of carotid plaque at 6-years follow-up.        





3 Subjects and methods 
 
3.1 Study population and ethics 
The Tromsø Study is a longitudinal population-based multipurpose cohort study carried out in 
the municipality of Tromsø, Norway. A total of seven cross-sectional health surveys, with high 
attendance rates, have been conducted (Tromsø 1-7) with 6-7 years intervals in the period 1974-
2017. CVD was initially the main focus of the study, but other research areas have been added 
throughout the years. “The aim has been to include large, representative samples of the 
population of Tromsø, with invitation of whole birth cohorts and random samples”.
73
 Overall 
participation rates were high, ranging from 79% in the 5
th





Tromsø 4-7 included a second visit with a more extensive examination for some of the 
participants. Subjects eligible for the second visit were identified before they were invited to the 









 If they attended the first visit, they were invited to the 
second visit 2-4 weeks later. Ultrasound examination of the right carotid artery was performed 
for the first time at the second visit of Tromsø 4 (1994/1995) and repeated in Tromsø 5 
(2001/2002), Tromsø 6 (2007/2008) and Tromsø 7 (2016/2017). The papers included in this 







 Tromsø surveys and had reliable carotid ultrasound measures on plaque 
presence and total plaque area (Figure 4). In the 4
th
 survey, all inhabitants aged 55-74 years and 
5-10% samples in other 5-year age groups (25-54 and 75-85 years) were offered an ultrasound 
examination of the right carotid artery. All participants who were invited to the second visit in 
Tromsø 4 and who were still alive and resided in Tromsø, were invited to follow-up ultrasound 
examinations in the 5
th
 (2001/2002) and 6
th 
(2007/2008) surveys. In addition, all individuals aged 
50-62 or 75-84 and a 20% random sample of subjects aged 63-74 were invited to the second visit 
of Tromsø 6. The number of participants who attended the ultrasound examinations were 6727, 






 survey, respectively. All subjects who participated in 
Tromsø 4-6 were given information brochures (Appendix 1) and were asked to give written 
consent to medical research prior to the examinations. Participants were free to withdraw their 
consent at any time. Participants without valid written consent to medical research (n=71) were 
excluded. The study was approved by the Regional Committee for Medical Health and Research 




Population Registry of Norway. Inclusion criteria differed in the three papers included in this 
thesis and are displayed in the flowchart below. 
 
 




Participants - Paper I 
The study participants were recruited from the 4
th
 survey of the Tromsø Study.
73
 Eligible were 
all who participated in the carotid ultrasound examination in the 4
th
 survey (1994/1995; baseline) 
and had CRP measurements, complete information on all relevant TRFs and outcomes (plaque 





 survey, respectively, of whom 4590 participants from the 5
th
 and 2838 participants 
from the 6
th
 survey had valid information on all covariate and outcome measures, and these were 
included in the analyses. The maximal follow-up time was 13 years. The participants attended on 
average 2.2 surveys, and 2595 subjects had complete covariate and outcome information 
assessed at all three surveys. Of the 6503 participants included in the study, 1530 attendants died 
and 455 moved out of the municipality during the follow-up period (1994/2008).  
Participants - Paper II 
Eligible for this study were participants who attended one or more carotid ultrasound 






 surveys. Participants without valid written consent (n=71), 
participants with known pre-baseline history of IS (n=121) or MI (n=527), and participants who 
did not have complete information on CRP, ultrasound measurements and relevant TRFs 
(n=467) in at least one of the attended surveys were excluded. Thus, our population consisted of 
10 109 unique individuals, of whom 4932 attended once, 2505 twice and 2672 attended three 
surveys (Figure 5). Subjects were followed from the date of enrollment until December 31, 2013. 
During follow-up 671 and 1079 participants experienced first time IS and MI, respectively, 2249 
participants died and 721 moved from the municipality.  
 
 
Figure 5 Overview of study inclusion. Dots indicate participation at the survey, and lines indicate observation 
periods. A total of 10 109 unique individuals were included in the study, of whom 4932 attended once, 2505 





Participants - Paper III 





 surveys of the Tromsø Study. Four groups were randomly selected from the 
ultrasound cohort on the basis of carotid ultrasound findings at follow-up. Group 1: Study 
participants who had no plaque at baseline nor at follow-up (n=126); Group 2: Study 
participants without plaque at baseline and novel plaque detected at follow-up (n=187); Group 
3: Study participants with prevalent plaque at baseline and stable plaque (no increase in total 
plaque area) at follow-up (n=194); Group 4: Study participants with prevalent plaque at baseline 
and progression of plaque (increase in total plaque area) detected at follow-up (n=196). There 
were originally 200 subjects in each group and they were matched on age and sex. Because of 
missing blood samples the total number of subjects in the study was 703, the groups remained 
balanced with regards to age and sex, but the number of participants was not equal in the four 
groups. 
3.2 Cardiovascular risk factors  
Information on TRFs was collected by physical examination (blood pressure and body mass 
index (BMI)), non-fasting blood samples (total cholesterol, HDL-C, glycosylated hemoglobin 
(HbA1c)) and self-administered questionnaires (prevalent diabetes, current smoking, former MI 
and stroke, and use of antihypertensive, lipid lowering and diabetic medication) (Appendix 2). 
Diabetes was defined as self-reported diabetes, daily use of oral diabetic medication or insulin, 
or HbA1c levels >6.5%. CVD was defined as previous MI or stroke. Further details are 
presented in the papers.  






) were applied in 
analyses. We used time-varying covariates, meaning that subjects who attended multiple surveys 
had their exposure variables and TRFs updated at each survey. In Paper III, we used baseline 
measurements of TRFs. 





 survey, B-mode ultrasonography was performed with an Acuson Xp10 128, 
ART-upgraded duplex scanner equipped with a 7.5 MHz linear-array transducer. In the 6
th
 
survey, a GE Vivid 7 scanner with a linear 12-MHz transducer was used. Different sonographers 
did the baseline and follow-up scanning, but followed standardized  examination techniques, 




study training protocol. The far and near walls of the right common carotid artery, the bifurcation 
(bulb) and the internal carotid artery (six locations) were scanned for the presence of plaques. A 
plaque was defined as a localized thickening of the vessel wall of more than 50% compared with 
the adjacent intima-media thickness. For each plaque, a still image was recorded with the 
transducer parallel to the vessel wall and perpendicular to the point of maximum plaque 
thickness. Each plaque was manually outlined and total plaque area (TPA) was calculated as the 




   
 
Figure 6 – Measurements of plaque area in the carotid artery. (A) Plaque of low echogenicity in the far wall of the 
common carotid artery. (B) Outlining of the plaque area which measures 20.8 mm
2
. (C) Plaque of high echogenicity 




3.4 Blood biomarkers 





 surveys) or Hitachi 917 (5
th
 survey) autoanalyzer (Roche Hitachi, Mannheim, Germany), with 
reagents from Roche Diagnostics (Mannheim, Germany). Samples from the 4th survey were 





 surveys were analyzed at time of the surveys. The lower detection limit of the high-sensitivity 
CRP assay was 0.03 mg /L, and measurements of CRP lower than 0.03 mg/L were set at this 
value. The analytical coefficient of variation for CRP levels between 0.1 mg/L and 20 mg/L was 




In Paper III, a panel of 28 novel biomarkers that previously had shown promising results on the 
association with CVD were selected and analyzed in blood obtained at baseline. The selected 
biomarkers have proposed links to atherosclerosis through different pathophysiological 
mechanisms; inflammatory markers (CRP, fibrinogen, white blood cells (WBC), monocyte 
count, neopterin, IL-6, IL-18, ICAM-1, VCAM-1, caspase-1, MMP-9, TIMP-1, D-dimer, PCT, 
protein S-100); markers of oxidative stress (MPO, Cu/Zn SOD);  metabolic markers 
(adiponectin, leptin, ApoA1, ApoB100, ApoB100/ApoA1 ratio); markers of hemodynamic stress 
(BNP, CT-proAVP, MR-proADM, MR-proANP); and markers of renal function (creatinine, 
cystatin-C). The study blood samples underwent no more than three freeze/thaw cycles from 
time of receipt to protein data production. All samples were kept at 4º C between sample 
dilutions, and were otherwise stored at -70º C until assay production.  Fibrinogen, creatinine, and 
WBC were measured at the Department of Clinical Chemistry, University Hospital of North 
Norway, Tromsø. All other biochemical analyses were performed at the Mainz Biomarker 
Laboratory (details in Paper III). According to manufacturers, all inter- and intra-assay 
coefficients of variation were below 10%, except inter-assay coefficients for adiponectin, IL-18 
and PCT which ranged between 10 and 20%. 
3.5 Ascertainment of clinical endpoints 
Based on data from hospital records, autopsy records and death certificates, an end-point 
committee of trained physicians validated hospitalized and out-of-hospital events of incident IS 
and MI. By national unique 11-digit identification numbers, the Tromsø Study participant list 
was linked to national and local diagnosis registries including the National Causes of Death 
Registry, the Population Registry of Norway, the discharge diagnosis registry (outpatient 
diagnoses included) at the University Hospital of North Norway (UNN). UNN is the only 
hospital in the municipality of Tromsø, the nearest hospital is located approximately 250 km 
away by road (148 km by air). Fatal events that occurred outside of hospital were identified 
through linkage to the national Causes of Death Registry at Statistics Norway, and death 
certificates, autopsy reports, and information from additional sources, such as records from 
nursing homes, general practitioners, and ambulance services, were used for validation. 
Discharge letters from hospitalizations in other hospitals were also collected when appropriate. 
To identify all possible first-ever MI and IS cases, we used a wide search strategy that included 
the International Classification of Diseases (ICD) 9 codes 410-414, 430-438 and 798-799 from 




rapidly developing clinical signs of focal or global disturbance of cerebral function, with 
symptoms lasting ≥24 hours or leading to death with no apparent cause other than vascular 
origin, when CT, MRI or autopsy had ruled out intracerebral or subarachnoid hemorrhage. 
Modified WHO MONICA/MORGAM
75
 criteria for MI were used, and included clinical 
symptoms and signs, findings in electrocardiogram, values of cardiac biomarkers and autopsy 
reports if applicable. At the University Hospital, biomarkers used included creatine kinase (CK) 
and its MB fraction (CK-MB) throughout the study period, and troponin from 2000. Biomarker 
levels were generally recorded three times during the first 3 days following admission or MI 
onset. When circumstances suggestive of invalid biomarker values were present, the significance 
of biomarker results were downregulated. Cases meeting diagnostic criteria for definite or 
probable fatal or non-fatal first-ever MI were classified as MI. Silent MIs as defined by ECG 




3.6 Statistical analyses 
SAS statistical software package SAS 9.4 (SAS Institute, Cary, NC, USA) was used for all data 
analyses. Baseline characteristics were presented as percentages, means with SDs, medians with 
interquartile ranges or geometric means for non-normally distributed variables. When assessed 
as continuous variables, TPA was square root transformed (sqrtTPA) and CRP log transformed 
to approximate normal distribution and improve regression model fit. Associations were 
investigated in age and sex adjusted models and subsequently in models adjusted for traditional 
risk factors (multivariable-adjusted). Sex-stratified associations were assessed in Paper I and II, 
but not in Paper III due to lack of statistical power. A two-sided level p-value <0.05 was 
considered as significant in all analyses, except when examining interactions where p-value <0.2 
was considered statistically significant. More detailed descriptions of the statistical methods are 
found in the papers, whereas main points are highlighted below. 
Paper I 




the outcome (dependent) 
variables and CRP was the exposure (independent) variable. Cross-sectional and prospective 
associations were examined.
  
When plaque was treated as a dichotomous variable, generalized estimating equations with a 




by an exchangeable correlation structure. In this structure, the correlations between subsequent 
measurements on the same individual are assumed to be the same, irrespective of the length of 
the time interval.
77
 Odds ratio (OR) of plaque presence compared to no plaque was estimated for 
a defined change in CRP (1 SD increase or higher risk categories compared to CRP <1 mg/L).  
When examining the cross-sectional associations between CRP and TPA (continuous variable), 
we used linear mixed models. Correlated observations within individuals were adjusted for by 
adding a random intercept to the model, allowing intercepts to differ between subjects, but 
estimated regression coefficients for the covariates are the same for all subjects.
77
 Linear mixed 
models calculates the β-coefficient, which represents the estimated change in TPA associated 
with a defined change in CRP.  
A second linear mixed model was set up to simultaneously assess the cross-sectional and 
prospective relationship between CRP and TPA.
78
 The cross-sectional component analyzed the 
association between baseline CRP and estimated TPA at baseline, whereas the prospective 
component analyzed the association between baseline CRP and TPA progression rate (CRP x 
time) during the observation period.
79
 These models were fit with random intercepts and slopes, 
allowing both for baseline TPA and progression of TPA over time (slope) to differ between 
individuals. The normality assumption for linear mixed models was confirmed by graphical 
inspection of the residuals.  
Paper II 
First-ever IS and MI were
 
the outcome variables. The exposure variables were CRP in 
predefined risk categories (CRP <1, CRP 1-3 and CRP >3 mg/L) and categories of TPA (no 
plaque, below and above the median TPA). Cox proportional hazard regression models with 
time-varying covariates and age as time scale
80
 were used to assess the association between CRP 
and TPA alone and in combination (CRP+TPA) with risk of IS and MI. Follow-up time and risk 
estimates were calculated separately for IS and MI. By assigning new observation periods with 
updated values of risk factors at the time of subsequent study attendance, we utilized individual 
person data from repeated surveys, thereby taking into account changes in exposure status during 
follow-up. Due to differences in event censoring, the 10 109 participants contributed with 17 668 
observation periods for IS and 17 454 observation periods for MI.  
For each exposure variable, we calculated incidence rates and hazard ratios (HRs) with 95% CIs 




person’s instantaneous risk of experiencing the disease of interest, at any time-point in one group 
(exposed) compared to another group (unexposed). The impact of CRP on the relationship 
between TPA and the two outcomes was assessed by calculating the percentage change of HR in 
the different TPA categories when CRP (log-transformed) was added to age- and sex-adjusted 
models. Multiplicative interactions between CRP and TPA were assessed. To investigate 
synergistic effects of atherosclerosis and CRP on the risk of IS and MI, we calculated incidence 
rates and HRs for the other eight constellations of TPA and CRP, and these were compared to 
the no-plaque group with CRP <1 mg/L. Additive interaction and synergism was evaluated using 
the Rothman synergy index
81
 to determine whether the joint effects of CRP and atherosclerosis 
on the risk of IS and MI exceeded the sum of effects from each factor alone in age- and sex-
adjusted models. A synergy index greater than 1.0 suggests that the effect of the joint exposures 
of two risk factors is greater than the sum of the separate effects. 
Finally, the added value by TPA and CRP in risk prediction was evaluated by comparing the 
discrimination power of a model based on the Framingham risk factors with models that 
additionally included TPA alone, CRP alone, and TPA and CRP together. We calculated 
Harrell’s C-index
82
, relative integrative discrimination improvement (IDI) and net 
reclassification improvement (NRI).  
For all Cox proportional hazard regression models, the proportional hazard assumption was 
verified by visual inspection of log–log survival plots. 
 
Paper III 
Plaque group at follow-up was the
 
outcome variable, and the 28 biomarkers measured in blood 
obtained at baseline were exposure variables. We used general linear models to assess 
differences in biomarker levels across plaque groups. False discovery rates (FDR) were 
calculated to adjust for multiple comparisons.
83
 For each biomarker that significantly differed 
between groups, multinomial logistic regression models were used to assess the association 
between baseline biomarker level and plaque group, adjusted for age and sex and further 
adjusted for TRFs. The no-plaque group was defined as reference category. Odds ratios (OR) for 
outcome were reported per 1 SD change in continuous variables or for presence vs. absence of 
binary variables. All significant biomarkers in univariable models and TRFs were candidates for 





We also performed analyses to evaluate the composite measure of the aggregate number of 
biomarkers in the highest third with respect to plaque progression.
84
 We considered the 
biomarkers which were significantly associated with plaque progression after adjustment for 
TRFs, and used a logistic regression model to estimate OR for being in the plaque progression 
group versus the no-plaque group according to number of biomarkers in the upper tertile.
85-87
 
 Missing data 3.6.1
In Paper I, observations with complete data on outcome, exposure and adjusting variables were 
included in the analyses. In Paper II, missing data were handled by carrying forward values from 
previous surveys, when applicable. In Paper III, missing data were assumed to be missing at 
random and handled by multiple imputation by chained equations in SAS, using the FCS 
command to impute 20 data sets.
88, 89
 This method handles different types of variables 
(continuous, binary and categorical). The imputed values are drawn from the posterior predictive 
distribution of the missing data, conditional on the observed data. Rubin’s rule was used to 
combine the results for the imputed data sets. The combined estimate is the mean of the 
individual regression coefficients from each of the 20 data sets. The total variance is determined 







4 Main results 
 
4.1 Paper I 
In cross-sectional analyses, we confirmed an association between CRP and carotid plaque 
prevalence as well as TPA in both sexes. After adjustment for TRFs, the cross-sectional 
associations were most prominent in men; CRP was associated with TPA in men only at 
baseline, but in both sexes when considering all surveys. However, the magnitude of the 
association remained larger in men. For women, there was a significant higher plaque prevalence 
when CRP was >3 compared to CRP < 1 mg/L (OR 1.20, 95 % CI 1.04, 1.39). For men, this 
association was weaker (OR 1.15, 95 % CI 0.99, 1.34). When treated as a continuous variable, 
CRP was associated with plaque prevalence in men only. 
For men, baseline CRP >3 mg/L vs. <1 mg/L was associated with TPA progression (p=0.03). 
However, in multivariable-adjusted models, baseline CRP did not predict TPA-progression in 
either sex. In men who were plaque-free at baseline, the risk of novel plaque formation increased 
significantly with baseline level of CRP. The risk for plaque at end of follow-up was 44% higher 
in men with baseline CRP >3 mg/L compared to men with baseline CRP <1 mg/L (OR 1.44, CI 
1.08, 1.92). However, this association was attenuated to non-significant upon adjustment for 
TRFs. There was no association between baseline CRP and novel plaque formation in women.  
4.2 Paper II 
Serum CRP levels and carotid atherosclerosis were individually associated with increased risk of 
IS and MI independent of TRFs. CRP level >3 mg/L vs. <1 mg/L was associated with increased 
risk of IS (HR 1.84, 95% CI 1.49, 2.26) and MI (HR 1.46, 95% CI 1.23, 1.73) in multivariable-
adjusted models. There was no significant interaction with sex for either outcome. Both TPA 
below and TPA above the median were associated with higher risk of IS and MI compared to no 
plaque. For IS, HRs (95 % CIs) were 1.33 (1.08, 1.65) and 1.65 (1.36, 2.01), referring to TPA 
below and above median, respectively. The corresponding HRs (95 % CIs) for MI were 1.31 
(1.11, 1.55) and 1.64 (1.41, 1.92). For MI, but not for IS, there was a significant interaction 
between plaque category and sex (p=0.02), suggesting a stronger association between TPA and 




TPA showed a weak correlation to CRP with Spearman correlation coefficient of 0.13 (p 
<0.001), and risk estimates for subjects with atherosclerosis were only slightly attenuated by 
adding CRP to the models (1.7– 8.6%). For both outcomes, the joint presence of TPA > median 
and CRP >3 mg/L were associated with the highest incidence rates. However, a synergistic effect 
was evident for IS only, with a synergy index of 1.72 (95% CI 1.06, 2.81). There were no 
significant multiplicative interactions between CRP and TPA categories for either outcome.  
TPA alone and the combination of CRP and TPA achieved a significant improvement in risk 
prediction beyond Framingham risk factors, with most prominent effects in the group classified 
at intermediate risk by Framingham risk factors. For IS, the highest categorical NRI was seen 
when including both variables (CRP+TPA) as continuous variables, 6.6% (p=0.007) for the 
population and 21.6% (p<0.001) for the intermediate risk group. For MI, the highest overall NRI 
of 5.0% (p=0.01) for the population and 12.0% (p=0.02) for the intermediate risk group were 
seen when both variables were included as categorical variables. 
4.3 Paper III 
The crude baseline level of 12 biomarkers differed significantly between the four plaque groups 
(no plaque, novel plaque, stable plaque and plaque progression). These markers were CRP, 
fibrinogen, WBC, neopterin, D-dimer, IL-6, caspase-1, ICAM-1, ApoA1, ApoB100, 
ApoB100/ApoA1 ratio and MPO.  Adjustment for multiple comparisons revealed FDR < 0.05 
for seven biomarkers (fibrinogen, WBC, IL-6, caspase-1, ICAM-1, MPO and ApoB100/ApoA1 
ratio). The mean baseline levels of these biomarkers were, except for two, highest in the plaque 
progression group and lowest in the no-plaque group. The exceptions were neopterin and 
ApoA1. The highest baseline level of neopterin was observed in the no-plaque group. The 
highest level for ApoA1 was observed in the novel plaque group.  
Age- and sex-adjusted levels of fibrinogen, ApoB100, ApoB100/ApoA1 ratio, WBC, CRP, 
MPO, D-dimer, caspase-1, and IL-6 were significantly associated with plaque progression. In 
addition, an increase in caspase-1 increased the corresponding odds of novel plaque formation, 
while higher neopterin level decreased the odds for novel plaque formation. The associations 
between MPO, caspase-1 and IL-6 and plaque progression and between neopterin and novel 
plaque formation remained significant after adjustment for TRFs. When subjects with former 
CVD were excluded, IL-6 and neopterin remained the only significant biomarkers for plaque 




0.94), respectively.  In the final regression analysis, which included TRFs and the 12 significant 
biomarkers from the univariable models, IL-6 remained a significant predictor of plaque 
progression using a backward selection procedure. 
A multimarker model suggested that OR of plaque progression increased with increasing number 
of biomarkers in the upper tertile (considering IL-6, caspase-1, and MPO). After adjustment for 
TRFs, individuals with two biomarkers in the upper tertile had a 2.2-fold higher odds, and 
individuals with three biomarkers in the upper tertile a 4.4-fold higher odds of plaque 







5.1 Methodological considerations 
 Study design 5.1.1
According to the epidemiologist Kenneth Rothman “the objective of an epidemiological study is 
to obtain a valid and precise estimate of the frequency of a disease or of the effect of an exposure 
on the occurrence of a disease in the source population of the study”.
90
 Cohort studies are 
observational studies where a group of people (cohort) is defined and investigated. The group 
consists of individuals who are at risk of developing a specific disease or health outcome. All 
individuals in the cohort will be observed for a period of time in order to measure the frequency 
of disease-occurrence (incidence) among those exposed to the suspected causal agent, compared 
to those not exposed.
91
 
Cross-sectional studies, in which exposure and outcome are assessed at the same point in time, 
provide important information on associations. However, association is not causation and cross-
sectional studies are affected by the antecedent-consequent bias, similar to the chicken and egg 
question (i.e., “which came first?”). In order to use findings from epidemiological studies in 
primary prevention and other interventions that aim at modifying the probability of the outcome 
of interest, it is essential to establish whether or not an association is causal.
92
 Inferring causation 
is the most challenging problem in epidemiology. The Bradford Hill criteria from 1965 comprise 
aspects of a statistical association (strength of association, consistency, specificity, temporality, 
biological gradient, plausibility, coherence, experiment, and analogy) and when present, 
strengthens the inference that the statistical association is also causal. The overarching questions 
that these criteria seek to address are whether confounding and bias are reasonable alternative 
explanations for the observed statistical association.
93
 The most important criterium is the rule of 
temporality, the cause has to precede the effect. In longitudinal studies, exposure is assessed at a 
certain point in time and the population under study is followed for a period of time with 
prospective ascertainment of the outcome of interest. Although longitudinal studies are not able 
to prove a causal relationship, the fact that exposure is assessed before outcome may support the 
Bradford Hill criteria of temporality and strengthen the possibility of a causal association. 




In medicine, the randomized controlled trial (RCT) is the gold standard for establishing 
causality. Randomization should ensure that the population groups remain close to similar in 
every aspect, except for the exposure (or intervention) under study. However, it may be 
impossible or unethical to randomize participants to potentially harmful exposures in order to 
study their effect on outcomes. This limits the utility of RCT’s in studying risk factors for 
disease. Another approach is genetic epidemiology with application of Mendelian randomization 
design, which can provide unbiased estimates of causal exposure-disease associations. The basic 
idea is to study associations between the inherited genetic polymorphisms, known to affect the 
presence or level of the exposure of interest (the phenotype) and its association to the outcome 
under study. This method requires a strong and specific association between the genetic trait and 
exposure of interest and absence of linkage disequilibrium, i.e. the genetic trait is linked with 
other genetic factors that influence the risk of outcome.
92
 
The papers in this thesis are all based on the Tromsø Study, which is a population based 
longitudinal cohort study with repeated health surveys. The main strengths of the Tromsø Study 
are the large sample size, the prospective design, and the repeated and standardized assessments 
of cardiovascular risk factors, blood samples, carotid ultrasound and CVD events in a general 
population. The nested case-control study design, which was applied in Paper III, combines 
some of the features and advantages of both cohort and case-control designs. The case groups 
consist of a representative sample of individuals with the outcome of interest (in this case 
subjects with novel plaque, stable plaque and progression of plaque) occurring in the specified 
follow up period of six years. The control group (subjects with no plaque at follow-up 
examination) was selected from individuals at risk at the same time as each case was defined. 
This design is less prone to selection and information bias compared to traditional case-based 
case-control studies. This is because cases and controls are selected from the same source cohort 
and exposures are assessed before the disease occurs unlike in a traditional cohort study.
92
 A 
properly executed case-control study nested in a cohort is valid if the corresponding analysis of 
the full cohort is valid.
94
 This study design is efficient for addressing research questions when 
additional information that was not obtained or measured for the whole cohort is needed. In our 
study, blood samples were collected at baseline and stored in freezers. The serum samples for 
cases and controls could thus be analyzed at reduced costs.
92
 
In population studies, providing information relevant to the general population and allowing 




Internal validity is a prerequisite of external validity. Accuracy, the degree to which a 
measurement or estimate represent the true value of the attribute being measured, is essential in 
epidemiology. Threats to the accuracy of epidemiological studies are random errors (lack of 
precision) and systematic errors (bias).
90, 92
 
 Internal validity 5.1.2
Internal validity refers to whether the inferences drawn from the sample to the population under 
study are valid.
90
 Internal validity may be threatened by three types of error; selection bias, 
information bias, and confounding. 
 Selection bias 5.1.2.1
Selection bias is systematic error in the recruitment or retention of study subjects. Selection bias 
is present when individuals have different probabilities of being included in the study sample 
according to relevant study characteristics. This results in the study participants being different 
from non-participants in regard to the exposure and outcome of interest. The validity of studies 
to document incidence or prevalence of disease or exposure in the source population relies on a 
sample of study participants that represents the actual population. The estimated association 
between exposure and outcome may also be biased if participation is influenced by exposure or 
the disease under study.
90, 92
 Whenever possible, study subjects should be chosen from a defined 
reference population. In the Tromsø Study, the invitation of total birth cohorts and random 
samples from other age groups based on information from the official population registry of 
inhabitants of Tromsø, ensures the invitation of a representative study population. Selection bias 
may still be a problem if participation rates are low. In Tromsø 4, the participation rate was high, 
77% of those invited to the first visit, and 76% of those eligible to the second visit participated. 
In Tromsø 5, the rate was even higher; 79% of those invited to the first visit and 85% of those 
eligible to the second visit participated. The participation rate was somewhat lower in the 6
th
 
survey, where 66% and 64% of those eligible attended the first and second visit, respectively. 
The main targeted age group was 40-80 years. For the youngest and the oldest age groups and 
for men, the participation rate tended to be lower.
73
 The participation rate was also lower among 
those who had not participated in previous surveys of The Tromsø Study. The educational level 
was higher among participants than in the general Tromsø population. Responders tended to be 
non-smokers and married compared to non-responders.
73
 Recently, another Norwegian cohort 




had lower socioeconomic status, higher mortality and higher prevalence of several chronic 
diseases. Non-participants had less healthy lifestyle in terms of tobacco smoking and physical 
activity, and poorer general health.
95
 The Tromsø Study is comparable to HUNT. Legal 
restrictions have precluded analyses of mortality and morbidity among non-attenders. However, 
a mortality follow-up study of persons invited to CVD surveys in 5 areas of Norway found that 
age-adjusted all-cause mortality rate was 3.7 times higher in non-attending women and 2.2 times 
higher in non-attending men, compared with attendees.
96
 
Selection bias may also occur in a cohort study if there are differential losses to follow-up, 
meaning that individuals who are lost to follow-up have different probabilities of the outcome of 
interest than those who remain in the cohort. This can occur when losses to follow-up are related 
to morbidity and mortality from causes other than the outcome of interest (competing risk of 
death), refusal or migration.
92
 Lower mortality rates have previously been documented in 
participants who attended multiple surveys, compared to those who attended only Tromsø 4.
73
 
When considering clinical endpoints such as IS and MI, the loss to follow-up is negligible due to 
usage of the unique personal identity number to search in official health registries. When 
evaluating changes in carotid TPA, which requires repeated ultrasound measurements, the 
statistical power to detect associations with the exposure under investigation may be diminished 
if subjects with the most severe atherosclerosis are lost to follow-up. Survival bias, with higher 
representation during follow-up of attendees with a more favorable risk profile, compared to 
diseased persons of the same birth cohort, may represent a source of selection bias. Differences 
in baseline characteristics between subjects who were lost to follow-up compared to subjects 
who attended follow-up examinations, were assessed in Paper I and confirmed that subjects with 
the most unfavorable levels of TRFs and atherosclerosis at baseline, were more likely to drop out 
from follow-up examinations. In Paper I, the use of linear mixed models and generalized 
estimating equations enable the inclusion of information from participants who only attended 
one survey and ability to update information on CRP, TRFs and carotid plaque on subsequent 
study attendance for assessment of cross-sectional associations. The method of updating CRP, 
plaque status and TRFs on subsequent study attendance was also applied in Paper II. However, 
when assessing the prospective associations in Paper I and III, attendance in two or more surveys 
was required. In this situation a biased relative risk or rate ratio estimate will only ensue if losses 
to follow-up are biased according both to outcome and exposure (differential).
92
 High rates of 




supporting biased estimates of association due to non-participation.
97, 98
 Hence, we do not 
suspect that the associations between circulating biomarkers and atherosclerosis are different in 
the participants who were lost to follow up than for those who remained in the study. 
There were attempts to improve participation rates and thereby reduce selection bias by sending 
invitation-reminders, having easily available study centers (e.g., in a shopping center) and 
promoting the health benefits of participation on the individual and community level.  
 Information bias and misclassification 5.1.2.2
Information bias results from “imperfect definitions of study variables or flawed data collection 
procedures”.
92
 It follows, that a significant proportion of the study participants may be 
misclassified, i.e. placed in an incorrect exposure, covariate or outcome category. There are two 
types of misclassification bias; non-differential (independent of other study variables) and 
differential (dependent on other study variables). Non-differential misclassification occurs when 
the degree of misclassification of exposure is independent of case-control status or vice versa. 
The effect of non-differential misclassification is usually attenuation of the effect estimate. 
Differential misclassification occurs when the rate of misclassification differs between the 
groups being compared. The error in the effect estimate resulting from differential 
misclassification is difficult to predict. Misclassification of covariates (potential confounders) 
may also affect the efficiency of adjustment for confounding effects. Non-differential 
misclassification of a confounder tends to bias the association estimate toward the null 
hypothesis.
92
 Sources of error resulting in misclassification may be random (lack of precision, 
reliability) or systematic (lack of validity, bias). Reliability (reproducibility) refers to the extent 
to which the results obtained by a test are replicated if the test is repeated. Reliability is reflected 
through the confidence interval and depends on study size and study efficiency. Validity refers to 
the method’s ability to measure what it is intended to measure, i.e. to distinguish between those 
who have a disease (or other characteristics) and those who do not. High reliability is a 
prerequisite for high validity.
90, 92
 In cohort studies, the tests that are used may not be the best 
available tests with regard to sensitivity and specificity. A large amount of healthy individuals is 
to be tested. Therefore, the test should not be too time-consuming, expensive or invasive, but still 
have acceptable test-performance characteristics. The validity of the tests used should be 







Traditional risk factors 
Exposure identification bias may affect cohort studies when there are technical or other sorts of 
bias in the baseline measurements. Since exposure and adjusting variables are assessed before 
the outcome of interest occurs, such errors tend to be non-differential with regard to disease 
status. Blood pressure and BMI were assessed in the Tromsø Study. Weight and height were 
measured, and BMI was calculated using standardized methods. Blood pressure was recorded by 
specially trained personnel with an automatic device. Three readings were recorded with one-
minute intervals. The average of the final two readings was used in the analyses in order to 
reduce misclassification due to random measurement error.  
In case-control studies, more serious exposure identification bias may occur when exposure is 
assessed after disease status is ascertained. The outcome may influence the reporting of cases 
and controls differentially (recall bias), and result in differential misclassification. When a well-
defined cohort, such as the Tromsø Study, is available, a nested case control study allows the 
evaluation of certain hypothesis free of recall bias. However, in cohort studies recall bias may be 
present at the outset of the study when categorization of individuals by level of exposure relies 
on recalled information from distant or recent past.
92
 Information about smoking status, use of 
lipid lowering and antihypertensive medication and history of former diseases, such as diabetes, 
stroke, MI and hypertension, was obtained through self-administered questionnaires at baseline. 
This type of information is prone to respondent bias and recall bias, which may result in 
misclassification. When people feel stigmatized by a condition or habit, they are more likely to 
give misleading answers (respondent bias). Smoking may be a sensitive topic leading to 
misclassification of smoking status. 2.1% of the “never-smokers” in Tromsø 6 had reported >10 
pack-years in one of the previous surveys.
99
 However, validation studies on self-reported 
smoking have shown that the information given in questionnaires is in general accurate.
100
 We 
used current smoking as a measure of smoking, as data on previous smoking habits, including 
calculation of pack years, is more prone to recall bias.  
The sensitivity of self-reported diabetes has been found to be moderate to good in previous 
studies.
101
 To increase sensitivity, diabetes was defined as self-reported diabetes, regular use of 
insulin or oral antidiabetics or HbA1c >6.5%. As the study participants were unaware of any 
hypotheses about the relation between the variables under study, the misclassifications of self-




Blood samples were for practical reasons assessed non-fasting. Regarding total cholesterol and 
HDL cholesterol, fasting or eating before blood collection does not have a marked effect on 
measurements. Non-fasting triglycerides are problematic because of large variation in pre-and 
postprandial levels, and triglycerides were therefore not included in analyses. 
Blood biomarkers 
The exposure variables of main interest in our study were biomarkers assessed in blood samples. 
Performance characteristics of biomarker immunoassays should be known and acceptable. The 
coefficient of variation (CV) is a measure of the analytic random variation or imprecision of a 
test. It is the standard deviation expressed as a percentage of the mean value of two sets of paired 
observations. It is calculated for each pair of observations and then averaged over all pairs.
92
 
When each sample is measured duplicate the degree to which the duplicate results differ may be 
assessed by calculating the intra-assay CVs. When many samples are tested, it is often necessary 
that blood samples are run on multiple assay plates. The inter-assay CV is an expression of plate-
to-plate consistency. Inter-assay CVs of less than 15% are generally acceptable. Intra-assay CVs 
should be less than 10%. Simulation studies have demonstrated that the chance of finding a more 
than 1.5 fold difference in two measurements of the same sample when the coefficient of 
variation is <10% has a probability of <0.001.
102
 CVs should be reported for concentrations that 
reflect the range of results found in the specimens. According to manufacturers, all inter- and 
intra-assay coefficients of variation were below 10%, except inter-assay coefficients for 
Adiponectin, IL-18 and PCT, which ranged between 10-20%. The analytical coefficient of 
variation for CRP levels between 0.1 mg /L and 20 mg/L was <4%. Although the coefficient of 
variation was small, it may have led to random errors in marker measurements and attenuation of 
risk estimates.  
If the stability of biomarkers is affected by freezing, thawing, or storage, bias may be introduced 
by the use of frozen blood samples. CRP stability in frozen samples is previously reported to be 
acceptable with high correlations between CRP values obtained before and after storage.
103
 In 
Paper III, the 28 markers were analyzed only once in frozen blood samples obtained at baseline. 
Pro-inflammatory cytokines are short acting and prone to fluctuations causing substantial within-
person variation. Using only baseline values tend to underestimate the real association between 
biomarkers and outcome due to the regression dilution effect. It is advised to collect samples at 
several points in time and use the average of all values as this tends to prevent non-differential 
misclassification.
92




6707 subjects had duplicate measurements, of whom 6425 had CRP <10 mg/L at both visits. For 
these subjects, the Spearman correlation coefficient between visits was 0.75, intraclass 
correlation coefficient was 0.75 (95% CI 0.74, 0.76), and the intra-individual CV was 39.0% 
which is comparable to other studies
104 
and to within-person variability for total cholesterol and 
systolic blood pressure.
27
 Considering CRP risk categories (<1mg/L, 1-3 mg/L and>3 mg/L) 
33.3% of participants changed risk category between the two measurements. 52.4 % of 
participants who had CRP >3 mg/L at the first visit were still in this category upon the 
subsequent measurement. Others have found that 40% of patients with chronic coronary artery 
disease changed risk category between two consecutive measurements of CRP.
105
 It has been 
suggested that discrepancies concerning the incremental value of CRP in CVD risk prediction 
may arise from the substantial day to day variability of CRP blood levels, which may cause 
misclassification of subjects from low to moderate or high risk.
105   
Ultrasound measurements 
Carotid ultrasound assessment of plaque presence and total plaque area were exposure variables 
(Paper II) and outcome variables (Papers I + III). The reliability of the ultrasound assessment of 
plaque detection and plaque area measurement have been addressed in previous studies for all 
surveys and found to be acceptable. Details about the inter- and intra-observer reproducibility 
and inter-equipment variability have been published previously.
31, 74, 106
 At each survey, 
reproducibility was assessed by inviting a sample of the participants to a second ultrasound 
examination within three weeks from the first scan. On each occasion, two or three sonographers 
examined each subject. The sonographers had no knowledge of each other’s results or results 
from previous assessments. There were 107 paired observations in the 4
th
 survey, 83 in the 5
th
 
















Between- and within-sonographer agreement on plaque occurrence in Tromsø 4 was substantial 
with Kappa (κ) values (95% CI) of 0.72 (0.60, 0.84) and 0.76 (0.63, 0.89), respectively, 
indicating substantial agreement.
106
 Reproducibility of plaque detection did not differ 
significantly between the sonographers. The inter-observer agreement was 0.67 (0.58, 0.76) and 




, and 0.53 (0.40, 0.66) and 0.63 








Inter-observer and intra-observer variability of pairwise plaque area measurements are shown in 
Table 1. If the mean arithmetic difference is not equal to zero, this indicates systematic 
measurement errors (bias) between or within sonographers. The mean absolute difference 
represents the typical magnitude of this bias.
74
 The arithmetic differences between paired 
observations were plotted against their average to examine whether differences were constant 
over the range of measurements (Bland Altman plots), and no systematic errors were detected.
51
 
In the case of normally distributed differences, 95% of the differences will be found within a 
range of ±1.96 SDs of the mean arithmetic difference (limits of agreement). 
 
Table 1. Inter-observer and intra-observer variability of pairwise plaque area (mm
2







 surveys of the Tromsø Study. 
  Mean 
(SD) 
 Mean arithmetic 
difference 
(95% CI) 
 Mean absolute 
difference (SD) 
 Limits of 
agreement 
Inter-observer         
Tromsø 4/5*  13.9 (9.0)  -1.0 (-1.4, -0.6)  2.9 (3.4)  ± 8.6 
Tromsø 6
± 
 24.6 (15.0)  -0.8 (-0.01, 0.04)  6.1 (5.5)  ±16.0 
         
Intra-observer         
Tromsø 4/5, observer 1*  13.4 (7.9)  0.2 (-0.2, 0.7)  1.8 (2.5)  ± 6.1 
Tromsø 4/5, observer 2*  13.8 (8.3)  0.0 (-0.5, 0.6)  2.1 (3.2)  ± 7.5 
Tromsø 6
±
  23.8 (12.7)  9.6 (-2.6, 5.3)  6.7 (7.0)  ± 18.9 
*Single plaque measurements. 
± 
Total plaque area. Reproduced with permission from M. Herder.
51
 




 and the 6
th
 surveys, and non-
standardized uptake angles is likely to have increased the measurement error between surveys. 
The inter-equipment variability between GE Vivid 7 and Acuson XP10 was tested in 79 subjects, 
of whom 38 had ≥1 plaques. All subjects were examined with Acuson XP10 first. To minimize 
the influence of sonographer and reader variability, all examinations were performed by the 
same sonographer. Readings of TPA were done by another person, blinded to the identity of the 
participants. For TPA, the mean absolute difference was 6.5 mm
2
 and the mean arithmetic 
difference 2.4 mm
2
 (95% CI, −0.5, 5.4), indicating no systematic differences between machines. 
The coefficient of variation was 26.4% and the correlation coefficient 0.89. In the analyses, we 




(95% CI, −0.06, 0.50), the mean absolute difference 0.68, the coefficient of variation 13.2%, and 
limits of agreement ±1.7.
31
 
In Paper I, the impact of imprecision in measurements on plaque progression is partly diminished 
by the large sample size. In Paper II, we defined three categories of plaque; TPA below and 
above the median, while subjects with no plaque constituted the reference category. We aimed to 
reduce the effect of measurement errors related to change of equipment and sonographers by 
defining TPA medians separately at each survey for men and women. In order to decrease the 
impact of imprecision in the plaque measurements on our estimates in Paper III, we used the 
mean absolute difference between two observers as a measure of the typical magnitude of the 
measurement error in observations. Accordingly, stable plaque was defined as change in TPA of 




 To reduce the risk of misclassification in the plaque progression 





 surveys was 38.6 mm
2 
(range 29.8, 124.5) in the plaque progression 
group, and 0.30 mm
2  (range -2.86, 2.87) in the stable plaque group. Other choice of cutoffs 
would probably have affected the risk estimates. The ideal situation would have been to assess 
the associations between circulating biomarkers and change in TPA in all participants of both 
Tromsø 4 and 5, but this was not possible due to limited resources. 
A limitation of our study is that our ultrasound protocol only included examination of the right 
carotid artery, whereas plaques in the left carotid artery were not acknowledged. Previous studies 
have reported on the symmetry in distribution and composition of carotid plaques.
107, 108
 Total 
wall volumes of the left and right carotid arteries were found to correlate with concordance 
correlation coefficient of 0.71.
108
 Although most individuals had bilateral carotid disease, 
unilateral plaque was more often found to be located in the left carotid artery, and left-sided 
plaques were thicker than plaques on the contralateral side.
107 
In the conduct of the study, the reproducibility of the ultrasound measures could possibly have 
been improved by the use of standardized uptake angles, more intensive training, and use of 
fewer sonographers. However, the latter was hard to achieve due to large examination volumes 






Clinical endpoint ascertainment 
To ensure accurate classification of endpoints IS and MI in Paper III, several steps were taken 
(details outlined in section 3.5). The loss to follow-up was negligible due to usage of the unique 
personal identity number to search official health registries. One single hospital provides all 
hospital care in the region, which facilitates the completeness of our outcome registries. 
Nonetheless, some IS and MI remained undoubtedly unidentified. Case identification was 
retrospective, and some non-hospitalized, non-fatal cases may not have been identified.  Reasons 
for this are typically sparse or atypical symptomatology or old age leading to non-referral and 
non-detection. Improvements in radiological imaging and implementation of CT and MRI 
modalities may have increased sensitivity in detection of small ischemic lesions during the 
course of the study. Our definition of IS was based on clinical symptoms and exclusion of 
hemorrhage. However, improved treatment options leading to more rigorous case seeking 
behavior among clinicians with lower threshold for referral and increased public awareness, may 
have led to higher detection rates at the end compared to the beginning of the study. Regarding 
MI, the biomarkers used for diagnoses changed during the course of the study and from year 
2000 troponins, which are more sensitive, were included and enabled the detection of smaller 
amounts of cardiac necrosis.
76
 Women tend to have more atypical symptoms and a higher 
prevalence of unrecognized silent MIs.
109
 An increased awareness of heart disease in general, 
and in women particularly, in recent years may have led to a higher detection rate at the end of 
the study.
110
 The outcome identification biases described above are suspected to be non-
differential and may have attenuated the association estimates. 
 Confounding and interaction 5.1.2.3
A confounding variable (confounder) is a factor, which distorts the true association between 
exposure and outcome, as it may influence both the magnitude and direction of the association. 
The confounding variable is associated with both the outcome and the exposure, but not affected 
by either the exposure or outcome. It accounts for some of the observed association between the 
exposure and outcome.
92
 The TRFs, i.e. age, smoking, total cholesterol, HDL-C, systolic blood 
pressure, diabetes, BMI, and use of antihypertensive drugs
 
and lipid lowering drugs, were 
considered potential confounders as previous research have indicated an association with CVD, 
atherosclerotic disease,
31, 41, 111, 112
 and inflammatory markers.
26, 27
 In our papers, levels of these 
TRFs varied across CRP categories (Paper I), plaque categories (Paper III) and in subjects with 




confounders. A confounder can be statistically adjusted for by including it in a multivariable 
analysis together with the exposure variable under study. The idea behind adjustment, is to use a 
statistical model to estimate what the association between exposure and outcome would be at a 
constant level of the suspected confounding variables. Whether a TRF acts as a confounder may 
be evaluated by different strategies. The “significance test of the covariate” strategy relies on the 
confounder being revealed by the significance level of each TRF’s respective regression 
coefficient in multivariate analyses.
92
 However, this method may be inaccurate because the p-
value of the covariate is solely a reflection of the association between the confounder and the 
outcome. More commonly used is the “change-in-estimate” strategy, in which confounders are 
defined as variables that alter the unadjusted exposure-outcome effect by a certain percentage. A 
cut-off of 10% is regularly cited in the literature.
90
 This strategy has been claimed to be more 
accurate as it accounts for both covariate-outcome and covariate-exposure association. In Paper 
I, we evaluated the impact each TRF had on the association between CRP and carotid 
atherosclerosis, by singly including each TRF in the age-adjusted models and observing the 
change in regression coefficients. In Paper II, we evaluated CRP as a confounder in the 
association between carotid TPA and CVD events (IS and MI).  
In general, a potential confounder should not be an intermediate step in the causal pathway 
between the suspected risk factor and the outcome. It is considered inappropriate to adjust for an 
intermediate cause or a mechanistic link. Exceptions to this rule occur when the investigator 
intentionally explores alternative mechanisms that could explain the association between the 
exposure and outcome of interest.
92
 If CRP and atherosclerosis represent intermediate steps in 
the pathway between TRFs and clinical CVD events, it would not be suitable to adjust for CRP 
or atherosclerosis when examining the association between smoking and MI. On the other hand, 
if smoking influences both CRP level and risk for MI, smoking should be adjusted for when 
examining the association between CRP and MI. Independent of their status as potential 
confounders, adjustment for TRFs is grounded when the research question is: “Do novel 
biomarkers add incremental value to prediction of plaque formation and progression beyond 
information obtained from TRFs?” Nevertheless, if a residual association between inflammatory 
markers and atherosclerosis progression exists after adjustment for TRFs, this does not 
necessarily mean that a true association or a causal pathway exists. Residual confounding may 
explain the association. Controlling for imperfectly measured blood pressure or an incorrectly 




addition, unknown confounders that have not been accounted for may be present (e.g., other 
inflammatory markers) and some known potential confounders may not have been included in 
the analyses due to missing information (e.g., periodontitis, previous infections) or uncertainty 
related to these data (e.g., alcohol consumption and physical activity). In addition, any observed 
observation may occur merely by chance. 
Whether to adjust for pre-baseline CVD was considered for Paper I and III. The risk of CVD is 
greater in individuals with a history of previous CVD, and plaques in the carotid artery serves as 
a surrogate endpoint of CVD. Over-adjustment may occur when adjustment is unintentionally 
carried out for a variable that is in the causal pathway between the exposure and outcome, or so 
strongly related to either the exposure or the outcome that the true relationship is distorted.  
Over-adjustment may occur when different variables representing overlapping constructs are 
simultaneously adjusted for, and their collinearity would cause the corresponding regression 
coefficients to be meaningless. Diastolic blood pressure was highly inter-correlated (Pearsons 
r=0.77) with systolic blood pressure and therefore not included in analyses due to issues of 
multicollinearity. Over-adjustment can obscure a true effect or create an apparent effect when 
none exists.
92
 Instead of adjusting for CVD, we assessed the effect of inflammatory markers on 
plaque development separately in subjects without former CVD in sensitivity analyses (Paper 
III). This implicates that the effects of biomarkers are assessed in a primary prevention setting. 
The population under study may be stratified according to certain risk factors to examine 
interaction (effect modification), i.e., whether the exposure variable has varying effects at 
different levels of another variable. By stratifying according to sex, we could examine whether 
the effect of CRP on plaque development or CVD events was different in men and women 
(Paper I+II). In Paper II, we examined whether CRP predicted IS and MI differently in the 
presence and absence of plaque. If interaction is present, crude risk estimates differ between 
strata. We also assessed the interaction by adding an interaction term to the model (CRP x TPA). 
In comparison with stratified analysis, assessing interaction by the use of interaction-terms in 
multivariable-adjusted models, increase the statistical efficiency and also allows for evaluation 
of interaction between continuous variables.
92
  
Several studies indicate that the joint presence of several novel biomarkers increase the 
predictive value in assessment of cardiovascular risk (“multimarker approach”).
85
 A combination 




of single tests alone.
113
 This strategy is already in use when examining the presence of multiple 
TRFs.
92
 The within-individual variability in level of inflammatory markers may at least partially 
be rectified by combining more than one inflammatory index for prediction. In this regard, 
additive interaction is of interest. It is difficult to evaluate additive interaction in regression 
analyses, but stratified analyses can be done to evaluate this. In Paper II, we assessed the additive 
interaction of TPA and CRP on risk of IS and MI. In Paper III, we assessed whether 
simultaneously raised levels of multiple circulating biomarkers, which were individually 
associated with plaque progression, altered the OR for being in the plaque progression group.  
 Temporal changes in variables 5.1.3
In cohorts with long follow-up, temporary fluctuations in modifiable risk factors (CRP, TPA and 
TRFs) over time may result in underestimation of the true association between exposure and 
outcome (regression dilution bias).
114
 An approach to minimize the impact of such bias is to 
perform analyses with time-varying covariates, and such methods were applied in Papers I and 
II. In Paper II, the first time-point that a participant could enter the study was in 1994, and they 
were followed for a maximum of 19 years until end of follow-up December 31, 2013. In the 
Tromsø Study, information on how risk factors change within an individual during the course of 
the study is often available due to multiple measurements on the same individual at different 
surveys. Therefore, we chose to update risk factor information in analyses. For instance, the 
prevalence of smokers decreased dramatically during the course of the study. In a time-fixed 
model, using only information from the time of study entrance, those who stopped smoking 
during follow-up would be misclassified as smokers during the remaining follow-up. If these 
subjects due to smoking cessation in fact had a lower risk of MI, the association between 
smoking and MI would be diluted.
115
 
In Paper III, we used risk factors measured at baseline as exposure variables because the aim was 
to explore the predictive ability of these markers. Repeated biomarker samplings could have 
enabled monitoring the change in biomarker level over time in relation to outcome. A more 
frequent assessment of risk factors in general may have reduced measurement errors and 
reflected true exposure levels over time.
51
  
When modeling associations of change in a continuous variable, such as TPA, which has been 
measured on several occasions, the phenomenon of regression to the mean should be considered. 




subsequent measurements. This variation may be caused by random measurement error or 
random fluctuations in a subject, and represents an alternative explanation for change-scores in 
non-randomized studies such as cohort studies. Within an individual, extreme values are likely to 
be followed by less extreme values, closer to the subjects’ true mean. Within groups, regression 
to the mean is important to recognize especially, when comparisons are done in groups that are 
categorized on the basis of initial values.
116
 Many authors recommend adjustment for baseline 
values in all prospective studies of change to avoid the effect of any random differences in the 
initial levels across the groups that are being compared.
116
 However, inclusion of the measured 
baseline as a covariate can also result in biased estimates, exacerbated by measurement error.
79
 
In Paper I, measured baseline TPA was not included when modeling TPA progression. In the 
linear mixed model, the cross-sectional and prospective associations between exposures and 
TPA were jointly modeled. Baseline TPA was accounted for by the cross-sectional term, 
estimating the baseline TPA using both fixed and random effects. Adjusting for an estimated 
baseline, allows us to control for cross-sectional confounding without inducing bias.
79
  
 Missing data 5.1.4
Missing data occurs in nearly all epidemiological studies. There are several reasons for this, 
including inadequate response to questionnaires, equipment failure, and loss or errors in 
laboratory handling of samples. Three categories of missing mechanisms have been proposed; i) 
missing completely at random, where the probability of missingness is unrelated to both 
observed and unobserved data, ii) missing at random, where the probability of missingness is 
conditional on the observed data, and iii) missing not at random, where the probability of 
missing depends on unobserved data.
89
  
In Paper I, we used complete case analyses, losing 224 individuals (3.3%) of the original Tromsø 
4 population due to missing values in one or more variables. Complete case analyses assume that 
data is missing completely at random. As the percentage of individuals with missing data was 
small, we believe that their exclusion does not influence the results substantially. In Paper II, we 
carried forward observations when applicable. This allowed us to include observations from 
subjects who had missing data for one or more variables in subsequent surveys if they had 
observations for these variables in a previous survey.  
In Paper III, there were up to 11% of participants who had missing information for one or more 




loss or errors in laboratory handling of samples, we did not suspect this to bias the study sample. 
The subjects with missing values were similar to subjects with complete values on all 
observations with regard to relevant exposure and outcome measures. However, we performed 
multiple imputation to gain more power in the statistical analyses. In the regression model, 
where all biomarkers which significantly differed across plaque groups were included together, 
the percentage of missing values was greatest (15%). Thus, we assumed data to be missing at 
random, and used observed data to impute 20 data sets. 
 Statistical considerations 5.1.5
We aimed to utilize all acquired longitudinal data, including repeated measurements on the same 
individuals by updating values of exposure, outcome and confounding variables in the case of 
subsequent study attendance. However, when data are collected multiple times from the same 
individual, these observations are not independent of each other and this must be accounted for 
in the analyses.
77
 In this regard, generalized estimating equations and linear mixed models are 
applicable statistical techniques. (Paper I)  
In Paper II, we chose to use age as time scale in Cox models with time varying covariates. Time-
on-study as time scale may introduce bias if the covariates included are associated with age and 
especially in the setting of time-varying covariates.
80
 When age is used as time-scale, the risk of 
outcome is compared between subjects at the same age, instead of the same follow-up time, 
ensuring a more effective adjustment for age.
80
 
Sensitivity analyses may be used to obtain a range of “corrected estimates” under different 
assumptions about the levels of misclassification.
92
 CRP rises in cases of acute infections and 
inflammation. In Paper I, we aimed to ensure that our results were not confounded by former 
history of CVD and temporary acute inflammation. Therefore, we repeated the analyses with 
exclusion of subjects with self-reported former CVD (n=545) and observations of CRP >10 
mg/L (n=668). Prospective analyses with TPA as outcome measure were also repeated including 
only subjects with prevalent plaque at baseline. To evaluate associations between CRP and TPA 
progression in subjects where change could truly be evaluated, analyses were also rerun only on 




In Paper II, sensitivity analyses were performed by regular Cox models with time-fixed 
covariates, using values of exposure and confounder information at time of study entrance, and 
each individual contributing data only once. 
In Paper III, analyses were carried out for the whole study sample, and separately for subjects 
without former history of CVD to assess the predictive value of biomarkers in a primary 
prevention setting. In addition, complete case analyses were compared to results from imputed 
data sets.  
With a retention p-value of 0.05, there is a 5% probability of making type I errors (detecting 
false positive associations). When the number of statistical tests performed simultaneously is 
increased, the chance of type I error will increase. Various methods are used to correct 
hypothesis-testing procedures under these circumstances. The popular Bonferroni correction is 
based on the concept of familywise error rate, which is the probability of making one or more 
type I errors in all the hypotheses tests conducted. The retention p-value is down-regulated 
accordingly for each conducted hypothesis test. For example, if 1000 proteins were to be tested, 
we would test each protein at a significance level of 0.00005. This is a conservative method with 
the cost of a loss in statistical power, which may lead to missed findings. False-discovery rate 
(FDR) methods, which control the proportion of events reported as significant that are actually 
false positives, is probably a more appropriate method to correct for multiple testing. While the 
Bonferroni false positive rate of 0.05 means that 5% of all results will be truly negative, the FDR 
value of 0.05 means that 5% of declared positive results are truly negative. If many p-values fall 
into the range where the null hypothesis of no association should be rejected, the FDR is much 
less conservative.
83
 It thus adjusts for the actual p-value distribution of the data, and balances 
type II (cases for which the null hypotheses is false, but our decision rule does not yield a 
significant result) vs. type I error. The risk of type II error increases with the number of variables 




Novel risk markers should be evaluated, not only on their individual predictive abilities, but also 
on the predictive value added beyond established predictors. Difference in the area under the 
receiver operating characteristic curve (AUC) is a common method to compare two models. 
AUC summarizes how well the model separates subjects who did and did not experience an 




costs (false positive or 1-specificity). AUC is calculated by comparing the estimated probability 
of all possible pairs in a dataset between individuals experiencing an event and those not 
experiencing an event. If the individual experiencing an event has a higher predicted probability, 
that pair would be labeled ‘concordant’ and assigned a value of 1. Conversely, if the individual 
experiencing an event has a lower probability, the pair would be labeled ‘discordant’ and 
assigned a value of 0. AUC or C-statistic will be the average of all pairs and ranges from 0.5 (no 
discrimination) to 1 (perfect discrimination).
68
 Measures of discrimination such as the C-statistic, 
are not able to detect small improvements in model performance, if a marker is added to a model 
that already includes important predictors. NRI quantifies to which extent a model which 
includes the new predictor, improves the classification in clinically meaningful predefined risk 
categories for participants with and without the outcome, compared to the baseline model with 
established predictors.
68
 NRI is the sum of NRI for cases plus NRI for non-cases. NRI for cases 
is the percentage of cases correctly classified upwards minus the percentage of cases erroneously 
classified downward by the new model, compared to the baseline model. NRI for non-cases is 
the percentage of non-cases correctly classified downwards minus the percentage of non-cases 
erroneously classified upwards by the new model.
68
 Definitions of these risk categories are 
however arbitrary and differs across studies complicating comparisons. To circumvent this 
problem, the category-free continuous NRI or IDI may be evaluated. IDI does not require 
predefined risk thresholds. IDI represents the estimated improvement in the average sensitivity, 
minus estimated decrease in average specificity summarized over all possible thresholds of the 
model with the added predictor, compared to the baseline model. The absolute IDI depends on 




5.2 External validity 
External validity refers to the ability to generalize results from our study to other populations. 
Ensuring internal validity is necessary for external validity. Random errors have less impact in 
large samples. Misclassification of exposure variables in longitudinal studies is usually not a 
substantial problem, since they will be non-differential and will in general underestimate the true 
association.
92
 The Norwegian Population Registry was the source for the invitations to the 
Tromsø Study. The age and sex distribution and risk factor levels in the Tromsø Study is not 
substantially different from the Norwegian population, and comparable to other Western 




Tromsø population consists mainly of Caucasians and extrapolation to populations of other 
ethnicities may be limited. Hence, our findings should be applicable to similar middle-aged 
European populations.   
5.3 Ethical considerations 
In the information brochure given to individuals upon invitation, the dual aim of the Tromsø 
Study is presented (Appendix 1). On the individual level, the aim is to identify individuals who 
either suffer from CVD or are at high risk of developing CVD without knowing it. Identification 
of these individuals is important in order to initiate appropriate preventive treatment strategies. 
On the public research level, the aim is to gain new knowledge about the occurrence of diseases 
(cardiovascular, cancer etc.), the risk factors for diseases and how these diseases can be 
prevented.  
Chapter 8 in The Norwegian Health Research Act deals with transparency and the right of access 
to research. It states that “research participants have the right of access to person- identifiable 
and pseudonym personal health data about themselves. The data, that access is granted to, must 
be presented in a way that is adapted to the capabilities and the needs of the individual”.
117
 If 
consented to, information about certain selected individual results in the Tromsø Study were 
passed on to the general practitioner for further follow-up. These results included blood pressure, 
height, weight, HDL-C, and total cholesterol. Lifestyle cohort research studies are “non-
interventional”. The sample has been randomly selected to be representative for the population 
under study. However, with the feedback of individual findings, the sample may receive a more 
aggressive preventive approach with respect to lifestyle and medications because of being part of 
the study, more than what is expected for the general population. This may introduce bias and 
jeopardize the validity of the study. Observer bias (interviewer bias) is introduced if the 
interviewer treats cases and controls differently, and this could result in differential 
misclassification. This problem has been addressed in the Tromsø Study in general, by having 
trained test personnel that are not directly involved in the research and therefore not biased by 
scientific hypotheses in their measurements. Standard protocols and standard informational 
procedures contribute to minimizing errors. The test personnel were masked to the ultrasound 
findings in previous surveys. However, when study participants were informed about the 
presence of plaques in the their carotid artery, this might have increased their motivation for 
lifestyle changes and influenced the initiation of preventive treatments,
118, 119
 introducing biased 




In longitudinal studies, researchers must balance the crucial need to maintain a representative 
sample population with the responsibility to offer health advice. Also, the feedback of results 
may raise unnecessary health concerns among the participants. When considered to be ethically 
tenable, bias related to influencing on the cohort’s health development may partly be prevented 





5.4 Discussion of main results 
 C-reactive protein in atherosclerosis - A risk marker but not a causal factor?  5.4.1
In Paper I, we report cross-sectional associations between CRP and prevalent plaque and 
between CRP and TPA, which were stronger in men than in women and independent of TRFs. In 
prospective analyses, age-adjusted baseline CRP predicted TPA progression and novel plaque 
formation in men, but not in women. When adjusted for TRFs, baseline CRP did not predict 
novel plaque formation nor TPA progression in neither men nor women.  
The role of CRP in atherosclerosis has been debated continuously during the last decades. Is it a 
causal factor or an epiphenomenon to the atherosclerotic process? CRP has shown ability to 
predict CVD in a meta-analysis comprising individual participant records from 54 long-term 
prospective studies.
27
 In small case-control trials, CRP was associated with the presence of 
carotid artery stenosis.
120, 121
 CRP was also cross-sectionally associated with IMT in a meta-
analysis of individual participant data from 20 prospective cohort studies (PROG-IMT) 
involving 49 097 participants free of pre-existing CVD.
122
 Our research group has previously 
reported a cross-sectional relationship between CRP and TPA in men,
123
 but not all studies have 
confirmed an independent cross-sectional association between CRP and carotid plaque.
124, 125
 
The strength and consistency of cross-sectional associations differed somewhat between the 
statistical models applied in our study. While CRP levels have shown a dose–response 
relationship to CVD risk independently of TRFs in prospective studies, the data on associations 
with extent of carotid atherosclerosis are inconclusive.
38
 Schulze Horn et al.
126
 found an 
association between CRP and IMT in 3092 middle-aged participants. However, CRP was 
associated with IMT to the same degree as to more advanced stages of atherosclerosis, indicating 




In our study, the association between CRP and carotid atherosclerosis was weaker in women 
than in men. The association between baseline CRP and TPA in women was attenuated to non-
significant upon adjustment for TRFs. Except for a cross-sectional study on the Framingham 
offspring,
127
 most other studies support our findings and report a stronger association between 
subclinical carotid atherosclerosis and CRP in men.
123, 128-130
 On average, women experience 
their first CVD event (MI or stroke) 7-10 years later in life than men, and a protective effect of 






 Previous work from our research group and others, have also documented 
a lower prevalence of carotid plaque in women than in men at the same age.
31, 133
 The male-to-
female ratio in plaque prevalence peaks at age 45-49 years and then declines steadily.
69
 A sex 
difference in plaque morphology has also been reported with men having a higher proportion of 
echolucent plaques than women throughout life.
69, 134
 Echolucent plaques are associated with 
higher intraplaque inflammation. Calcification and inflammation may represent distinct 
processes within the atherosclerotic plaque, and calcification is associated with stable 
asymptomatic carotid disease.
135
 Anti-inflammatory effects of female sex-hormones may shift 
the atherosclerotic process in females towards a less inflammatory, more calcifying and slower 
progressive development, which in turn may explain the less prominent association between 
CRP and plaque in women.  
A few other population-based studies have reported on the prospective association between CRP 
and subclinical atherosclerosis.
122, 125, 136, 137
 Some have found baseline CRP to predict 
progressive atherosclerotic disease defined as increase in plaque score and progression of 
stenosis.
136, 138, 139
 In a study of 486 subjects, of whom 72% were 65 years or older, CRP was an 
independent predictor of new carotid plaques within three years.
125
 The Austrian Stroke 
Prevention Study demonstrated a significant relationship between baseline CRP and baseline 
carotid atherosclerosis, as well as progression of atherosclerosis during the observational period 
of 6 years.
137
 However, CRP did not predict progression of IMT in the PROG-IMT meta-
analysis.
122
 Our study did not confirm the temporality criterion of a causal relationship, as high 
levels of CRP did not independently predict plaque formation and progression. Differences in 
time span, exposure level, study design, analytic strategies and publication bias may have 
threatened the consistency of published results. 
Whether CRP reflects a response to TRFs or rise secondarily due to inflammatory processes 
within the atherosclerotic plaque is not clear. CRP is linked to abdominal obesity, insulin 
resistance, diabetes mellitus, hypercholesterolemia, and cigarette smoking.
27, 67, 140
 Abdominal 
adipocytes produce inflammatory cytokines, including IL-6, which is a potent messenger for 
CRP secretion in the liver.
140
 Results from the Multi-Ethnic Study of Atherosclerosis indicated 
that in the absence of obesity, CRP was not associated with coronary calcium and only weakly 
associated with IMT, whereas obesity was related to both imaging outcomes,
141




complex interplay between metabolic disorders, inflammation and serum lipids in atheroma 
formation.  
Serum levels of CRP have been associated with vulnerable plaque features detected by MRI
142
, 
but not plaque inflammation assessed by FDG-PET
143, 144
 or immune pathological analysis.
145
 In 
addition, results regarding its associations to unstable plaque features such as echogenicity are 
diverging.
120, 123
 Although CRP is associated with prevalent atherosclerosis beyond TRFs, these 
associations are weak and inconsistent. Other circulating inflammatory markers may better 
reflect the inflammatory process within the plaque, and thereby show higher sensitivity and 
specificity for the detection and monitoring of inflammatory atherosclerotic disease.
21, 37, 146
 
Evidence drawn from experimental manipulation, particularly RCTs in which disease risk 
declines following an intervention or cessation of exposure, is the strongest support for causal 
inference. Data suggest that cardiovascular preventive medication, such as lipid lowering agents, 
angiotensin converting enzyme inhibitors, angiotensin receptor blockers, antidiabetic agents, 
anti-inflammatory and antiplatelet agents and beta-adrenoreceptor antagonists, lower serum 
levels of CRP.
147
 Treatment with statins reduces both low-density lipoprotein cholesterol and 
CRP levels. Reduction of CRP by statins is proposed to contribute to additional CVD risk 
reduction benefit beyond that obtained from cholesterol lowering.
41
 However, in the Heart 
Protection Study of 20 536 participants randomized to simvastatin 40 mg vs. placebo, baseline 
CRP levels did not predict benefit of therapy, and there was clear evidence of benefit in subjects 
with both low LDL and low CRP at baseline.
148
 In the Anglo-Scandinavian Cardiac Outcomes 
Trial (ASCOT), CRP did not predict outcome in relation to statin treatment.
149
 Mendelian 
randomization studies both in the Copenhagen study,
150
 and in a combined study of 194 418 
participants, including 46 557 patients with prevalent or incident coronary heart disease,
151
 
concluded that CRP gene variants associated with increased CRP levels did not lead to increased 
risk of ischemic atherosclerotic disease. When using anti-sense oligonucleotide targeted to CRP 
production and pharmaceutical grade CRP infusions, no upstream effects on systemic 
inflammation were observed in direct response to alterations in CRP production.
146
 In addition, 




All in all, our results and the current body of evidence do not support a causal role for CRP in the 




mechanisms. Thus, our findings indicate that CRP may be considered as a risk marker, a 
potential tool to identify subjects with prevalent atherosclerosis, but questions its role as a 
therapeutic target in haltering progressive atherosclerotic disease. 
 
 Joint effect of carotid plaque and CRP in determination of CVD risk. 5.4.2
In Paper II, we found that both elevated serum levels of CRP >3 mg/L and carotid total plaque 
were individually associated with increased risk of IS and MI. For plaque area, the RR estimates 
in our study were stronger for women than men, concordant with previous findings from the 
Tromsø Study suggesting that assessment of carotid plaque may be a more important tool for risk 
stratification of women than men.
154
 CRP is evidently linked to increased risk of CVD, yet the 
underlying mechanisms behind these associations are not fully understood. As discussed in Paper 
I, it has been suggested that inflammatory active and rupture-prone plaques may themselves be a 
source of CRP.
140
 However, as CRP only minimally attenuated the risk in individuals with 
prevalent plaque, our results suggest that CRP and prevalent plaque do not represent the same 
underlying risk factor,  i.e. unstable atherosclerotic plaques,  in relation to clinical outcomes.  
Novel biomarkers that may improve the identification of subjects at risk and guide preventive 
treatment are long awaited. Assessment of carotid plaque has been proposed as a risk modifier in 
subjects classified to be at intermediate risk by TRFs.
155
 NRIs added by plaque-measures in 
CVD risk prediction have previously been reported by the Multi-Ethnic Study of Atherosclerosis 
(MESA), Atherosclerosis Risk in Communities Study (ARIC) and Three City Study, ranging 
from 7.7-13.1% for the whole population and approximately 20% for the intermediate risk 
groups
156-159
 concurring with our findings. Some of these studies included IMT in addition to 
plaque measures and the studies differed somewhat in plaque assessment methods as well as 
definition of outcomes. Plaque in the carotid artery may be considered an end organ 
manifestation of genetic and environmental risk factors that serves as a proxy of generalized 
atherosclerosis, calling for more aggressive risk factor management. Whether carotid ultrasound 
assessment leads to treatment decisions, which improves outcomes and justifies the cost-
effectiveness of screening is not clarified. The most recent European Guidelines on CVD 
prevention recommend that atherosclerotic plaque detection by carotid artery scanning may be 
considered as a risk modifier in CVD risk assessment for individuals with calculated CVD risks 
around the decisional thresholds for medical intervention based on the major TRFs. However, it 
is suggested that less than 10% of the population who test positive for atherosclerosis will 
experience a near-term event.
67




disease activity is therefore essential to improve the selection of vulnerable patients and cost-
effectiveness of screening with carotid ultrasound in the primary prevention setting.  
CRP is the most extensively studied circulating biomarker in relation to CVD. In a large meta-
analysis of individual participant data (n= 246 669), addition of CRP to TRFs yielded a modest 
significant improvement in C-index by 0.0039 (p <0.001),  and NRI of 1.52%.
160
 For subjects 
classified to be at  intermediate risk by TRFs, incorporation of CRP in the risk assessment model 
resulted in 5.2% being reclassified to a higher risk category, thus eligible for statin therapy. 
Adhering to current CVD prevention guidelines, this could potentially prevent one additional 
CVD event in 10 years from 400-500 subjects screened.
160
 Controversy about the usefulness and 
prognostic value of CRP in CVD prediction still remains.
161, 162
  
Few studies have explored whether CRPs ability to predict CVD is dependent on the presence of 
atherosclerosis.
48, 163-165
 Experimental studies have indicated that CRP may initiate mechanisms 
involved in plaque rupture and thrombus formation.
166, 167
 Transgenic mice that express human 
CRP demonstrate accelerated thrombosis after arterial injury, compared to non-transgenic 
control mice,
168
 and administration of CRP to human beings activates the blood coagulation 
system.
169
 These observations suggest that CRP increases the risk of CVD by activating the 
blood coagulation system, rather than by promoting atherosclerotic plaque progression. Thus, an 
interaction between higher serum levels of CRP and inflammatory active plaques may increase 
the risk of thromboembolic complications, and explain the attributable risk of CRP in CVD.
170
 
The joint presence of elevated CRP and plaques >TPA median was associated with the highest 
risks of both IS and MI, but synergistic effects were evident for IS only. This concurs with 
results from the Cardiovascular Health Study, where Cao and colleagues simultaneously 
measured carotid intima-media thickness, plaque characteristics, and CRP, and found that all 
three parameters independently predicted 12-year incidence of CVD events and mortality in 
5888 elderly participants.
163
 Elevated CRP was a particularly useful predictor in the presence of 
subclinical atherosclerosis with a 72% increase in risk for CVD and 52% increase in total 
mortality. By contrast, CRP did not add predictive power in the absence of carotid 
atherosclerosis. Cumulative event rates suggested a possible additive interaction for composite 
CVD and all-cause mortality with an excess risk attributable to the interaction of CRP and 
subclinical atherosclerosis of 54% for CVD death and 79% for all-cause mortality. Additive 
effects of CRP and extent of coronary artery disease on risk for future MI in angina patients have 
also been reported.
48




were associated with CVD events with a similar magnitude in the presence and absence of 
atherosclerosis, and the researchers concluded that the presence of atherosclerosis assessed by 
IMT and plaque did not influence the association between biomarkers and CVD.
164
 However, 
additive interaction of these measures was not assessed in that study.
164
 The significance of CRP 
as a risk marker may in addition differ according to plaque subtype and vulnerability, non-





 concluded that elevated CRP is a predictor of adverse cardiovascular events in 
asymptomatic self-referred middle-aged Korean patients with non-calcified coronary plaques, 
but not in patients with calcified or mixed plaques on coronary CT scan. In that population, the 
highest event rate was found in patients with non-calcified plaques and hsCRP >3 mg/L.
165
 
Regression dilution bias due to intra-individual changes in CRP and plaque status may play a 
role in prospective studies with long follow-up and may have led to bias towards the null. To our 
knowledge, no previous studies have assessed these additive effects using time-varying exposure 
variables.  
As Mendelian randomization studies and animal studies have not supported a causal role of CRP 
in CVD, it may be more likely that CRP is a non-specific marker of inflammation that rises 
secondarily to up-stream processes more, directly linked to the pathogenesis of CVD.
146
 
However, a limitation of Mendelian randomization studies is that the power to detect meaningful 
gene–environment interaction is low.
172
 To our knowledge, it has not been tested whether gene 
polymorphisms associated with increased serum levels of CRP may have different effects in 
determining CVD events in the presence and absence of atherosclerosis. 
CRP is closely correlated with diabetes mellitus, hypercholesterolemia, and cigarette smoking.
27, 
67, 140
 These are all conditions that lead to a pro-thrombotic state.
67
 CRP has been found to inhibit 
release of plasminogen activator inhibitor (PAI-1) from vascular ECs,
173, 174
 and induce tissue 
factor expression by monocytes
175
 and SMCs in vitro,
176
 thereby shifting the fibrinolytic balance 
to promote intravascular fibrin formation. CRP is mainly found as a circulating pentamer in the 
circulation. When CRP binds to one of its ligands, for instance in a denaturizing oxidative 
environment, it dissociates in a non-reversible manner to non-soluble monomers (mCRP). 
Recent research suggests mCRP to be an effector; a potential regulator of signaling pathways 
associated with thrombosis, angiogenesis and inflammation, whereas pentameric CRP acts as a 
facilitator.
177
 Thus, further knowledge about the binding ligands which lead to dissociation and 




Simultaneous assessment of carotid atherosclerosis and CRP led to minimal, but significant 
improvements in risk prediction judged by C-index and categorical NRI. TRFs have well-known 
limitations for accurate assessment of individual cardiovascular risk.
67, 178
 Thus, our results 
suggest that the combined assessment of subclinical atherosclerosis and CRP may improve CVD 
risk stratification. 
 Interleukin-6 is a predictor of plaque progression 5.4.3
In Paper III, we reported IL-6 as an independent predictor of plaque progression. MPO and 
caspase-1 were independent predictors of plaque progression, but these effects disappeared when 
excluding subjects with former CVD, suggesting an association to more advanced stages of 
atherosclerosis. Neopterin was found to be protective of novel plaque formation (OR 0.73, 95% 
CI 0.57, 0.93).   
IL-6 is a master pro-inflammatory cytokine. It is produced by different cell types, including 
activated monocytes, macrophages, endothelial cells, adipocytes and TH2-cells, upon induction 
by vasoactive peptides, ROS and other cytokines. IL-6 amplifies the inflammatory cascade by 
stimulating hepatic synthesis of acute phase reactants, such as CRP and fibrinogen and is also a 
pro-coagulant cytokine.
179
 IL-6 has a variety of other functions, including activation of 
endothelial cells, activation of the hypothalamic-pituitary-adrenal axis, oxidation of lipoproteins 
and promotion of lymphocyte proliferation and differentiation.
30
 IL-6 has shown ability to 
predict cardiovascular events in more than 25 prospective epidemiological cohort studies. 
According to a meta-analysis performed by the Emerging Risk Factors Collaboration, 1 SD 
increase in log transformed IL-6 yielded a 25% increased risk of future CVD events.
26
 IL-6 was 
associated to IMT in a meta-analysis of 14 832 participants
180
 and to severity of coronary artery 
calcium score in another study.
181





 in high risk populations. Compared to CRP, evidence more 
uniformly suggests a causal role of IL-6 in atherosclerosis. In murine experiments, exogenous 
administrated IL-6 enhanced the development of fatty streaks,
184
 and lifetime IL-6 deficiency 
was associated with enhanced atherosclerotic plaque formation.
185
 Mendelian randomization 
studies also suggest that IL-6 signaling pathways play a causal role in CVD. In two meta-
analyses of polymorphism in the IL-6 signaling pathways, individuals with a variant in the IL-6 
receptor that impairs IL-6 signaling had lower levels of CRP as well as a decreased risk for 
coronary heart disease.
186
 Drawbacks when considering IL-6 as risk marker are issues related to 




clinically approved assay for IL-6 exists.
146
 The picture is further complicated by the fact that IL-
6 has shown ability to exert both pro- or anti-atherogenic effects depending on the environmental 
circumstances and whether it acts through the classic membrane IL-6 receptor or trans-signaling 
through the soluble receptor. Selective interference with the IL-6 trans-signaling represents a 




There is a growing interest in caspase-1 and its effects in pyroptosis and activation of IL-1β 
concerning atherosclerosis and plaque destabilization. Pyroptosis is a pro-inflammatory form of 
cell death, uniquely dependent on caspase-1 and suspected to play an important role in plaque 
destabilization. Plaque cholesterol can activate the multimolecular signaling complex NLRP3 
inflammasome.
17
 Activation of the NLRP3 inflammasome results in caspase-1-mediated 
production of IL-1β and ultimately IL-6, which amplify the inflammatory cascade. This finding 
offers a mechanistic link between hypercholesterolemia and vascular inflammation.
18
 To our 
knowledge, the association between caspase-1 and progressive atherosclerotic disease is not 
previously documented. Expression of NLRP3, caspase-1, IL-1β, and IL-18 mRNA was 
significantly increased in carotid artery plaque tissues obtained during endarterectomy surgery 
compared to normal arteries from transplant donors.
17
 IL-1β secretion appeared to be an 
important pathway in carotid plaque tissue in a larger study of gene expression in carotid 
atherosclerosis.
135
  Linking caspase-1 and IL-1β activation to plaque progression is especially 
relevant concerning the recently published Canakinumab Anti-inflammatory Thrombosis 
Outcomes Study (CANTOS).
187
 In CANTOS, canakinumab, a monoclonal antibody against IL-
1β, was tested for secondary prophylaxis in 10 061 post myocardial infarction patients with 
elevated levels of CRP. Results suggested a significant 15% lower rate of recurrent 
cardiovascular events in the group using canakinumab at a dose of 150 mg every 3 months 
compared to placebo at 48 months. These results thus encourage further research on the detection 
and testing of anti-inflammatory therapies targeted to the central inflammatory signaling (IL-1 – 
TNFα – IL-6) pathway for CVD prevention.
187
  
MPO is an enzyme secreted by activated macrophages, and is linked to both oxidative stress and 
inflammation. MPO may reduce the bioavailability of NO, resulting in endothelial dysfunction, 
in particular endothelium dependent vasorelaxation.
188
 MPO is involved in the oxidation process 
of LDL, promoting foam cell formation in the vascular wall.
189
 Finally, MPO may play a role in 






may thus be involved at all stages of atherosclerosis from initiation to plaque rupture.
190
 MPO 







, and increased risk of CVD events, and may show additive effect to subclinical 
atherosclerosis in CVD risk determination.
191
    
Our results regarding neopterin contradict the findings from other studies.
192, 193
 However, a 
recent paper support anti-inflammatory and anti-atherosclerotic properties of neopterin by 
in vitro and in vivo experiments. The authors suggest that neopterin increases in circulating 
blood in patients with coronary artery disease to counter inflammation and atherosclerosis.
194
  
As many of the markers are inter-correlated and probably reflects aspects of the same biological 
processes, the simultaneous assessment of multiple markers may increase sensitivity and 
specificity of unstable atherosclerosis. Our results suggest that IL-6, caspase-1 and MPO should 





6 Conclusions and implications for future research 
 
Imaging of subclinical atherosclerosis and circulating biomarkers of inflammation provide 
promising strategies for improving our ability to identify individuals at increased risk of CVD, 
and to guide and evaluate interventions.   
Our findings did not support a causal role of CRP in the formation and progression of 
atherosclerosis, but suggested CRP to be a marker of prevalent atherosclerosis. The joint 
presence of carotid atherosclerosis and CRP was associated with the highest risk of both IS and 
MI, suggesting that the combined assessment of these measures may improve clinical risk 
prediction.   
The novelty of CRP as a risk marker of CVD is limited. However, the mechanistic way by which 
CRP relates to CVD is still not fully understood. In addition to animal studies, gene expression 
studies and Mendelian randomization studies, our approach studying the associations between 
potential biomarkers and different stages of disease development (subclinical and clinical) is 
useful for improving our understanding of mechanistic links.  
When deciding to use certain biomarkers in CVD risk assessment, it is important that such 
markers influence on treatment decisions which subsequently lead to reductions in the risk for 
clinical events and improve quality of life for patients. Regarding CRP and plaque assessment in 
the carotid arteries, future research should aim to document the cost-effectiveness of screening. 
If therapies, which lead to plaque regression and lower levels of inflammatory markers, indeed 
decreases the risk of CVD events, this will further support the use of these biomarkers as 
surrogate endpoints and in individual monitoring of treatment effects. This may again benefit 
studies aimed at evaluating the effect of new preventive treatments, compared to large, 
protracted and costly studies based on reducing CVD events. 
Future research should also aim to establish a molecular signature for unstable atherosclerosis 
that improves CVD risk prediction at the individual level. IL-6, MPO and caspase-1 represent 
promising markers in this regard. As many of the inflammatory biomarkers are inter-correlated 
and may exert both pro-inflammatory and anti-inflammatory effects, statistical methods which 




Still a great amount of clinical CVD events cannot be prevented by available drug therapies, 
including statins.
195
 The ultimate test of the inflammatory hypothesis in atherosclerosis relies on 
anti-inflammatory targeted drug trials. So far, two large randomized controlled trials of post 
myocardial infarction patients have followed this approach, the CANTOS trial
187
 and the 
ongoing Cardiovascular Inflammation Reduction Trial (CIRT).
72
 Better knowledge of the 
cellular and molecular mechanisms involved in atherosclerosis holds promise to unravel new risk 
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Typing error in the abstract: β = 0.0.029 (CI, 0.003-0.056) should be β = 0.029 (95% CI, 0.003-
0.056). 
In Supplemental Table 1; For Tromsø 6; n should be =2838, not 2828. 
 
Paper III 
In the “Materials and Methods” section 2.1. Subjects: it was erroneously stated that the 5
th
 survey 
was performed in 2000/2001. It should read 2001/2002. Almost all examinations were performed 
in 2001, whereas a few were done in January 2002. 
An error had also occurred in the methods section on page 3, second paragraph (2.4. 
Ultrasonography). The paragraph is now printed correctly below. 
Progression of plaque was defined as an increase in TPA above the mean absolute difference 
(2.9 mm
2
) between 2 independent measurements performed by 2 independent sonographers, as a 
measure of the typical magnitude of the measurement error. Stable plaque size was defined as 
change in TPA of less than ±2.9 mm
2
. To reduce risk of misclassification in the plaque 
progression group, we included subjects with the largest TPA progression. 
































You are invited to the large health survey 
in the municipality of Tromsø 1994 - 95      
We will start in the outskirts of 
the municipality. Here, the 
examination will take place in 
schools and other premises – 
see the information in the 
invitation accompanying this 
letter.
From late October 1994 until 
summer 1995, the examination 
will take place in Mellomveien 
50 (the Elisabeth centre; the old maternity hospital). 
We prefer that you attend at the location specified in 
the invitation letter.
Because we offer this examination to everyone born 
1969 or earlier.
The survey is first and foremost aimed at cardiovascular 
diseases, but is also important to gather new knowledge 
about other serious chronic diseases (amongst them 
cancer). 
This time we will also study musculo-skeletal pain 
conditions, for instance fibromyalgia. Therefore, some 
people will be invited to a separate examination in the fall 
of 1995.
Large cardiovascular surveys were carried out in Tromsø 
in 1974, 1979-80, and 1986-87. The attendance rate was 
high, and several cases of cardiovascular disease were 
detected – who are now being treated. 
The surveys have also contributed with important 
knowledge to combat these diseases. The knowledge we 
What is the purpose?
Why did you receive this offer?     
We will reach everyone gained through the previous 
surveys, made the 
University of Tromsø to one 
of the renowned research 
centres in the world with 
regard to cardiovascular 
diseases. Again, we aim to 
detect hitherto undiscovered 
cardiovascular disease. We 
also hope to reach those at 
particular high risk, so that 
they may get the possibility
of prevention and other
measures to stop the development of disease. 
Cardiovascular diseases are still one of our largest 
health problems.
Not only for your own sake ...
The examination not only is important for you personally. 
It is also important that the results may be used in medical 
research, for instance by using them together with 
information about disease that occur in the future. Thereby
we will learn more about how cardiovascular 
diseases, cancer, and other population diseases 
develop, and how they may be prevented. By 
attending the survey, you are helping to fight these 
diseases.
the content of lipids (e.g. cholesterol), calcium and a 
liver enzyme. The result of these measurements will 
be forwarded to your doctor if you consent. The 
result of other analyses will be used for medical 
research only. The blood sample will be frozen to 
make it possible to perform other blood analyses in 
order to study disease development. Before such 
analyses are performed, the study will be presented 
to the Regional Ethical Committee of North Norway.
Measurement of height and weight
Measurement of blood pressure
Blood sample. In this sample, we will measure 
The examination includes
ECG is a test that registers the heart
activity. We will use 
a simplified version, 
and the results will 
be used for research 
purposes only.
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Questionnaire
Special examination. Everybody born between 1920
 
The information about you will be treated 
confidentially. The information will be stored and 
used according to the rules set by the Data 
Inspectorate and the Regional Ethical Committee of 
North Norway. For the information to be used in 
medical research, you have to consent. Your consent 
is also necessary if your doctor shall have the results 
of the analyses (and which you will be mailed the 
results of) and of your answers to the questionnaire 
enclosed with this letter. When attending, we 
therefore ask you to give your consent that:
Questionnaire
–1939 and a sample of the others, will be offered a more
extensive examination for free. The content of the 
examination varies somewhat, but will provide a better 
examination of the heart, the aortic artery, atherosclerosis, 
and the tendency to osteoporosis. You will get an 
appointment for the examination when you attend. 
This you will find on the reverse side of the invitation 
letter. Please fill in the questionnaire beforehand and 
bring it to the examination site. If some questions are 
difficult to answer, you may get some help when you 
attend.
About consent
- a letter with your results is sent to your family doctor, 
and will be stored in your medical record 
- that your blood sample may be used for medical 
research. The purpose of such research is to learn about 
causes of diseases.
- that your results may be used for medical research, by 
linking that information with other health- and disease 
registries (for instance cancer registry and causes of 
death registry) and with information form the previous 
health surveys in Tromso. Before the information is 
used for analyses, your name and personal identification 
number will be removed. Even if you give your consent 
now, you may withdraw your consent later.
Follow-up examination
Places that will be visited by the health
Some of those who are examined may later be referred 
to their own doctor for a more thorough control. If you 
are in need of treatment, you will be offered such 
treatment.
       What does it cost?           
A small fee is necessary for this examination. It is very 
modest compared to the actual cost. You will find the 
amount in the letter you have received now. The 
special examination is free of charge. If you will need 
an examination by your own doctor or at the Regional 
hospital, you will have to pay the ordinary fee.
Because of the blood pressure measuring, we ask you 
to wear clothes that are sleeveless or with short sleeves 




      Sincerely
The municipality health service
The Faculty of medicine, University of Tromsø
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The health study in Troms  invites some of theø
participants for a free special study. 
The Special Study uses advanced technology which 
makes images of blood vessels and the heart, and 
provides information on skeletal structure and fatty 
tissue. X-ray technology is not used, but rather
YOU ARE INVITED TO 
THE SPECIAL STUDY
Ultrasound of blood vessels and the heart
The arteries in the neck and stomach are studied. 
This gives information whether the arteries are 
clogged or whether they are diluted/contracted. 
The shape of the heart and its functionality is 
looked at in 50 per cent of the participants.The special study
Why are you invited?       
The Special Study involves Practical information
ultrasound or light-waves 
which are reflected against 
a small device held to the 
skin (pictured). These 
tests do not penetrate the 
skin, are not painful and 
have no known side-
effects. The Special Study 
also involves blood- and 
urine samples, as well as 
registering heart activity 
(ECG). 
We do not have the opportunity to offer the Special 
Study to everyone. We invite all men and women 
born between 1920 and 1939 and some randomly 
picked from other age-groups. 
Many diseases evolve gradually over long periods 
of time without people’s awareness, but with 
advanced methods it is possible to detect changes 
early. In certain cases prevention or treatment can 
be initiated even before the disease develops. In 
other cases we are not sure what the changes 
signify and further research is necessary. The 
Special Study is therefore a unique offer which not 
only has value to you personally; the results are 
used in medical research which breeds increased 
knowledge about how diseases initiate and how 
they can be prevented and treated. 
What is the purpose?
Study of bone density and amount of fat
The measurements are used to determine risks 
of osteoporosis and fractures, and whether 
there is a correlation between body fat and 
disease.
ECG
ECG is registering heart activity which also 
provides information concerning heart disease. 
Urine sample
The urine samples are used to indicate kidney 
function through measuring the amount of protein 
and creatinine substances. The result is most 
accurate if urine from the separate days are examined.  
Blood sample
Blood samples are examined for fatty 
substances and substances which indicate how 
the kidneys work, metabolism (calcium and 
sugar) and blood clotting. The blood sample is 
frozen so it can be used for later research. 
Further follow up
If we think further examination 




may be asked to take 




The examination will take place in the second floor 
at Elisabeth center; the old maternity hospital 
(Mellomveien 50) - at the floor above the Tromsø
study. The examination takes 1 to 1.5 hours and is 
free of charge.
We hope you can use the time appointed.
Date and time is given in the brochure. If you need 
to change appointment, we ask that you notify us by 
calling 77 64 59 00
Urine sample
You have been given three urine glasses marked 1, 
2 and 3. We wish that you take a morning urine 
sample in each glass in the last three days before 
the special study. You have therefore got a glass for 
every morning. Note the following:
1. Please urinate a small amount of urine in the toilet
before you take the urine sample. Last morning 
sample is taken on the day you come to the survey.
2. State the date on each urine glass.
3. It is an advantage if samples can stay cold.
4. Deliver all three glasses when you come to the
survey.
Use of medicine
On the next page please make a note which 
medications you've used the past week. This can be 
important when interpreting the results.
Clothing
Because of the blood pressure measuring, we ask 
you to wear clothes that are not tight on the arm. 
When examining the heart, it is necessary to 
undress the upper body. At examination of the aorta 
some clothes must be pulled down so that the 
abdominal region is exposed.
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About consent
The information about you will be treated confidentially. 
The information will be stored and used according to the 
rules set by the Data Inspectorate and Norwegian law. 
The study has been recommended by The Regional 
Committee for Research Ethics. Should further 
examinations be required, we ask your consent to 
forward relevant data to your doctor or the Regional 
Hospital in Troms . We also request that you uponø
arrival give your consent to:
that we forward your results to your doctor or 
the Regional Hospital in Troms  if you needø
further examination.
that your results may be used for medical 
research through combining them with other 
health- and disease registries as well as 
information from previous health studies in 
Troms . Prior to analysing the results yourø
name and social security number will be 
removed. 
that your blood sample may be stored and 
used for medical research.
that the Health Examination in Troms  mayø
contact you later with a request to participate 
in other studies.
Even if you give your consent now, you may later 
reconsider and deny the use of your results.
Use of medicine
The special study
is part of the health survey 
in Troms , and organizedø
by the University of Troms ,ø
Faculty of Medicine in 
cooperation with the 







To interpret the results we want information about 
medication use in the last week. Please state 
name, strength and dose of all medications that 
you are using. If in doubt about filling, bring the 
drugs. We will then be able to help you.
Name of medicine  Strength     Dose
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  Welcome to the fifth round
  of the Tromsø Study!
-a collaboration between:
Department of Community Medicine, 
University of Tromsø
National Health Screening Service
You will find more information about the health survey on 
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Would you like to participate in 
the fifth survey of the Tromsø study? 
Why a new round of 
the Tromsø study?      
Large health studies were 
conducted in Tromsø in 1974, 
1979-80, 1986-87, and 1994-95. 
These surveys have given us 
important knowledge concerning 
cardiovascular epidemiology and 
other serious diseases, such as 
cancer. 
The main purpose of another 
Tromsø study is to monitor any 
changes in the health of the population since last survey. We will 
analyze the information we have about a person, both personal data 
and results from analysis of frozen blood, and see if there are 
relationships to diseases that occur. This way we learn more on how 
cardiovascular diseases, cancer and other major diseases develop 
and how they can be prevented. 
We ask everyone who participated in the Special Study in the Tromsø 
study in 1994-95 and a selection of others older than 29 years.
Why are we asking you to participate?
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What does the study include? 
    The Tromsø study is first and foremost a 
research project. Through following up 
as many as possible from the study of 
1994-95, we gain valuable information of 
health and disease in the population of 
Tromsø. 
Participants’ general health status will be examined with regard to 
certain diseases and risk conditions. If you have a high risk of 
developing cardiovascular diseases you will be notified of this.
On the day of the examination you will be guided through the survey 
and there will be an opportunity to ask questions. Your height, weight 
and waist circumference is measured, as well as blood pressure, and a 
blood sample is taken. Your lung capacity is determined, in addition 
to simple tests of vision and strength. Tests to determine osteoporosis 
is are also conducted.
The blood sample may later be analyzed for fatty substances, blood 
sugar, indicators of infections, diet, hormones, liver- and kidney 
function, and bone markers.
The blood which is frozen will be used for medical research only, in 
order to find factors influencing disease. In most cases this means 
that data from people with a disease is compared to data from those 
without it. The comparison is done on already collected data and the 
new analysis from the frozen blood.
With this letter a questionnaire is attached. We kindly ask you to 
complete this form at home and bring it on the day of the 
examination.
Everyone who participated in the Special Study in 1994-95 is also 
offered to take part in another Special Study. This study provides 
information on the heart and the main arteries in neck and abdomen, 
and offers a more detailed analysis on tendency of osteoporosis. 
This survey is also located at the Elisabeth-center in Tromsø. A time 
will be scheduled for you and information is provided upon arrival. 
If you are unsure of how to answer a question, leave it blank. You 
will be aided at the examination.
Everyone who participates in the study will be given an additional 
questionnaire of other factors which might affect your health. The 
questionnaire is to be completed at home and sent to the National 
Health Screening Service in the enclosed envelope.
We might want to analyze parts of the DNA from the frozen blood 
cells. Because DNA is important for the regulating and development 
in human being, we need knowledge on DNA to understand why 
diseases evolve. Analysis of this kind are only conducted after the 
Data Inspectorate has given a permission and if The Regional 
Committee for Research Ethics has no objections to the analysis. 
The Questionnaires
Future analysis of blood
Where are you going to meet?
The survey will for the vast majority take 
place in Elizabeth Center in Tromsø. For some 
of the outer places in the municipality, the 
survey will take place locally. Those 
concerned are notified in this letter.
On the front page of the questionnaire that you 
receive with this letter are the opening hours 
for the health survey and when you have to 
attend the survey. If you cannot attend at that 
time, you are welcome any another time 
during the opening hours of the survey. There 
is no need to tell us about this ─ just show up 
when we are open.
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When will you receive your results?  
That the results, after legal approval from the Data Inspectorate, may 
be linked with information about you in other registries, to be used for 
research purposes. This might be registries including information on 
health, pension and disease, and also data on income, education and 
occupation, in addition to information from previous health studies in 
Tromsø. Examples of such registries are the Cancer Registry, the 
Cause of Death registry and population censuses. In these cases your 
name and social security number are removed when data is analyzed. 
When you attend the study, you will be asked to sign a consent form 
where  you agree to the following six points:
That we may contact you with recommendations of follow ups, 
treatment or prevention of disease.
That we may ask you to participate in similar studies in the future.
That we may use the results for medical research.
That the blood sample may be stored and used for medical 
research. All use of this sample will only take place after approval 
from the Data Inspectorate and if The Regional Committees for 
Research Ethics has no objections. 
That the blood sample may also be used for analysis of DNA.
Even if you approve to this now, you are entitled to change your 
opinion later and also ask to have your profile deleted from the 
registry. You may also decline to consent to one or more of the points 
above. The Data Inspectorate has given consent to this fifth survey of 
the Tromsø Study, and the Regional Committee for Research Ethics 
has no objections. We keep your results confidential and safe. 
Everyone employed in the Tromsø Study has signed a confidentiality 
agreement. 
About four weeks after you participated in the study you will receive 
a letter wherein your recorded values for cholesterol, blood pressure 
and blood sugar are stated. You will also receive more information 
on the different risk factors.
People who are found to be at particularly high risk of developing 
cardiovascular diseases and diabetes will be recommended to seek 
further examination from their own doctor.
We need your consent
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YOU ARE INVITED TO
THE SPECIAL STUDY
The Special Study
The Special Study uses advanced technology which 
makes images of blood vessels and the heart, and 
provides information on fatty tissue content  and skeletal 
structure. The latter requires x-ray equipment, although 
in very low doses. The three former is done with 
ultrasound, reflecting it against a small device held to the 
skin (pictured). These tests do not penetrate the skin 
and are not painful. The Special Study also involves 
blood-, urine-, and respiratory tests, as well as 
registering heart activity (EKG). Moreover, basic memory 
tests and word recognition tests are conducted, as well 
as the degree of finger mobility. 
Why are we asking you?
We invite everyone who participated in the Special 
Study in 1994-95 to take part now. 
What is the purpose?
Many diseases evolve over a long period of time, but 
with advanced methods it is possible to detect 
changes early. In certain cases prevention or 
treatment can be initiated even before the disease 
develops. In other cases we are not sure what the 
changes signify and further research is necessary. 
We are especially interested in studying the changes 
since 1994-95 and their implication towards disease 
developing later. This way we hope to increase 
knowledge on how diseases initiate and how they can 
be prevented and treated. 
THE SPECIAL STUDY INVOLVES
Ultrasound of blood vessels and the heart
❖ The arteries in the neck and stomach are 
studied. We then see if the arteries are clogged 
or if they are diluted/contracted. The shape of 
the heart and its functionality is looked at in 50 
per cent of the participants.
Study of bone density and
amount of fat
❖ The measurements determine risk of 
osteoporosis and fractures, and if there is a 
correlation between body fat and disease.
ECG and blood pressure
❖ ECG is registering heart activity which provides 
information on heart diseases. An ECG is done 
by attaching sensors to arms, legs and chest. 
Blood pressure is checked on both the upper 
arm and the ankle. 
Respiratory test
❖ Through breathing into a machine, lung function 
is determined.
Blood sample
❖ Blood samples are examined for fatty substances 
and substances which indicate how the kidneys 
work, metabolism (calcium and sugar) and blood 
clotting. DNA can also be analyzed from the 
blood sample. The blood sample is frozen so it 
can be used for later research. 
Further follow up
• If more examinations or
treatment are required
it will be offered to
you.
• Some participants
may be asked to




Place and time 
The examination will take place in the 2nd floor of 
the Elizabeth Center - the old maternity hospital 
(Mellom-veien 50) on the floor below the Tromsø
study. The examination takes about 1.5 hours and is 
free of charge.
We hope you can use the time appointed.
Date and time is given in the brochure. If you need
to change appointment, we ask that you notify us by
calling 77 64 48 16 or e-mail: Tromsous@ism.uit.no
Urine sample 
You have been given three urine glasses marked 1,
2 and 3. We wish that you take a morning urine
sample in each glass in the last three days before
the special study. You have therefore got a glass for
every morning. Follow the instructions provided with 
glasses.
Fall
You are asked to register falls until the Special 
Study.
Clothing 
Because of the blood pressure measuring and 
sampling of the ECG, , we ask you to wear clothes 
that are not tight on the arm and the leg. When 
examining the heart, it is necessary to undress the 
upper body. At examination of the aorta some 
clothes must be pulled down so that the abdominal 
region is exposed.  At the examination of bone 
density, you will not undress yourself, but it is 
important not to have metal objects in the clothes. 
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Vil du være med i den 6. Tromsøundersøkelsen?
» viktig forskning
» undersøkelse av egen helse
» forebygging av helseproblemer
Invitation 6th Survey (Norwegian)
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Hva er Tromsøundersøkelsen?
Tromsøundersøkelsen er et stort forskningspro-
sjekt. Opplysninger som samles inn skal brukes 
til å gi oss kunnskap som kan bedre menneskers 
helse. 
Den første Tromsøundersøkelsen ble gjennom-
ført allerede i 1974, og dette er den sjette i rekken. 
Et viktig mål med undersøkelsen er å få kunnskap 
om hvorfor noen blir syke mens andre beholder 
god helse gjennom livet.
Visste du at ..?
Den som deltar på Tromsøundersøkelsen får også 
en enkel undersøkelse av sin egen helse. 
Hva forskes det på i 
Tromsøundersøkelsen?
Tromsøundersøkelsen gjennomføres først og 
fremst for å kunne øke kunnskapen om de store 










Undersøkelsen vil også bli benyttet til forskning om 
bruk og effekter av legemidler, trivsel, livskvalitet, 
livsstil, døgnrytme, smerter, sosial ulikhet, fysisk 
aktivitet, kosthold, bruk av helsetjenester og alter-
nativ behandling.   Det vil også bli undersøkt om 
miljøgifter kan påvises i blodet og om disse inn-
virker på helsa. 
Videre vil det bli gjort forskning på kvinnesyk-
dommer, sykdommer i fordøyelsesorganer, allergi, 
nyrer og urinveier, nervesystemet, sanseorganer 









som følge av disse sykdommene eller tilstandene. 
En del av prosjektene vil spesielt undersøke sam-
spillet mellom arv, miljø, sykdom og helse. Til slike 
prosjekter vil det bli hentet ut DNA (arvestoff ) fra 
blodprøvene. 
Det er allerede planlagt mange forskningspro-
sjekter som skal benytte data fra Tromsøunder-




Ved å delta på Tromsøundersøkelsen er du med 
på å bidra til forskning om hvordan sykdom kan 
forebygges og behandles, hva som fremmer god 
helse, og hva som er årsak til helseproblemer. 
Hvorfor spør vi deg?
Alle som møtte til spesialundersøkelsene i 
Tromsøundersøkelsen i 1994 og 2001, og et tilfel-
dig uttrukket utvalg av personer som er over 30 
år og som er innbyggere i Tromsø kommune, blir 
spurt om å delta. 
Alle er viktige!
Hver deltaker er like viktig, enten du er ung eller 
gammel, frisk eller syk. Det har vært stort fram-
møte til de tidligere Tromsøundersøkelsene. Godt 
oppmøte er viktig for gode forskningsresultater. 
Det er en styrke for forskningen at de som har 
vært med i tidligere Tromsøundersøkelser møter 
fram på nytt.
Frivillig 
Det er frivillig å delta. Det vil ikke få noen 
konsekvenser for deg dersom du ikke deltar 
eller velger å trekke deg fra undersøkelsen på et 
senere tidspunkt. Du må ikke gi noen begrunnelse 
dersom du ønsker å trekke deg fra undersøkelsen. 
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Visste du at ..?
Du kan delta på Tromsøundersøkelsen selv om 
det er deler av undersøkelsen du ikke ønsker å 
være med på. 
Din helse
Cirka fire uker etter undersøkelsen vil du få et brev 
med resultatene fra målinger av kolesterol og 
blodtrykk. Dersom det er nødvendig, vil du bli an-
befalt å ta kontakt med din fastlege. Det blir ikke 
gitt rutinemessig tilbakemelding om resultater av 
andre blodprøver eller målinger. 
Dersom resultatet av prøvene viser at det er nød-
vendig med oppfølging av lege eller henvisning 
til spesialist, vil du bli orientert om det. Ved behov 
for henvisning til spesialist, vi vil sørge for at slik 
henvisning blir sendt. 
Du kan reservere deg mot å få vite resultatene av 
prøvene dine. Men hvis et prøveresultat er slik at 
det er nødvendig med rask legebehandling, vil du 
uansett bli kontaktet.
Tromsøundersøkelsen er gratis. Trenger du videre 
undersøkelse / oppfølging av fastlegen eller i 
spesialisthelsetjenesten, betaler du vanlig egen-
andel.  
Slik foregår undersøkelsen
Sammen med dette informasjonsskrivet ligger 
det et ark med praktiske opplysninger og beskjed 
om hvor og når du kan møte fram. Her står også 
åpningstidene for undersøkelsen. Hvis du vil delta 
og den foreslåtte tiden ikke passer, kan du komme 
en annen dag. Du trenger ikke melde fra om dette 
på forhånd. 
Unngå før undersøkelsen
For at resultatene skal bli mest mulig korrekt, er 
det en fordel om du avstår fra alkohol og smerte-
stillende medisiner 12 timer før undersøkelsen. 
Påkledning
Vekt og høyde, liv- og hoftevidde måles med lett 
påkledning, men uten sko. For at det skal gå raskt 
å måle blodtrykk, er det en fordel om du har plagg 
som ikke strammer over armen og benet. Ha 
gjerne et kortermet plagg innerst.
Spørreskjema
Sammen med denne brosjyren har du fått et 
spørreskjema som du skal fylle ut og ta med til 
undersøkelsen. Hvis du er i tvil om hvordan du skal 
svare på et eller flere av spørsmålene, lar du det 
stå åpent. Personalet på undersøkelsen hjelper 
deg da med utfyllingen om du ønsker det.
Utfylte svar i spørreskjema er like viktig for forsk-
ningen som resultater fra blodprøver og under-
søkelser.
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Regelmessig bruk av legemidler
Ved frammøte til undersøkelsen vil du bli intervjuet 
om hva slags legemidler du har brukt regelmessig 
de siste fire ukene, og om noen av de legemidlene 
du har brukt siste 24 timer. Navn på legemidler du 
bruker fast kan besvares i skjemaet på forhånd. Ta 
gjerne med deg legemidlene du bruker ved fram-
møte til undersøkelsen. 
Undersøkelser
Når du møter fram, vil kvalifisert helsepersonell 
veilede deg gjennom undersøkelsen og svare på 
spørsmål. Du vil bli intervjuet og få utlevert et 
nytt spørreskjema med en frankert svarkonvolutt. 
Spørreskjemaet kan også besvares mens du er til-
stede på undersøkelsen, og du vil kunne få hjelp 
underveis. Hver enkelt undersøkelse varer bare 
noen minutter. Totalt vil undersøkelsen vare cirka 
en time.
De måler høyde, vekt, hoftevidde og livvidde, 
de måler blodtrykket og tar blodprøve av deg. I 
tillegg vil følgende undersøkelser bli gjort:
Beintetthetsmåling (måling av beinmasse) 
i den ene armen med svake røntgenstråler.  
Målingene brukes til å undersøke risiko for 
beinskjørhet og brudd.
Bakterieprøve fra nese og hals fra om lag 
halvparten av deltagerne, for å se etter gule 
stafylokokker, en bakterie som normalt finnes 
på hud og slimhinner hos mennesker, men 
som i enkelte tilfeller kan forårsake alvor-
lige infeksjoner. Prøven gjøres med fuktet 
vattpensel.
Smertefølsomhet som måler hvordan kropp-
en reagerer på smerte.  Du blir bedt om 
å holde hånden i isvann i opptil 1 minutt.  
Underveis registreres blodtrykk og du angir 
hvor mye smerte du kjenner. Du kan ta hånd-
en ut av vannet før tiden er ute hvis det blir 
for ubehagelig.
Hårprøve.  Vi vil be om å få noen hårstrå for å 






Fysisk aktivitet og kosthold. Vi planlegger at  
utvalgte deltakere vil bli bedt om å registrere 
fysisk aktivitet (aktivitetsmålere som skritt-
tellere og lignende) og kosthold i en periode.
Blodprøver
Blodet fordeles på fem glass, men til sammen ut-
gjør det ikke mer enn 45 milliliter, som er mindre 
enn en tidel av det en blodgiver gir. For de aller 
fleste vil det være tilstrekkelig med ett stikk.  Disse 
analysene blir gjort:
Måling av kolesterol og andre fettstoffer, 
blodsukker, blodlegemer, stoffskifteprøver, 
hormoner, markører for betennelsesreaksjon-
er, allergi, mage- og tarmfunksjon, lever- og 
nyrefunksjon samt muskel- og beinmarkører.
DNA (arvestoff ) vil bli lagret til bruk i forsk-
ningsprosjekter som er omtalt i denne bro-
sjyren og som kartlegger sammenhengen 
mellom arv og miljø, sykdom og helse. DNA vil 
ikke bli brukt til andre formål enn forskning.
Miljøgifter, blant annet sporstoffer, spor-
metaller og organiske stoffer. Forekomsten i 
blodet skal sammenlignes med tilsvarende 
målinger i andre befolkninger. Forskere vil 
studere om miljøgifter kan påvirke helsa vår. 
Spesialundersøkelsen 
Når første del av Tromsøundersøkelsen er 
gjennomført, kan du bli forespurt om å delta i en 
eller flere deler av Spesialundersøkelsen noen uker 
senere. Over halvparten vil bli spurt om dette. Hele 
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varigheten vil være avhengig av hvor mange deler 
du blir spurt om å være med på. Ved oppmøte til 
Spesialundersøkelsen vil det bli tatt ny blodprøve 
som skal brukes til samme formål som beskrevet 
for første del av undersøkelsen. Deler av blod-
prøven blir frosset ned for senere bruk i forskning 
som er beskrevet i denne brosjyren. 
Hvilke undersøkelser gjøres i 
Spesialundersøkelsen?
Ultralyd av blodårene (arteriene) på halsen. 
Undersøkelsen gjøres for å se etter for-
kalkninger og innsnevringer av årene.  
Undersøkelsen kartlegger også  blodforsyn-
ingen til hjernen.
Ultralyd av hjertet gjøres for å undersøke 
hjertets form og funksjon. 
Måling av beintetthet i rygg/hofte og  
kroppens fettmengde. Målingene brukes til 
å undersøke risiko for beinskjørhet og brudd, 
og for studier om sammenhengen mellom 
kroppsfett, beinmasse og brudd.
Fotografering av øyebunn. Fotografiet vil 
vise tilstanden for blodkarene i øyet som 
også sier noe om blodkarene i kroppen. Ved  
øyestasjonen tas fotografi av øyebunnen din. 
Deltagerne får en øyedråpe i hvert øye en 
tid før fotografering for at pupillene skal ut-
vide seg. Dette kan svi noe og synet kan for-
bigående bli noe uklart. Effekten går gradvis 
over, og etter en time er den borte. I tillegg vil 
det gjøres en enkel synstest som du vil få svar 
på umiddelbart.
Tester av hukommelse gjøres ved hjelp av 
enkle spørsmål og omfatter også evne til 
gjenkjenning av ord og grad av fingerbeve-
gelighet.
EKG og blodtrykk. EKG er en registrering av 
hjerterytmen som også kan gi informasjon 
om hjertesykdom. Ved registrering festes led-
ninger til kroppen. Blodtrykket måles både på 







Pusteprøve. Dette er en enkel undersøkelse 
av lungefunksjonen. Du skal puste så hardt du 
klarer gjennom et munnstykke. Hvor mye luft 
som blåses ut pr. sekund, er et mål på lunge-
funksjonen din.
Ny bakterieprøve fra nese og hals. Prøven 
utføres på samme måte som i første del av  
undersøkelsen. 
Urinprøve. Du vil bli bedt om å avlevere 
urinprøver fra de tre siste dagene før  
spesialundersøkelsen. Du gis alt nødvendig 
utstyr. Urinen blir lagret til bruk i forskning 
som er beskrevet i denne brosjyren.
For å sikre høy kvalitet på forskningsdata ønsker 
vi å undersøke et lite utvalg som møter til under-
søkelsen to ganger med circa en ukes mellomrom. 
De som er aktuelle vil bli forespurt om dette ved 
frammøte.
Nye prosjekter
Noen deltakere vil i ettertid bli spurt om å delta 
i videre undersøkelser.  Hvis dette gjelder deg, vil 
du få en forespørsel i posten. Du er ikke forpliktet 
til å delta selv om du har deltatt i andre deler av 
Tromsøundersøkelsen. Omtale av alle delprosjek-
tene finner du på nettsiden vår:
http://www.tromso6.no
Forsikring og finansiering 
Deltakere i Tromsøundersøkelsen er forsikret 
gjennom Norsk Pasientskadeerstatning.  
Tromsøundersøkelsen er finansiert av Uni-
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Etikk, personvern og sikkerhet
Du kan være trygg på at informasjon som gis til 
Tromsøundersøkelsen vil bli behandlet med res-
pekt for personvern og privatliv, og i samsvar med 
lover og forskrifter. Alle medarbeidere som jobber 
med undersøkelsen har taushetsplikt. Opplysnin-
gene som samles inn vil bare bli brukt til godkjen-
te forskningsformål.
Alle opplysninger om deltakere vil bli lagret på 
datamaskin. Navn og personnummer blir fjernet 
og erstattet med en kode. Kodenøkkelen oppbe-
vares separat og kun noen få, autoriserte medar-
beidere har tilgang til denne. 
Den enkelte forsker får ikke tilgang til opplys-
ninger som gjør det mulig å identifisere enkelt-
personer. Hver enkelt deltaker har en rett til å vite 
hvilke opplysninger som er lagret om en selv.
For alle  prosjekter kreves det at prosjektlederen 
tilhører en kompetent forskningsinstitusjon.
Tromsøundersøkelsen har konsesjon fra Data-
tilsynet og er godkjent av Regional komité for  
medisinsk forskningsetikk, Nord-Norge.
Sammenstilling med andre registre
Opplysninger om deg fra den sjette Tromsøunder-
søkelsen kan bli knyttet sammen med opplys-
ninger fra tidligere Tromsøundersøkelser. For 
enkelte prosjekter kan det være aktuelt å sammen-
stille opplysninger om deg med opplysninger fra 
barn, søsken, foreldre og besteforeldre hvis disse 
har deltatt i Tromsøundersøkelsen.
For spesielle forskningsprosjekter kan det være 
aktuelt å sammenstille informasjon fra Tromsø-
undersøkelsen med nasjonale helseregistre som 
Reseptregisteret, Medisinsk fødselsregistrer, 
Kreftregisteret, Norsk pasientregister og Døds-
årsaksregisteret, og andre nasjonale registre over 
sykdommer som det forskes på i Tromsøunder-
søkelsen. 
I tillegg kan det være aktuelt å innhente helseopp-
lysninger fra primær- og spesialisthelsetjenesten 
til bruk i forskning på sykdommer og helsepro-
blemer som er nevnt i denne brosjyren, for 
eksempel hjerte-karsykdom, diabetes og bein-
brudd. I slike tilfeller innhentes nytt samtykke, 
eller annen type godkjenning (dispensasjon fra 
taushetsplikten).
Informasjon fra Tromsøundersøkelsen kan også 
bli sammenstilt med registre ved Statistisk sen-
tralbyrå, for eksempel om miljø, befolkning, utdan-
ning, inntekt, offentlige ytelser, yrkesdeltakelse og 
andre forhold som kan ha betydning for helsa. 
Slike sammenstillinger krever noen ganger 
forhåndsgodkjenning av offentlige instanser, 
for eksempel Regional komité for medisinsk for-
skningsetikk, Datatilsynet eller NAV. 
Bruk av innsamlede data i framtiden
Data fra Tromsøundersøkelsen vil kun bli brukt til 
forskning og vil ikke kunne brukes til andre for-
mål. 
Opplysninger og prøver som du gir, blir oppbevart 
på ubestemt tid til bruk i forskning til formål som 
nevnt i denne brosjyren. I noen tilfeller kan det bli 
aktuelt å gjøre analyser av blodprøver ved forsk-
ningsinstitusjoner i utlandet. Hvis dette gjøres, vil 
det skje i en slik form at våre utenlandske sam- 
arbeidspartnere ikke kan knytte prøvene opp mot 
deg som person.
Hva som er aktuelle problemstillinger i medisinsk 
forskning forandrer seg hele tiden. I framtiden kan 
data bli brukt i forskningsprosjekter som i dag 
ikke er planlagt, forutsatt at det er i samsvar med 
gjeldende lover og forskrifter. For alle slike nye 
prosjekter kreves det at prosjektet er godkjent av 
Regional komité for medisinsk forskningsetikk og 
Datatilsynet. 
Tromsøundersøkelsen informerer om nye forsk-
ningsprosjekter på:  http://www.tromso6.no 
Her kan du også lese om forskningsresultatene 
fra Tromsøundersøkelsen. Forskningsresultater vil 
ellers bli publisert i internasjonale og nasjonale 
tidsskrifter, på faglige konferanser og møter. Det 
vil ikke være mulig å identifisere enkeltpersoner 
når forskningsresultatene offentliggjøres. 
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Samtykke 
Hvis du vil delta i den sjette Tromsøundersøkelsen, 
må du gi skriftlig samtykke til dette. Personalet på 
Tromsøundersøkelsen vil kunne gi mer informa-
sjon om undersøkelsen, og kan svare deg dersom 
du har spørsmål i forbindelse med samtykket.
Det er viktig å vite at selv om du sier ja til dette nå, 
kan du senere ombestemme deg. Du kan når som 
helst etter undersøkelsen trekke ditt samtykke til-
bake. Allerede innsamlede data blir lagret videre, 
men kan ikke lenger knyttes til deg som person, og 
dine data vil ikke bli brukt i nye forskningsprosjek-
ter. Du kan be om at blodprøven din blir ødelagt. 
Hvis du vil trekke tilbake ditt samtykke, henvend 
deg til:
Tromsøundersøkelsen, Inst. for samfunnsmedisin
Universitetet i Tromsø
9037 Tromsø
telefon: 77 64 48 16
telefaks: 77 64 48 31
e-post: tromsous@ism.uit.no
internett: www.tromso6.no
Hvis vi i framtiden ønsker å forske på nye spørsmål 
som ikke er beskrevet i denne brosjyren, kan det 
bli nødvendig å be deg om et nytt samtykke.
Vil du delta?
Følgende tekst er en kopi av dokumentet du blir bedt om å signere når du møter fram til undersøkelsen:
Samtykke til bruk av helseopplysninger i forskning - den 6. Tromsøundersøkelsen
I brosjyren jeg har fått tilsendt, har jeg lest om undersøkelsens innhold og formål, og jeg har hatt 
mulighet til å stille spørsmål. Jeg samtykker herved i å delta i undersøkelsen [dato/signatur].
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Tromsøundersøkelsen
Institutt for samfunnsmedisin, Universitetet i Tromsø
9037 TROMSØ
telefon: 77 64 48 16
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      The Health Survey is coming to Tromsø. 
This leaflet will tell you when and where. You will 
also find information about the survey in the enclosed 
brochure. 
     We would like you to fill in the form overleaf and 
take it with you to the examination. 
    The more people take part in the survey, the more 
valuable its results will be. We hope, therefore, that 
you will be able to come. Attend even if you feel 
healthy, if you are currently receiving medical 
treatment, or if you have had your cholesterol and 
blood pressure measured recently. 
Yours sincerely, 
Municipal Health Authorities 
Faculty of Medicine - University of Tromsø 
National Health Screening Service 
 Electoral ward No. Municipality Social security No.Date of birth 
HEALTH SURVEY 
Invitation
Welcome to the Tromsø Health Survey!
“THIS IS YOUR
       CHANCE”
“THIS IS A REAL 
OPPORTUNITY- TAKE IT!”
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 What is your current state of health? 
 Do you have, or have you had: 
 Do you use blood pressure lowering drugs? 
Have you during the last year suffered from pains 
and/or stiffness in muscles and joints that have 
lasted continuously for at least 3 months? 
 Have you in the last two weeks felt: 
How has your physical activity in leisure time been during this 
last year? 
How many cups of coffee do you drink daily? 
Are you a teetotaller? 
How many times a month do you normally drink 
alcohol?        
 Did any of the adults at home smoke while 
you were growing up? 
 Do you currently, or did you previously, live together
 with daily  smokers after your 20th birthday? 
 If "YES", for how many years in all? .............
 How many hours a day do you normally spend 
in smoke-filled rooms? .....
Do you yourself smoke: 
If you previously smoked daily, how long 
is it since you quit?.........................................
If you currently smoke, or have smoked 
previously:       
How many glasses of beer, wine or spirits do you  
normally drink in a fortnight?
What type of margarine or butter do you usually use on 
bread?     
What is the highest level of education you have completed?
What is your current work situation? 
How many hours of paid work do you have per 
week? 
Do you receive any of the following benefits? 
Have one or more of your parents or 
siblings  had a heart attack or had
angina (heart cramp)? ..............................
Tick one box only. 
Poor 




Angina pectoris (heart cramp)   













 Put 0 if you do not spend time in smoke-filled rooms. 
Cigarettes daily?    
Cigars/ cigarillos daily? 
A pipe daily?
How many cigarettes do you or did you 
usually smoke per day?    
How old were you when you began 
daily smoking?
How many years in all have you smoked 
daily?   
Think of your weekly average for the year. 
Time spent going to work counts as leisure time. 
Light activity (not   
sweating/out of breath)  
Hard activity (sweating/
out of breath) ..........
Coarsely ground coffee for brewing
Other coffee
Hours per week
None    Less than 1 1-2   3 or more
Put 0 if you do not drink coffee daily.     
Put 0 if less than once a month.  .....
Do not count low-alcohol beer. 
Tick one box only. 
Do not count low-alcohol beer. 
Put 0 if less than once a month. 
Don't use butter/margarine 
Butter .............
Hard margarine 
Soft margarine ....... 
Butter/margarine mixtures
Light margarine  
7-10 years primary/secondary school,       
modern secondary school
Technical school, middle school, vocational 
school, 1-2 years senior high school 
High school diploma       
(3-4 years)........................




Unemployed, on leave without payment
Sickness benefit (sick leave) 










Beer Wine  Spirits 
 No. of  
hours  







 Age first  






Yes No Don't know
No  A little  A lot 
 Very 
 much
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 The main aim of the Tromsø Study is to improve our 
knowledge about cardiovascular diseases in order to aid 
prevention. The survey is also intended to improve our 
knowledge of cancer and other general conditions, such as 
allergies, muscle pains and mental conditions. Finally, the 
survey should give knowledge about the older part of the 
population. We would therefore like you to answer the 
questions below. 
    This form is a part of the Health Survey, which has been 
approved by the Norwegian Data Inspectorate and the 
Regional Board of Research Ethics. The answers will only 
be used for research purposes and will be treated in strict 
confidence. The information you give us may later be stored 
along with information from other public health registers in 
accordance with the rules laid down by the Data 
Inspectorate and the Regional Board of Research Ethics. 
     If you are in doubt about what to answer, tick the box that 
you feel fits best. 
     The completed form should be sent to us in the enclosed 
pre-paid envelope. 
Thank you in advance for helping us. 
Yours sincerely, 
Faculty of Medicine National Health 
University of Tromsø Screening Service 
 If you do not wish to answer the questionnaire, tick the box below 
and return the form. Then you will not receive reminders. 
I do not wish to answer the questionnaire ..................................
 Date for filling in this form: ..............................
Day   Month   Year
 Who do you live with?      
 Tick once for each item and give the number.        Yes    No   Number
Spouse/partner ..............................................
Other people over 18 years ...........................
People under 18 years ...................................
 What type of house do you live in? 
Villa/ detached house ....................................
Farm ...................................................................
Flat/apartment ...................................................
Terraced /semi-detached house ......................
Other ...................................................................
How long have you lived in your present home? .............
 Is your home adapted to your needs? .............
 If "No", do you have problems with: 
Living space ...................................................
Variable temperature, 





Other (please specify) ...................................
Spouse/partner Would y  like to move into a retirement home? ..
How will you describe the type of work you had for the last 5-10   
years before you retired? 
Mostly sedentary work? ..........................................
(e.g. office work, mounting)     
Work that requires a lot of walking? .........................
(e.g. shop assistant, housewife, teaching) 
Work that requires a lot of walking and lifting? .......
(e.g. postman, nurse, construction) 
     
Did you do any of the following jobs    
(full-time or part-time)? 




How old were you when you retired? ............................
What kind of pension do you have? 
Basic state pension ..............................................
An additional pension ...........................................





Yes   No 
Years 
years  









How was your family's financial situation during your              
childhood? 
If you did not live in Norway, give country instead of municipality
 
In which Norwegian municipality did you live at the age of 1year?  
CHILDHOOD/YOUTH  
PREVIOUS WORK AND FINANCIAL SITUATION 
   HOME    
Tromsø Health Survey 
for the over 70s 
Heavy manual work .....................................................
(e.g. forestry, heavy farm-work, heavy construction)
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Yes   No 
Yes   No 
Yes   No 
Yes   No 
Yes   No 
 No A little 
   ILLNESS IN THE FAMILY       HEALTH AND ILLNESS    
   YOUR OWN ILLNESSES    
    SYMPTOMS      
Tick for the relatives who have or have ever had 
any of the following diseases: 
Has your state of health changed in the last year?
 Yes, it has got worse ..............................................
No, unchanged ...........................................................
Yes, it has got better ..................................................
How do you feel your health is now compared to       
others of your age? 
Much worse .............................................................
A little worse ...............................................................
About the same ..........................................................
A little better ...............................................................
Much better .................................................................
Have you ever had:                
Hip fracture ....................................................
Have you ever had:      Wrist /f rearm fr cture ..................................
Whiplash  .......................................................
Injury requiring  hospital admission ...........
Gastric ulcer  .................................................
Duodenal ulcer  .............................................
Gastric/duodenal ulcer surgery ...................
Have you ever had, or do you have: 
Tick one box only for each item. Give your age at the time. 
If you have had the condition several times, how old were 
you last time? 
Neck surgery ..................................................
Tick one box only for each item. 
Cancer  ......................................................................






Fibromyalgia/fibrositis/chronic pain syndrome ......
Psychological problems for which you have sought help 
Thyroid disease ..........................................................
Liver disease ............................................................







Allergy and hypersensitivity 
Atopic eczema (e.g. childhood eczema) .............
Hand eczema .........................................................
diarrhoea/vomiting or similar in the last 6 months?
Food allergy ...........................................................
Other hypersensitivity (not allergy) ....................
How many times have you had a common cold, influenza (flu), 
times    
Hey fever ............................................................
Have you had this in the last 14 days? .................
Tick "None" if none of your relatives have had the disease.                  
Mother Father Brother Sister Child  None 
Cerebral stroke or brain haemorrhage  









- age when they got
diabetes ..........................................
Do you cough about daily for some periods 
of the year? ..................................................................
If “Yes”:     
Is your cough productive? ................................
Have you had this kind of cough for as long 
as 3 months in each of the last two years? ......
Have you had episodes with wheezing in your chest?
If "Yes", has this occurred:        
Tick one box only for each item. 
At night ....................................................................
In connection with respiratory infections ................
In connection with physical exertion .......................
In connection with very cold weather ...................
Have you noticed sudden changes in your pulse 
or heart rhythm in the last year? ................................
Have you lost weight in the last year? ......................
If “Yes”:   
How many kilograms? ............................................
How often do you suffer from sleeplessness? 
Never, or just a few times a year ...........................
1-2 times a month .......................................................
Approximately once a week .......................................
More than once a week ...............................................
If you suffer from sleeplessness, what time of 
the year does it affect you most? 
No particular time of year ......................................
Especially during the polar night ..............................
Especially during the midnight sun season ............
Especially in spring and autumn ..............................
Do you usually take a nap during the day? ....
Do you feel that you usually get enough sleep? 
Do you suffer from: 
Dizziness .......................................................
Poor memory ....................................................
Lack of energy ..................................................
Constipation .................................................
 Age  
  A lot 
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     BODILY FUNCTIONS       
MEDICATION AND DIETARY SUPPLEMENTS
   FAMILY AND FRIENDS   
 USE OF HEALTH SERVICES  
Does the thought of getting a serious illness ever 
worry you?             
Not at all ..................................................................
Only a little ..................................................................
Some ............................................................................
Very much ...................................................................
Can you manage the following everyday 
activities on your own without help from 
others? 
Walking indoors on one level ......................
Walking up/down stairs ....................................
Walking outdoors ..............................................
Walking approx. 500 metres ............................
Going to the toilet .............................................
Washing yourself ..........................................
Taking a bath/shower .......................................
Dressing and undressing .................................
Getting in and out of bed .................................
Eating .................................................................
Cooking ..........................................................
Doing light housework (e.g. washing up) ..........
Doing heavier housework (e.g. cleaning floor) 
Go shopping ......................................................
Take the bus ......................................................
Can you hear normal speech 
(if necessary with hearing aid)? .......................
Can you read (if necessary with glasses)? .....
Are you dependent on any of the following aids? 
Walking stick ................................................
Crutches ...........................................................




How many visits have you made during the past year   
due to your own health or illness: 
Put 0 if you have not had such contact 
To a general practitioner (GP)/emergency GP ........
To a psychologist or psychiatrist .................................
To an other medical specialist (not at a hospital) .......
To a hospital out-patient clinic .................................
Admitted to a hospital ....................................................
To a physiotherapist ......................................................
To a chiropractor .......................................................
To a acupuncturist .........................................................
To a dentist .....................................................................
To a chiropodist .........................................................
To an alternative practitioner (homoeopath, foot zone therapist, etc.)
To a healer, faith healer, clairvoyant ............................
Do you have home aid? 
Private ...........................................................
Municipal ..........................................................
Do you receive home nursing care? ...................
Are you pleased with the health care and home
assistance services in the municipality? 
Assigned family GP .................................
Home nursing care ......................................
Home assistance services ..........................
Do you feel confident that you will receive health 





Have you for any length of time in the last year used any of the 
following medicines or dietary supplements daily or almost daily? 
Indicate how many months you have used them. 








Heart medicines (not blood pressure) ...............
Insulin .......................................................................
Diabetes tablets  ......................................................
Drugs for hypothyroidism (Thyroxine) .............
Cortisone tablets .....................................................
Remedies for constipation .....................................
Dietary supplements: 
Iron tablets ...........................................................
Vitamin D supplements ...........................................
Other vitamin supplements ....................................
Calcium tablets or bone meal ............................
Cod liver oil or fish oil capsules ............................
Do you have close relatives who can give 
you help and support when you need it? .......




How many good friends do you have whom you  
can talk confidentially with and who give you 
help when you need it? ...............................................
Do not count people you live with, but do include 
other relatives! 
Do you feel you have enough good friends?
Do you feel that you belong to a community (group of people) 
who can depend on each other and who feel committed to each 
other (e.g. a political party, religious group, relatives, neighbours, 
work place, or organisation)? 
Strong sense of belonging ...................................
Some sense of belonging .........................................
Not sure ......................................................................






 No  
Yes With difficulty  No 
 No  Yes 
Number of times




 No  Yes 
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        FOOD HABITS           
     WELL BEING       
     MENSTRUATION       
       PREGNANCY        
        ESTROGEN           
How often do you normally take part in organised gatherings, 
e.g. sewing circles, sports clubs, political meetings, religious 
or other associations? 
Never, or just a few times a year ..........................
1-2 times a month ......................................................
Approximately once a week .....................................
More than once a week .............................................
How many meals a day do you normally eat      
(dinner and bread meals)? ...............................................
How many times a week do you eat warm dinner? ........
What kind of bread (bought or home-made) do you              
usually eat? 
Tick one or two boxes. 
The bread type is most similar to:
What kind of fat is normally used in cooking 






How much (in number of glasses, cups, potatoes or slices) do you   
usually eat/drink daily the following foodstuffs? 
Tick one box for each foodstuff. 
Milk of all types (glasses) ..................
Orange juice (glasses) ...........................
Potatoes ..................................................
Slices of bread in total (incl. crispbread)
Slices of bread with 
fish (e.g. mackerel in tomato sauce) 
cheese (e.g. Gouda/Norvegia) ...................
smoked cod caviare .......................
How many times per week do you normally 
eat the following foodstuffs? 
Tick for all foodstuffs listed. 
Yoghurt .........................................
Boiled or fried egg ...........................
Breakfast cereal/oatmeal, etc. .........
Dinner with   
unprocessed meat ........................
fatty fish (e.g. salmon/red-fish)
lean fish (e.g. cod) ....................
vegetables (fresh or cooked) .......
Carrots (fresh or cooked) ................
Cauliflower/cabbage/broccoli .........
Apples/pears ....................................
Oranges, mandarins, etc. ............
Your comments:       
How content do you generally feel with growing old? 
Good ........................................................................
Quite good ..................................................................
Up and down ..............................................................
Bad ...............................................................................
What is your view of the future?        
Bright ......................................................................
Not too bad .................................................................
Quite worried ..............................................................
Dark ..............................................................................
How old were you when you started  
menstruating? ................................................................
TO BE ANSWERED BY WOMEN ONLY  
How old were you when you stopped menstruating? 
How many children have you given birth to? ........
If you have given birth, fill in for each child the year of birth 
and approximately how many months you breastfed the child. 
If you have given birth to more than 6 children, note their birth 
year and number of months you breastfed at the space provided 
below for comments.   
Child  Year of birth: Number of months    
breastfed:  
Children
Have you during pregnancy    
had high blood pressure and/or             
proteinuria? .......................................................
If "Yes", during which pregnancy? 
High blood pressure ..................................
Proteinuria ..................................................
  First    Later   
Pregnancy      
 No  Yes 
Do you use, or have you ever used estrogen:              
Tablets or patches ...........................................
Cream or suppositories ...................................
If you use estrogen, what brand do you currently use?     
Now  Previously  Never
years 
years 
 Never   
 Less  
   than 1     




 Less    
 than 1  
None  
 White





  Coarse   
brown  
   Crisp   
  bread  
 Number  
Thank you for the help! Remember to mail the form today! 
Tromsø Health Survey 
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    The main aim of the Tromsø Study is to improve our 
knowledge about cardiovascular diseases in order to aid 
prevention. The survey is also intended to improve our 
knowledge of cancer and other general conditions, such as 
allergies, muscle pains and mental conditions.  We would 
therefore like you to answer some questions about factors 
that may be relevant for your risk of getting these and other 
illnesses. 
   This form is a part of the Health Survey, which has been 
approved by the Norwegian Data Inspectorate and the 
Regional Board of Research Ethics. The answers will only 
be used for research purposes and will be treated in strict 
confidence. The information you give us may later be stored 
along with information from other public health registers in 
accordance with the rules laid down by the Data Inspectorate 
and the Regional Board of Research Ethics. 
  If you are in doubt about what to answer, tick the box that 
you feel fits best. 
  The completed form should be sent to us in the enclosed 
pre-paid envelope. 
Thank you in advance for helping us. 
Yours sincerely, 
Faculty of Medicine  National Health 
University of Tromsø Screening Service
 
If you do not wish to answer the questionnaire, tick the 
box below and return the form. Then you will not receive 
reminders. 
I do not wish to answer the questionnaire ..................................
 Date for filling in this form:................................
 Day  Month  Year
In which Norwegian municipality did you live  at the age of 1 year? 
If you did not live in Norway, give country of residence instead of municipality.
How was your family's financial situation during your 
childhood? 
Very good ..............................................................
How many of the first three years of your life   
How many of the first 15 years of your life                  
 Who do you live with?                
Good ........................................................................
Difficult .....................................................................
Very difficult  .............................................................
 - did you live in a town/city? .......................................
 - did your family have a cat or dog in the home? .......
 - did you live in a town/city? .......................................





Yes No  
Yes No  
Yes No  
Yes No  
Yes  No   Tick once for each item and give the number .       
 Spouse/partner ............................................
 Other people over 18 years .........................
 People under 18 years ................................
How many of the children attend day care/kindergarten? ....




Terraced /semi-detached house ........................
Other ..................................................................
 How big is your house? ..................................................
 Approximately what year was your house built? ............
 Has your house been insulated after 1970?...............
 Do you live on the lower ground floor/basement? .....
 If "Yes", is the floor laid on concrete? ...................
What is the main source of heat in your home?   
Number   
Electric heating ......................................................
Wood-burning stove .................................................
Central heating system using:                  
Paraffin ...................................................................
Electricity ................................................................
Do you have fitted carpets in the living room? ............
Is there a cat in your home? .......................................
Is there a dog in your home? ......................................
If you have paid or unpaid work, how would you describe   
 your work? 
Mostly sedentary work? .........................................
(e.g. office work, mounting) 
Work that requires a lot of walking? ..........................
(e.g. shop assistant, light industrial work, teaching)  
Work that requires a lot of walking and lifting? ..........
(e.g. postman, nursing, construction) 
Heavy manual work? .................................................
(e.g. forestry, heavy  farm-work, heavy construction) 
Can you decide yourself how your work should be         
organised? 
No, not at all ..........................................................
To a small extent ......................................................
 Who do you live with?   Yes, to a large extent ................................................
Are you on call, do you work shifts or nights?.............
Do you do any of the following jobs (full- or part-time)?




Yes, I decide myself ..................................................
       HOME   
      WORK
CHILDHOOD/YOUTH
The Tromsø Health Survey                            
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   ILLNESS IN THE FAMILY  
   USE OF HEALTH SERVICES   
YOUR OWN ILLNESSES        SYMPTOMS      
Do you cough about daily for some periods of the year?
Have you ever had: 
Tick one box only for each item. Give your age at the time. 








Have you you ever had, or do you still have: 







Fibromyalgia/fibrositis/chronic pain syndrome .........





Allergy and hypersensitivity: 




Other hypersensitivity (not allergy) ....................
How many times have you had a cold, influenza (flu),
vomiting/diarrhoea, or similar in the last six months? 
Have you had this in the last 14 days?.......................
Tick for the relatives who have or have ever
had any of the following diseases: 
Tick "None" if none of your relatives have had the disease.               
Cerebral stroke or brain haemorrhage








age when they got
diabetes ..................................
If "Yes":     
Is your cough productive ? ..............................
Have you had this kind of cough for as long as
3 months in each of the last two years? ............
Have you had episodes of wheezing in your chest?
If "Yes", has this occurred:      
Tick one box only for each item.     
At night ................................................................
In connection with respiratory infections ..................
In connection with physical exertion ........................
In connection with very cold weather .......................
Have you noticed sudden changes in your pulse 
or heart rhythm in the last year?.................................
How often do you suffer from sleeplessness? 
Never, or just a few times a year .........................
1-2 times a month .....................................................
Approximately once a week ......................................
More than once a week .............................................
If you suffer from sleeplessness, what time       
of the year does it affect you most? 
No particular time of year ...................................
Especially during the polar night .............................
Especially during the midnight sun season .............
Especially in spring and autumn ..............................
Have you in the last year suffered from sleeplessness
to the extent that it has affected your ability to work?...
How often do you suffer from headaches? 
Rarely or never .....................................................
Once or more a month ...............................................
Once or more  a week ...............................................
Daily ...........................................................................
Does the thought of getting a serious illness ever 
worry you? 
Not at all ...............................................................
Only a little ................................................................
Some .........................................................................
Very much .................................................................
How many visits have you made during the past year 
due to your own health or illness:
Tick 0 if you have not had such contact 
To a general practitioner (GP)/Emergency GP ............
To a psychologist or psychiatrist .....................................
To an other medical specialist (not at a hospital) ............
To a hospital out-patient clinic .....................................
Admitted to a hospital ......................................................
To a medical officer at work .............................................
To a physiotherapist ....................................................
To a chiropractor .............................................................
To an acupuncturist .........................................................
To a dentist ..................................................................
To an alternative practitioner (homoeopath, foot zone therapist, etc.) 
To a healer, faith healer, clairvoyant  ..............................
Number of times 
the past year
Yes  No  
Yes  No  
Yes  No  
Yes  No  
Yes  No  
Age    
times     
Mother Father Brother Sister Child None  
Gastric/duodenal ulcer surgery ....................
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MEDICATION AND DIETARY SUPPLEMENTS            FOOD HABITS           
       FRIENDS      
Have you for any length of time in the past year used any of the 
following medicines or dietary supplements daily or almost daily? 
Indicate how many months you have used them. 
Put 0 for items you have not used. 
Medicines
Painkillers ............................................................







Dietary supplements            
Iron tablets ...........................................................
Calcium tablets or bonemeal ...................................
Vitamin D supplements ............................................
Other vitamin supplements ..................................
Cod liver oil or fish oil capsules ...............................
Have you in the last 14 days used the following             
medicines  or dietary supplements? 
Tick one box only for each item. 
Medicines            
months
good
friends    
Painkillers           .............................................................
Antipyretic drugs (to reduce fever) ...........................
Migraine drugs .........................................................
Eczema cream/ointment ..........................................
Heart medicines (not blood pressure) ......................




Other drugs for nervous conditions ..........................
Antacids ...............................................................
Gastric ulcer drugs ...................................................
Insulin .......................................................................
Diabetes tablets ........................................................





Calcium tablets or bonemeal ...................................
Vitamin D supplements ............................................
Other vitamin supplements ..................................
Cod liver oil or fish oil capsules ................................
- jam and other sweet spreads .......
confidentially with and who give you help when you need it? 259
Do not count people you live with, 
but do include other relatives!  
How many of these good friends do you have 
contact with at least once a month? .........................
Do you feel you have enough good friends? ...........
How often do you normally take part in organised   
gatherings, e.g. sewing circles, sports clubs, 
political meetings, religious or other associations?     
Never, or just a few times a year .........................
1-2 times a month ....................................................
Approximately once a week .....................................
More than once a week ............................................ Waffles, cakes, etc. ..................
Chocolate .......................................
Sugar-free ("Light") soft drinks .....








- lean fish (e.g. cod)  ....................
- fatty fish (e.g. salmon/redfish)
- sausage/meatloaf/ meatballs .....
Dinner with
- unprocessed meat......................
Breakfast cereal/ oat meal, etc. ...
Boiled or fried egg ........................
Yoghurt ....................................
How many times per week do you normally eat the following foodstuffs? 
How many good friends do you have whom you can talk
What kind of fat is normally used in cooking         
(not on the bread) in your home? 
A catering portion is enough for about
If you use butter or margarine on your bread, how many slices does   
a small catering portion normally cover? By this, we mean the 






Tick one or two boxes! 
The bread I eat is most similar to:
Sleeping pills 
How much (in number of glasses, cups, potatoes or slices) do you   
usually eat or drink daily of the following foodstuffs? 
Tick one box for each foodstuff. 
Full milk (ordinary or curdled) (glasses)
Semi-skimmed milk .........................
(ordinary or curdled) (glasses)
Tea (cups) .......................................
Orange juice (glasses) ....................
Potatoes .....................................
Slices of bread in total 
(incl. crisp-bread) ............................
Slices of bread with 
- fish 
(e.g. mackerel in tomato sauce) .....
- lean meat                    
(e.g. ham) .......................................
- fat meat                       
(e.g. salami) ....................................
- cheese (e.g. Gouda/ Norvegia) .........
- brown cheese ...............................







  Coarse 
brown  
   Crisp 
  bread 
Skimmed milk (ordinary or curdled) (glasses)
Tick a box for all foodstuffs listed. 
slices   
 Less 
 than 1 
 More 
than 6 
  Never 
 Less 
 than 1 
  almost  
daily 










What kind of bread (bought or hom -made) do you usually eat?         
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      ALCOHOL
How often do you usually drink   
Never, or just a few times a year .......
1-2 times a month ..............................
About once a week ............................
2-3 times a week ...............................
More or less daily ..............................
Approximately how often during the last year have you consumed 
alcohol corresponding to at least 5 small bottles of beer, a bottle 
of wine, or 1/4 bottle of spirits?            
Not at all the last year ...............................................
A few times ...............................................................
1-2 times a month .....................................................
1-2 times a week ......................................................
3 or more times a week ............................................
For approximately how many years has your alcohol       
consumption been as you described above? ..................
- before age 20 ..................................................
years
   spirits?   wine?beer?
 TO BE ANSWERED BY WOMEN ONLY 
      MENSTRUATION   
      PREGNANCY     
      WEIGHT REDUCTION   
      URINARY INCONTINENCE       
      CONTRACEPTION AND ESTROGEN  
- later .................................................................
If you have lost weight deliberately, about how many                 
kilos have you ever lost at the most? 
- before age 20 ..............................................................
- later .............................................................................
What weight would you be satisfied with 
(your "ideal weight")? ....................................................
How often do you suffer from urinary incontinence?
Never ...................................................................
Not more than once a month ...................................
Two or more times a month .....................................
Once a week or more ..............................................
Your comments:            
Do you use, or have you ever used: 
Oral contraceptive pills (incl. minipill) ...
Hormonal intrauterine device ....................
Estrogen (tablets or patches) ..............
Estrogen (cream or suppositories) ............
If you use oral contraceptive pills, hormonal intrauterine device,                 
or estrogen, what brand do you currently use? 
If you use or have ever used oral contraceptive pills: 
How many years in total have you taken the pill? .....
If you have given birth, how many years did you 
take the pill before your first delivery? .......................
If you have stopped taking the pill: 
       Age when you stopped? .....................................
Thank you for the help! Remember to mail the form today! 
The Tromsø Health Survey 
How old were you when you started                       
menstruating? ................................................................
If you no longer menstruate, how old were
you when you stopped menstruating? ...........................
you ever stopped having menstruation for      
6 months or more? ...................................................
If "Yes", how many times? ..................................
If you still menstruate or are pregnant:                         
What date did your last menstruation period begin?
Do you usually use painkillers to                       
relieve period pains? ............................................
How many children have you given birth to? .............
Are you pregnant at the moment? ....................
Have you during pregnancy had 
high blood pressure and/or proteinuria? ...........
If "Yes", during which pregnancy? 
High blood pressure ....................................
Proteinuria ...................................................
If you have given birth, fill in for each child the year of birth 
and approximately how many months you breastfed the child. 
Child Year of birth:  
About how many times have you deliberately tried to 
lose weight? Write 0 if you never have. 
Apart from pregnancy and after giving birth, have        
Yes  No 
day/month/year
 times  
  No Yes 
years
years
Number of months 
breastfed:
Yes  No 
Yes  No 
 children  
 Don't know  
 Pregnancy
First         Later  
Age when you started to take the pill? ......................
  times  





  times  
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Do not write here:




Questionnaire 1 (≥70 years), 5th Tromsø Survey
Questionnaire 1 (≥70 years), 5th Tromsø Survey





Fibromyalgia/chronic pain syndrome .....
Psychological problems for which you 
have sought help ....................................
A heart attack .........................................
Angina pectoris (heart cramp) ................
Cerebral stroke/brain haemorrhage ........
Have one or more of your parents or siblings had:
NoYes
What is your current state of health? (Tick only once)
Poor Not so good Good Very good
1   2   3   4
Do you get pain or discomfort in the chest when:
Walking up hills, stairs, or walking fast on level ground?
If you stop, does the pain disappear 
within 10 minutes? .............................................
Can such pain occur even if you are at rest?....
If you get such pain, do you usually:
Stop? Slow down? Carry on at the same pace?






A heart attack (heart wounds) or




E1. YOUR OWN HEALTH E3. COMPLAINTS
E4. TEETH, MUSCLE AND SKELETON
E5. EXERCISE AND PHYSICAL ACTIVITY
E6. BODY WEIGHT
E2. ILLNESS IN THE FAMILY
Below is a list of various problems.
Have you experienced any of this during the last week
(including today)?
(Tick once for each line)
Sudden fear without reason ..........
Felt afraid or anxious ....................
Faintness or dizziness ..................
Felt tense or upset ........................
Tend to blame yourself ..................
Sleeping problems.........................
Depressed, sad .............................
Feeling of being useless, worthless ..
Feeling that everything is a struggle










  1 2 3 4
How many teeth have you lost/extracted? Number of teeth
(disregard milk-teeth and wisdom teeth)
Estimate your body weight when you 
were 25 years old: kg.
Have you been bothered by pain and/or stiffness in 
muscles and joints during the last 4 weeks?
Neck / shoulders ....................
Arms, hands..........................
Upper part of the back ..........
Lumbar regions ....................








Have you ever had:
Fracture in wrist/forearm? ........................
Hip fracture?............................................
Have you fallen down during the last year? (Tick once only)
NoYes




(not sweating/out of breath).....
Hard physical activity
(sweating/out of breath)............
Less than 1None 1-2 3 or more
How has your physical activity been during this last year?
Think of a weekly average for the year.
Answer both questions.
1    2 3    4
Hours per week
1   2   3
Tick for the relatives who have or have
had any of the illnesses: (Tick for each line)
Cerebral stroke or 
brain haemorrhage ...
Heart attack




If any relatives have diabetes, at what age did they get 
diabetes (if for e.g. many siblings, consider the one who 









Father Brother Sister Child
None
of these
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Fruit, berries ...........




Fat fish (e.g. salmon, 
trout, mackerel, herring)
E7. EDUCATION
E8. FOOD AND BEVERAGES
E9. SMOKING
E10. BODILY FUNCTIONS AND SAFETY
How often do you usually eat these foods?
(Tick once for each line)
Do you use dietary supplements:
How many hours a day do you normally spend
in smoke-filled rooms? Number of total hours
Did any of the adults smoke at home
while you were growing up? ........................... 
Do you currently, or did you previously live
together with a daily smoker after your 20th 
birthday?
Do you/did you smoke daily? .................
If you have NEVER smoked daily;
Go to question E11  (BODILY FUNCTIONS AND SAFETY)
If you smoke daily now, do you smoke:
If you previously smoked daily, how
long is it since you quit? Number of years
If you currently smoke, or have smoked 
previously:
Cod liver oil, fish oil capsules ................
Vitamins and/or mineral supplements ...
How much of the following do you usually drink?













1    2    3   4    5    6
Yes, daily Sometimes No
Full milk, full-fat curdled 
milk, yoghurt ...........................
Semi-skimmed milk, semi-skimmed 
curdled milk, low-fat yoghurt .......
Skimmed milk, skimmed 
curdled milk .........................
Extra semi-skimmed milk ....
Juice ...................................
Water ..................................














1 2 3    4    5
123
1    2   3   4
How many years of education have 
you completed? Number of years
(include all the years you have attended school or studied)
Would you feel safe by walking alone in the evening
in the area where you live?
When it comes to mobility, sight and hearing, can you:
(Tick once for each line)
Do you because of chronic health problems have
difficulties with: (Tick once for each line)
Take a 5 minute walk
in fairly high pace? ................
Read ordinary text in newspaper,
if necessary with glasses? .........
Hear what is said in a
normal conversation? ............
Move around in your home? .................
Get out of your home by yourself? .......
Participate in organization or other 
leisure time activities? ..........................
Use public transport? ............................












How many cigarettes do you or did you 
normally smoke per day? Number of cigarettes
How old were you when you began 
daily smoking? Age in years
How many years in all have 
you smoked daily? Number of years














Approximately, how often have you during the last year  
consumed alcohol? (Do not count low-alcohol and alcohol-free beer)
When you drink alcohol, how many 
glasses or drinks do you normally drink? Number
Approximately how many times during the last 
year have you consumed alcohol equivalent to
5 glasses or drinks within 24 hours? Number of times
Filtered coffee ...........................................................
Boiled coffee/coarsely ground coffee for brewing .....



















1   2   3 4
5   6   7 8
Number of cups
How many cups of coffee and tea do you drink daily?
(Put 0 for the types you do not drink daily)
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Name of the medicine: Reason for use of Up to One year
(one name per line): the medicine: 1 year or more
Blood pressure lowering drugs .............
Cholesterol-lowering drugs ...................
Drugs for osteoporosis ..........................
Insulin.....................................................
Tablets for diabetes ................................
How much interest do people show for what you do?
(Tick only once)
How many associations, sport clubs, 
groups, religious communities, 
or similar do you take part in? Number 
(write 0 if none)
Do you live: At home? In an institution/shared apartment?
Do you live with:
Spouse/ partner?.......................
Other people? ...........................
How many good friends do you have?
Count the ones you can talk confidentially with
and who can give you help when you need it.
Do not count people you live with, but do include
your children and other relatives........................
How many times in the last 12 months
have you been to/used:
(Tick once for each line)
Are you confident that you 
will receive health care and 
home assistance if you need it?
E11. USE OF HEALTH SERVICES
E12. FAMILY AND FRIENDS
E13. CHILDHOOD/YOUTH AND AFFILIATION
E14. USE OF MEDICINES
E15. THE REST OF THE FORM IS TO
BE ANSWERED BY WOMEN ONLY
Do you use?
(Tick once for each line)
How old were you when you  
started menstruating? Age in years
How old were you when you 
stopped menstruating? Age in years




Do you use, or have you ever used estrogen?
How often have you during the last 4 weeks used the 
following medicines?














1   2   3   4   5
With medicines, we mean drugs purchased at pharmacies. 
Supplements and vitamins are not considered here
Painkillers non-prescription........ 




Other prescription medicines ....
Tablets or patches .....................
Cream or suppositories .............










If there is not enough space here, you may continue on a separate sheet that you attach.
How long have you
used the medicine
Never Previously Now
If you use estrogen, which brand you use now?
Have you ever used contraceptives pills? ......
1 2 3 4
A general practitioner (GP) ..............
Specialist (private or out-patient clinic)
Emergency GP (private or public).....
Hospital admission ...........................
Home nursing care ..........................
Physiotherapist ................................
Chiropractor .....................................







How long altogether have you lived  in the county?
How long altogether have you lived in 
the municipality?
Where did you live most of the time before the age of 16?
(Tick one option and specify)
Same municipality.........
Another municipality
in the county.................. Which one:
Another county in Norway Which one:
Outside Norway ........... Country:
Have you moved during the last five years?
No Yes, once Yes, more than once










































State the name of the medicines you are using now and the 
reason you are taking the medicines (disease or symptom):
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5.3 (Municipality) (County) (Country)
9.3 (Business) 9.4 (Occupation) 14.7 (Mark)
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Fibromyalgia/chronic pain syndrome ......
Psychological problems for which you  
have sought help  ............................................
A heart attack .........................................
Angina pectoris (heart cramp) ................
Cerebral stroke/brain haemorrhage .........
2.1 Have you suffered from pain and/or stiffness in 
muscles and joints during the last 4 weeks?
(Give duration only if you have had problems)
5.1 How long altogether have you lived in the county?
(Put 0 if less than half a year)
5.2 How long altogether have you lived in the municipality?
(Put 0 if less than half a year)
5.3 Where did you live most of the time before the age of 16?
(Tick one option and specify)
Same municipality ....
Another municipality
in the county .............. Which one:
Another county in Norway Which one:
Outside Norway ........ Country::
5.4 Have you moved within the last five years?
No Yes, one time Yes, more than once
1   2   3
NoYes
1.1 What is your current state of health? (Tick one only)
Poor Not so good Good Very good
1   2   3   4
1.4 Do you get pain or discomfort in the chest when:
Walking up hills, stairs or walking fast on level ground?
1.6 If you stop, does the pain disappear within
10 minutes? ...........................................................
1.7 Can such pain occur even if you are at rest?........
1.5 If you get such pain, do you usually:
Stop? Slow down? Carry on at the same pace?









Upper part of your back... 
Lumbar region .................
Hips, legs, feet ................
Other places ....................











2.2 Have you ever had:
Fracture in the wrist/forearm  ...................
Hip fracture?..............................................
1. YOUR OWN HEALTH 3. OTHER COMPLAINTS
4. USE OF HEALTH SERVICES
5. CHILDHOOD/YOUTH AND AFFILIATION
6. BODY WEIGHT
2. MUSCULAR AND SKELETAL COMPLAINTS
3.1 Below is a list of various problems. Have you experienced 
any of this during the last week (including today)?
(Tick once for each complaint)
Sudden fear without reason ....................
Felt afraid or anxious ..............................
Faintness or dizziness ............................
Felt tense or upset ..................................
Tend to blame yourself ...........................
Sleeping problems ..................................
Depressed, sad ......................................
Feeling of being useless, worthless ........
Feeling that everything is a struggle ......










1    2    3    4
4.1 How many times in the last 12 months have you been to/used:
(Tick once for each line)
General practitioner (GP) .......................
Medical officer at work ...........................
Psychologist or psychiatrist ....................
(private or out-patient clinic)
Other specialist (private or out-patient clinic)
Emergency GP (private or public) ..............
Hospital admission .................................











6.1 Estimate your body weight when you
were 25 years old: kg
1.3 Have you noticed attacks of sudden changes in 
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7. FOOD AND BEVERAGES 8. SMOKING
9. EDUCATION AND WORK
7.1 How often do you usually eat these foods?
(Tick once per line)
7.2 What type of fat do you usually use? (Tick once per line)
7.3 Do you use the following dietary 
supplements:
8.1 How many hours a day do you normally spend
in smoke-filled rooms? Number of total hours
8.2 Did any of the adults smoke at home 
while you were growing up? .................................
8.3 Do you currently, or did you previously live
together with a daily smoker after your
20th birthday? 
8.4 Do you/did you smoke daily? ..................
If NEVER: Go to question 9 : (EDUCATION AND WORK)
8.5 If you smoke daily now, do you smoke:
8.6 If you previously smoked daily, how
long is it since you quit? Number of years











Cod liver oil, fish oil capsules ..............
Vitamins and/or mineral supplements?
7.4 How much of  the following do you usually drink?
(Tick once per line)
7.5 Do you usually drink soft drink: with sugar 1 without sugar  2
7.6 How many cups of coffee and tea do you drink daily?
(Put 0 for the types you don't drink daily)
7.7 Approximately how often have you during the last year 
consumed alcohol? (Do not count low-alcohol and alcohol-free beer)
7.8 When you drink alcohol, how many
glasses or drinks do you normally drink? number
7.9 Approximately how many times during the last
year have you consumed alcohol equivalent to




















Yes, daily Sometimes No
1    2    3    4    5    6
Full milk, full-fat curdled milk, 
yoghurt ..................................
Semi-skimmed milk, semi-skimmed 
curdled milk,low-fat yoghurt ......
Skimmed milk, skimmed 
curdled milk ..............................
Extra semi-skimmed milk ......
Juice .....................................
Water ....................................
Mineral water (e.g. Farris, 
Ramløsa etc)
Cola-containing soft drink .....














1 2    3    4    5
Filtered coffee ..........................................................
Boiled coffee/coarsely ground coffee for brewing .....



















1   2   3 4
5   6   7 8
7.10 When you drink, do you normally drink:(Tick one or more)
Beer Wine Spirits 
9.1 How many years of education
have you completed? Number of years
(Include all the years you have attended school or studied)
9.2 Do you currently have paid work?
9.3 Describe the activity at the workplace  where 
you had paid work for the longest period in the
last 12 months. (e.g. Accountancy firm, school, paediatric 
department, carpentry workshop, garage, bank, 
grocery store, etc.)
Business:
If retired, enter the former business and occupation.
Also applies to 9.4
9.4 Which occupation/title have or had you at this workplace?
(e.g. Secretary, teacher, industrial worker, nurse,
carpenter, manager, salesman, driver, etc.)
Occupation:
9.5 In your main occupation, do you work as self-employed, 
as an employee or family member without regular salary?
9.6 Do you believe that you are in danger of losing 
your current work or income within the next 
two years? ...........................................................
9.7 Do you receive any of the following benefits?
Yes No





Sickness benefit (are on sick leave) .......................
Old age pension, early retirement (AFP) or
survivor pension ..................................................... 
Rehabilitation/reintegration benefit .........................
Disability pension (full or partial) .............................
Unemployment benefits during unemployment .......
Social welfare benefits ............................................
Transition benefit for single parents ........................
How many cigarettes do you or did you
normally smoke per day? Number of cigarettes
How old were you when you began
daily smoking? Age in years
How many years in all have you
smoked daily? Number of years
Yes    No
Yes No
Yes, full-time Yes, part-time No1              2            3
Self-employed Employee Family member
Oils
Number of cups
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Light activity
(not sweating/out of breath)...
Hard physical activity
(sweating/out of breath).........
Blood pressure lowering drugs ...................
Cholesterol-lowering drugs .........................
Reading, watching TV or 
other sedentary activity? ......................................... .........
Walking, cycling or other forms of 
exercise at least 4 hours a week? .....................................
(Include walking or cycling
to work, Sunday walk/stroll,etc.)
Participation in recreational sports, heavy gardening, etc.?
(Note: duration of activity at least 4 hours a week)
Participation in hard training or sports competitions, 
regularly several times a week? ........................................
None Less than 1 1-2 3 or more
10.1 How has your physical activity in leisure time been 
during this last year?
Think of a weekly average for the year.
Time spent going to work is count as leisure time. Answer both questions.
11.3 How much interest do people show for what you do?
(Tick only once)
11.4 How many associations, sport clubs,groups, religious
 communities or similar do you take part in?  Number
(Write 0 if none)
11.5 Do you feel that you can influence what happening
in your local community where you live? (Tick only once)
12.1 Have one or more of your parents or siblings
had a heart attack (heart wound) or
angina pectoris (heart cramp)? ..........................
12.2 Tick for the relatives who have or have
had any of the illnesses: (Tick for each line)
Cerebral stroke or 
brain haemorrhage .......
Heart attack




12.3 If any relatives have diabetes, at what age did they get
diabetes (if for e.g. many siblings, consider the one who 
got it earliest in life):
11.2 How many good friends do you have? Number of friends
Count the ones you can talk confidentially with
and who can give you help when you need it.
Do not count people you live with, but do include
other relatives.
10.2 Describe exercise and physical exertion in your leisure time.
If your activity varies much e.g. between summer and winter, 
then give an average. The question refers only to the last year.
(Tick the most appropriate box)
1 2 3    4
10. EXERCISE AND PHYSICAL ACTIVITY
11. FAMILY AND FRIENDS
12. ILLNESS IN THE FAMILY
13. USE OF MEDICINES
14. THE REST OF THE FORM IS TO
BE ANSWERED BY WOMEN ONLY
13.1 Do you use:
14.1 How old were you when you 
started menstruating? Age in years
14.2 If you no longer menstruating, how old were
you when you stopped menstruating? Age in years
14.3 Are you pregnant at the moment?
14.4 How many children have you 
 given birth to? Number of children
14.5 Do you use, or have you ever used?
(Tick once for each line)
13.2 How often have you during the last 4 weeks used
the following medicines?
(Tick once for each line)
13.3 For those medicines you have checked in points 13.1 and 























Mother's age Father's age Brother's age Sister's age Child's age
Father Brother Sister Child
None
of these
Yes, some Yes, a little No
Never 
tried




With medicines, we mean drugs purchased at pharmacies.
Supplements and vitamins are not considered here.
Painkillers non-prescription ....




Other prescription medicines ...
Oral contraceptive pills/mini pill/
contraceptive injection ................
Hormonal intrauterine device (IUD)
(not ordinary IUD)..
Estrogen (tablets or patches) .....
Estrogen (cream or suppositories)
State the name and the reason that you are taking/have taken
these (disease or symptom):











Name of the medicine: Reason for use of Up to 1 year
(one name per line) the medicine 1 year or more
If there is not enough space here, you may continue on a separate sheet that you attach
How long have you
used the medicine
Yes No Uncertain Above fertileage 






























but not now Never
14.6 If you use/have used prescription estrogen:
How long have you used it? Number of years
14.7 If you use contraceptive pills, mini pill, contraceptive 
injection, hormonal IUD or estrogen, what brand do you use?
1 2 3 4
1   2   3   4   5
11.1 Do you live with:
Spouse/partner?.........................................
NoYes
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c Neither good nor bad
c Bad 
c Very bad
2 How is your health compared to others in your age?
c Much better
c A little better
c About the same
c A little worse
c Much worse
3 Do you have, or have you had? Yes  No
Age first
time
Heart attack .............................................. c c
Angina pectoris ........................................ c c
Stroke/brain hemorrhage..................... c c
Atrial fibrillation ..................................... c c
High blood pressure ............................... c c
Osteoporosis .............................................. c c
Asthma ......................................................... c c
Chronic bronchitis/Emphysyma/COPD .... c c
Diabetes mellitus .................................... c c
Psychological problems (for which you 
have sought help )
c c
Low metabolism........................................ c c
Kidney disease, c c
Migraine ....................................................... c c
4 Do you have persistent or constantly recurring
pain that has lasted for 3 months or more?
c Yes c No
5 How often have you suffered from sleeplessness during 
 the last 12 months? 
c Never, or just a few times
c 1-3 times a month
c Approximately once a week
c More that once a week
6 Below you find a list of different situations.  
Have you experienced some of them in the last week







Sudden fear without reason c c c c
You felt afraid or 
worried ........................................ c c c c
Faintness or dizziness ........... c c c c
You felt tense or
upset ............................................. c c c c
Easily blamed yourself .......... c c c c
Sleeping problems .................. c c c c
Depressed, sad ......................... c c c c
You felt useless,
worthless ..................................... c c c c
Feeling that life is a struggle c c c c
Feeling of hopelessness with 
regard to the future .............. c c c c
7 Have you during the past year visited:
If YES; how many times?
Yes No   No. of times
General practitioner (GP) .................... c c
Psychiatrist/psychologist ...................... c c
Medical specialist outside hospital 
(other than general practitioner/psychiatrist) c c
Physiotherapist ..........................................c c
Chiropractor ............................................... c c
Alternative medical practitioner
(homeopath, acupuncturist, foot zone therapist, 
herbal medical practitioner, laying on hands 
practitioner,  healer, clairvoyant, etc.)
c c
Dentist/dental service ........................... c c
The form will be read electronically. Please use a blue or black pen 
You can not use comas, use upper-case letters.
2007 – 2008 Confidential
9 Have you undergone any surgery during the last 3 years?
c Yes c No
8 Have you during the last 12 months been to  
a hospital? Yes  No  No. of times
Admitted to a hospital ........................... c c
Had consultation in a hospital without admission;
At psychiatric out-patient clinic c c
At another out-patient clinic ..... c c
USE OF HEALTH SERVICES
HEALTH AND DISEASES
not including urinary 
tract  infection (UTI)
complaint
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19 What is your main occupation/activity? (Tick one)
c Full time work c Housekeeping
c Part time work c Retired/benefit recipient
c Unemployed c Student/military service
10 Do you take, or have you taken some of the  






Drugs for high blood pressure c c c
Lipid lowering drugs ................. c c c
Drugs for heart disease .......... c c c
Diuretics ........................................ c c c
Medications for 
osteoporosis .................................c c c
Insulin ............................................ c c c
Tablets for diabetes ................. c c c
Drugs for metabolism
Thyroxine/levaxin .................... c c c
11 How often have you during the last 4 weeks used











prescription ......... c c c c
Painkillers non- 
prescription .......... c c c c
Sleeping pills ........ c c c c
Tranquillizers  ..... c c c c
Antidepressants  ..c c c c
12 State the names of all medications -both those 
on prescription and non-prescription drugs- you 
have used regularly during the last 4 weeks.  
Do not include vitamins, minerals, herbs, natural  
remedies, other nutritional supplements, etc. 
When attending the survey centre you will be  
asked whether you have used antibiotics or  
painkillers the last 24 hours. If you have, you  
will be asked to provide the name of the drug,  
strength, dose and time of use. 
13 Who do you live with? (Tick for each question 
and give the number)
Yes No Number
Spouse/cohabitant ................................ c c
Other persons older than 18 years.. c c
Persons younger than 18 years ........ c c
14 Tick for relatives who have or have had
Parents Children Siblings
Myocardial infarction ..................... c c c
Myocardial infarction before 60 years c c c
Angina pectoris ................................. c c c
Stroke/brain haemorrhage .......... c c c
Osteoporosis  ..................................... c c c
Stomach/duodenal ulcer .............. c c c
Asthma ................................................. c c c
Diabetes mellitus ............................. c c c
Dementia ............................................. c c c
Psychological problems ................. c c c
Drugs/substance abuse ................. c c c
15 Do you have enough friends who can give you 
help when you need it?  
c Yes c No
16
Do you have enough friends whom you can talk 
confidentially with? 
c Yes c No
17 How often do you normally take part in 
organised gatherings, e.g. sports clubs, political 
meetings, religious or other associations? 
c Never, or just a few times a year
c 1-2 times a month
c Approximately once a week
c More than once a week
WORK, SOCIAL SECURITY AND INCOME 
18 What is the highest level of education you have 
completed? (Tick one)
c Primary, 1-2 years secondary school
c Vocational school
c High secondary school (A-level)
c College/university less than 4 years
c College/university 4 years or more
FAMILY AND FRIENDS
If the space is not enough for all medications, use an additional 
paper of your own.
USE OF MEDICINE
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25 How often do you exercise?  (With exercise we mean
for example walking, skiing, swimming or 
training/sports) 
c Never
c Less than once a week
c Once a week
c 2-3 times a week
c Approximately every day
36 How many years in all have you smoked daily? 
Number of 
years
35 How old were you when you began smoking daily?
Number of 
years
22 Do you work outdoors at least 25% of the time, or  
in cold buildings (e.g. storehouse/industry  
buildings)?
c Yes c No
23 If you have paid or unpaid work, which statement  
describes your work best?
c Mostly sedentary work
(e.g. office work, mounting)
c Work that requires a lot of walking
(e.g. shop assistant, light industrial work, teaching)
c Work that requires a lot of walking and lifting
(e.g. postman, nursing, construction)
c Heavy manual labour
24
c Reading, watching TV, or other sedentary 
activity.
c Walking, cycling, or other forms of exercise
at least 4 hours a week (here including walking or  
cycling to place of work, Sunday-walking, etc.)
c Participation in recreational sports, heavy gardening, 
etc. (note:duration of activity at least 4 hours a week)
c Participation in hard training or sports 
competitions, regularly several times a week.
26 How hard do you exercise on average?
c Easy- do not become short-winded or sweaty
c You become short-winded and sweaty
c Hard- you become exhausted
29 How many units of alcohol(a beer, a glass of wine or 
a drink) do you usually drink when you drink alcohol?
c 1-2 c 5-6 c 10 or more
c 3-4 c 7-9






27 For how long time do you exercise every time on average?
c Less than 15 minutes c 30-60 minutes
c 15-29 minutes c More than 1 hour
30 How often do you drink 6 units of alcohol or more  
in one occasion?
c Never
c Less frequently than monthly
c Monthly
c Weekly
c Daily or almost daily
28 How often do you drink alcohol?
c Never
c Monthly or more infrequently
c 2-4 times a month
c 2-3 times a week
c 4 or more times a week
21 What was the households total taxable income last
 year? Include income from work, social benefits
and similar
c Less than 125 000 NOK c 401 000-550 000 NOK
c 125 000-200 000 NOK c 551 000-700 000 NOK
c 201 000-300 000 NOK c 701 000 -850 000 NOK 
c 301 000-400 000 NOK c More than 850 000 NOK
34 If you currently smoke, or have smoked before: 








31 Do you smoke sometimes, but not daily?
c Yes c No




c Full disability pension
c Partial disability pension
c Unemployment benefits
c Transition benefit for single parents
c Social welfare benefits
37 Do you use or have you used snuff or chewing tobacco?
c No, never c Yes, sometimes
c Yes, previously c Yes, daily
PHYSICAL ACTIVITY
ALCOHOL AND TOBACCO
Old-age, early retirement or survivor pension
Sickness benefit (are in a sick leave)
Rehabilitation benefit
Describe your exercise and physical exertion in 
leisure time. If you activity varies much, for 
example between summer and winter, then give 
an average. The question refers only to the last 
year. (Tick the one that fits best)
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48 If you have given birth, fill in for each child: 
 birth year, birth weight and months of  
breastfeeding (Fill in the best you can)
Child Birth year Birth weight in grams








39 How many units of fruits or vegetables do you eat
on average per day? (units means for example
a fruit, a cup of juice, potatoes, vegetables)
Number of units
38 Do you usually eat breakfast every day?
c
40 How many times per week do you eat hot dinner? 
Number
42 How much do you normally drink the following?  







yoghurt ....................... c c c c c
Juice ............................ c c c c c
Soft drinks
with sugar ................. c c c c c
44 How often do you usually eat cod liver and roe? 
(i.e. “mølje”)
c Rarely/never c 1-3 times/yearc 4-6 times/year
























4 or more 
glasses 
/day
Do you currently use any prescribed drug  
influencing the menstruation? 
45 Do you use the following supplements? 
Daily  Sometimes  No
Cod liver oil or fish oil capsules ......... c c c
Omega 3 capsules (fish oil, seal oil) ........ c c c
Vitamins and/or mineral supplementsc c c
47 How many children have you given birth to?
Number
49 During pregnancy, have you had high blood  
pressure?  
c Yes c No
52 If yes, which pregnancy?
c The first c Second or later
53 Were any of your children delivered prematurely  
(a month or more before the due date) because  
of preeclampsia?
c Yes c No
55 How old were you when you started  
menstruating? 
Age
51 During pregnancy, have you had proteinuria?  
c Yes c No
50 If yes, which pregnancy?
c The first c Second or later
54 If yes, which child?
1st child 2nd child 3rd child 4th child 5th child 6th child
c c c c c c
43 How many cups of coffee and tea do you drink 
daily? (Put 0 for the types you do not drink daily)
Number of cups
Filtered coffee ...............................................
Boiled coffee (coarsely ground coffee for brewing)
Other types of coffee ..................................
Tea ......................................................................
56
Oral contraceptives, hormonal 
IUD or similar ........................................... c Yes c No
Hormone treatment for  
menopausal problems ........................... c Yes c No
46 Are you currently pregnant? 
c Yes c No c Uncertain
When attending the survey centre you will get a  
questionnaire about menstruation and possible use  
of hormones. Write down on a paper the names of  
all the hormones you have used and bring the paper  
with you. You will also be asked whether your  
menstruation have ceased and possibly when and  
why. 
 
41 How often do you usually eat these products? 
(Tick once for each line)
Potatoes .............................. c c c c c
Pasta/rice .......................... c c c c c
Meat (not processed) ............ c c c c c
Processed meat
(sausages/meatloaf/meatballs) c c c c c
Fruits, vegetables, berriesc c c c c
Lean fish ............................. c c c c c
Fat fish  ............................... c c c c c
(e.g. salmon, trout, mackerel, herring,  
halibut, redfish)
QUESTONS FOR WOMEN
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PROCEDURES FOR MEASUREMENTS OF INTIMA-MEDIA THICKNESS AND 
RECORDING AND MEASUREMENTS OF PLAQUE OF THE RIGHT CAROTID 
ARTERY.  THE TROMSØ-STUDY 1994/95 AND 2001  
by Oddmund Joakimsen 
Revised March  2001 
1. The Acuson ultrasound instrument is switched on.
2. A videocassette is inserted in the video recorder.
3. Check that the videotape has been wound to the right position, do not overwrite previous
recordings. The videocassette should not be removed from the recorder during the day.
4. Cassettes are marked with serial numbers, uneven numbers for Acuson I, even numbers for
Acuson II.
5. The initials and the identity numbers of the participant and the sonographer number (Einar
= 1, Stein Harald = 2, Technician = 3) are written on each ultrasound image recorded.
Labels with the ID-number of the participants are attached to the registration form, in
which all ultrasound data obtained from the participants are filled (plaque localization,
size, “missing measures” coding, etc.).
6. A RES-field, appropriately adjusted to a maximum width of the screen and a depth of a
little more than the preset size (> 2 cm) is positioned on the screen (This makes off-line
calibration easier).
7. The subject is examined in a supine position with the head slightly rotated to the left (15-
45 degrees). ECG-pads are attached to both arms and the right leg (or abdomen) (lead I),
and the right carotid is insonated by a 7.5 MHz ultrasound transducer.
8. The examination starts with identification of crossectional B-mode images of the carotid
artery, and, if necessary for identifying purposes in combination with colour-Doppler
and/or pulsed wave Doppler 5 MHz. The examination starts caudally in the neck, normally
just above the clavicle, then moving the probe upstream with simultaneous rotation
movements to search for plaques also at the circumference of the vessel. Thus, the carotid
artery is searched from the proximal part of the common carotid artery (CCA), upstream to
the bifurcation (BULB), and as far up in the internal carotid artery (ICA) as technically
possible. A PLAQUE is defined as a presumed atherosclerotic lesion of the intima layer of
the vessel wall presenting a focal protrusion of more than 50% of the intima-media
thickness (IMT) of the surrounding vessel wall, often with deviating echogenicity
compared to other part of the artery wall. Whether a plaque is present or not is a decision
taken by the sonographer during the examination. Live crossectional imaging of the whole
carotid artery is recorded on the videotape.
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9. An ultrasound examination sequence is then performed in the TRIPLEX -mode (i.e.,     
  combination of B-mode examination, pulsed wave Doppler, colour Doppler) 3-4 cm     
  proximally to the bifurcation and upstream 2-3 cm distally the bifurcation in the ICA.    
  The objective of this part of the examination is to look for stenotic areas along the artery   
  that causes hemodynamic disturbances. However, if plaques later during the B-mode  
  scanning procedure are found suspicious of a hemodynamic significant stenosis, a new  
  TRIPLEX examination is performed to re-evaluate the flow conditions. A LIVE    
  TRIPLEX-sequence of the relevant part of the carotid artery is recorded on the videotape   
  if a stenosis is suspected. 
 
10. B-mode longitudinal ultrasound scanning of the carotid artery is then performed. To get 
an optimal topographic reference, the examination is starting as proximally as possible in 
CCA. The probe is then moving upstream with simultaneous rotating movements to look 
for plaques in all segments, both the near and the far wall. If a plaque is found, a frozen 
image of the vessel-wall is taken – either directly by using the “FREEZE”- key, or by 
choosing on of the pictures from the cine-loop. It is important that the plaque is presented 
as distinctly as possible and after the guidelines according to elementary ultrasound 
principles such as vertical propagation of the ultrasound beam, presentation of the plaque 
in the full diameter of the vessel and not in chord, not cutting the plaque skew causing a 
falsely too large thickness of the plaque. To ensure the quality of plaque registration, 
some technical points may be of help: The plaque should be “attached” at its both ends to 
the typical double-lined intima-media structures visible on the B-mode image, and these 
double-lined structures should best be visible both in the near and the far wall at the same 
time. When the echogenicity obtained is as high as possible (as bright as possible), this is 
an indication that the ultrasound waves have cut the plaque optimally. An electronic 
calliper is put on the top of the plaque (at the interface between the surface of the plaque 
and the vessel lumen), and another calliper in the presumed transition zone between the 
media and the adventitia layer. The distance between the callipers is the thickness of the 
plaque, and that value is put on the registration form in the appropriate box. The B-mode 
image of the plaque is identified correctly by marking on the display what has been 
found, and where: PLAQUE ICA FW (a plaque in the far wall of the internal carotid 
artery), PLAQUE BULB NW (a plaque in the near wall of the bifurcation), etc. A short 
recording of approximately 5 sec. is videotaped. If more than one plaque is present at a 
site (e.g., in the far wall of ICA), the largest is chosen and recorded. 
 After identifying and recording of plaques, imaging procedures to get optimal 
measures of IMT from CCA and the BULB are performed. Optimal images are available 
when distinct double contours of the vessel wall typical for the intima-media complex can 
be seen. It is important that the longitudinal axis of the insonated vessel wall is 
perpendicular to the ultrasound beam direction. To avoid falsely too thick intima-media 
layer, the IMT should be measured in the full diameter of the artery and not in a chord. 
When satisfactory images are achieved, R-wave triggered IMT-registrations are recorded 
on a cine-loop containing more than 20 images. Afterwards, the images stored in the cine-
loop are scrutinized and 3 of most representative images, and each at least 10 images 
apart, are selected for recording on the videotape.  
 Regarding IMT measurements in the BULB, the start of the BULB is first identified 
and then marked with an arrow. This is the point where the parallel walls of the CCA are 
starting to diverge. If the probe throughout the recording process in the cine-loop has 
changed position, the placing of the arrow marker must be adjusted accordingly. It is 
important to underline that it is the sonographer who places the marker and not the off-
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line reader of the IMT-measurements. The arrow setting has to be as precise as possible, 
particularly when a plaque is located in the border zone between BULB and CCA to 
avoid over-or underestimating of IMT.  
       The target site for IMT measurements of BULB is the 1 cm area from the start 
of the BULB and upstream, distally. If only a part of this distance is measurable, a 
recording may, however, be performed on this shorter distance if the live sequence shows 
that this part of the vessel wall is representative of the rest of the 1 cm area. This shorter, 
measurable distance is marked with an electronic star. The 3 chosen images are marked 
BULB1, BULB2 and BULB3 and recorded on the videotape.  If no measurable image is 
possible to obtain, an image from the BULB is still recorded and marked MB, i.e., 
“missing bulb”. IMT measurements from the near wall of the BULB are not performed. 
 
  
11. Then a B-mode scanning of the CCA is performed, starting at the BULB and downstream     
as far as possible. Registration and measurements of plaque are done in the same way as 
mentioned above. The images with plaques are marked PLAQUE CCA FW and 
PLAQUE CCA NW, video recording is performed of both the live sequence and the 
frozen, marked images. R-wave triggered CCA IMT-registrations are recorded and the 3 
optimal images are chosen from the cine-loop as described in paragraph 10. It is 
important to get representative images also from the near wall since IMT-measurements 
from the CCA-NW will be done off-line. The arrow-marker is placed in the same position 
as for the BULB measurements. The target site for IMT measurements of CCA is the 1 
cm area from the start of the BULB and 1 cm downstream, proximally. The three images 
chosen to be recorded are marked CCA1, CCA2 and CCA3. If no measurable image is 
possible to obtain, an image from the CCA is still recorded and marked MC (”missing 
CCA”). All measurements on the far wall refer to the so-called “leading edge” principle 
(or “upper demarcation line”). These structures are not being different in thickness when 
the emitted power (mW/cm2) or of the ultrasound instrument’s gain setting are changed 
(nor are biological different conditions of subjects examined). 
 Near wall measurements, however, are performed on ”far edge” principles, which 
means that IMT to some degree may be dependent on some of the technical conditions 
mentioned above (e.g., gain setting). Standardized examination conditions therefore are 
particularly important for the near wall measurements. It is, however, not possible, in 
technical terms, to obtain such ideal conditions because individually instrument adjusting 
alternatives always are more or less involved in processing optimal B-mode images. 
However, setting of functions such, as emitted power of ultrasound, preprocession, 
postprocession, gainsetting, etc. should be standardized as much as possible. Biologic 
inter-individual differences (obesity, position of the neck arteries, short or long necks, 
etc.) causing need of some different adjustments, however, are not possible to 
standardize. If the visibility of IMT and plaques is not optimal, the gainsetting (both the 
general and the segmental) should first be adjusted to improve the quality of the image. 
The gain should all the time be set high enough to identify soft, echolucent plaques but 
not too high to conceal small plaques due to “ultrasound noise”. Only as an exception, 
adjustments of the other functions should be done. 
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12. Scoring of plaque-echogenicity. We aim at the highest echogenicity as possible since
false too low echogenicity is a common problem due to several reasons: The plaque is cut
too skew by the ultrasound beam, the longitudinal axis of the insonated vessel wall is not
parallel to the ultrasound probe surface causing sub-optimal reflection of ultrasound
energy (scattering), a far wall plaque is located within a ultrasound shadow from a
calcified near wall plaque due to sub-optimal insonation angel. We therefore use the
ultrasound signals from the media-adventitia interface as a reference of echogenicity to
enhance precision on morphology scoring. This structure is easy to identify and is always
presenting as high-echogenic, and is also localized close to the target, the atherosclerotic
plaque.
      In a 4-step scale from 1 to 4, the media-adventitia echogenicity and plaques of similar 
echogenicity is given a value of 4. On a grey-scale, such objects appear white or close to 
white. A plaque of grade 1 consequently reflects no or almost no ultrasound signals and 
appears black or dark grey on images. Flowing blood appearing black on ultrasound 
images is the reference structure on this end of the scale. Grade 2 and 3 represent 
intermediary echogenicity: grade 1, the plaque consisting of more echolucent than 
HFKRJHQLFPDWHULDO echogenic material); grade 3, more echogenic than echolucent 
(> 50% echogenic material). Apart from the ultrasound reference structures used in this 
protocol, the echogenicity scoring is similar to previous reports in the literature.1, 2   
      Grade 5 represents plaques that are not possible to classify on ultrasound of technical 
reasons (e.g., plaques in the far wall concealed by the echo shadow from calcified near 
wall plaques, not possible to angling of the probe to obtain representative images, plaque 
localized to high upstream to get high-quality images, etc.) 
      When a plaque is heterogeneous and consists partly of high-echogenic and partly of 
low-echogenic material, the scoring of echogenicity is based of an overall impression of 
the dominating plaque echogenicity. When more than 80% of the plaque is of a given 
echogenicity, the echogenicity is scored as if the whole plaque consisted of this 
echogenicity although the rest of the plaque echogenicity was differing 2 or 3 grades from 
the dominating class of echogenicity. If the percentage is below 80%, interpolating is 
performed by judgement.  
     Thus, plaque echogenicity is classified as follows: 
Grade 1: Echolucent  (0- 20 % of plaque material is high-echogenic). 
Grade 2: Predominant echolucent (21-50 % of plaque material is high-echogenic). 
Grade 3: Predominant echogenic (51-79 % of plaque material is high-echogenic). 
Grade 4: Echogenic (80-100 % of plaque material is high-echogenic). 
Grade 5: Missing, not classifiable 
    In the same way, a total echogenicity status for an artery is determined if more than one 
plaque is present. The same limit of 80% is the basis of scoring of total plaque area.  
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AFTER EXAMINATION: 
13. Do not remove the cassette from the video recorder before the end of the day, or when the
cassette is full.
14. Check that the registration form is completed appropriately. In the ”Remarks” box,
coding for reasons for missing of measurable images should be done:
   MB 1= missing images from BULB due to obesity. 
   MB 2= missing images from BULB due to a steep angle between CCA and BULB. 
   MB 3= missing images from BULB due to technically difficult examinations. 
   MB 4= missing images from BULB due to previous surgery or radiation. 
   MB 5= other reasons 
   In the same way, missing coding for CCA and ICA is performed: MC 1, MC 2, etc. 
A referral form to Department of Neurology, University Hospital, Tromsø is completed when 
a suspected carotid stenosis or occlusion are found. Two criteria for defining a stenosis are 
used. Either a velocity increase across an atherosclerotic plaque in BULB of 0.1 m/sec. or 
more or 0.2 m/sec. in ICA, compared to the reference velocity distally in ICA; or a plaque 
thickness that constitutes 35% or more of the lumen diameter at the plaque site. The 
velocities should be manually angle-corrected for the angle at which Doppler-beams are 
emitted into the vessel. Occlusion is suspected when the open lumen of the artery is not 
visible on B-mode or if there is a visible occluding plaque in the artery, and there is no 
detectable flow in the artery by pulsed Doppler or by colour-Doppler. The referral threshold 
should be low to avoid false negative stenosis cases. The person, who is referred, should be 
given a written and verbal information of the finding and clinical implications before living 
the room.       
      References: 
      1: Geroulakos G. et al. Br J Surg. 1993;80:1274-1277 
      2: Steffen CM. et al. Aust. NZ J Surg. 1989;59:529-534 
      English version June 2005 Stein Harald Johnsen 
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Procedure for measurements of intima-media thickness and plaques in the 
right carotid artery. The Tromsø Study 2007-8. 
1. Switch on Vivid 7.
2. Select New Exam and log in using your user credentials.
3. For every new participant: Select New Exam, then Search/Create patient. Place cursor in
Patient ID. Scan participant barcode using scanner. Select Create patient.
4. The participant’s personal code will appear on the upper left hand side of the screen, your
user credentials will appear to the right of date and time, followed by application mode
“Carotid”.
5. Attach ECG electrodes to both arms and left leg of participant. Red on right arm, yellow on
left arm and green on left leg. Select Physio to activate ECG function at multifunction
buttons right beneath the two rectangular screen displays. Select ECG to display ECG
readings on screen.
6. Participant should be placed in the supine position, with head/neck tilted backwards and
slightly to the left. Cover clothes in the neck with tissue paper. Apply gel at probe or at
participant’s neck.
7. Start examination by acquiring transversal scans of carotid artery. Start at the level of the
clavicle and proceed distally along common carotid artery. If necessary, use color Doppler
(select Color) to identify the artery.  From the bifurcation, proceed along the internal carotid
artery to the level of the jawbone as far as technically possible. The purpose is to identify
the common carotid artery, the bifurcation and the internal carotid artery as well as
identifying possible plaques in these locations. (See pt. 9 for identification of plaques).
8. Switch to longitudinal examination of carotid artery. Start as proximal as possible and
proceed slowly distally. Be sure to tilt the probe as to cover the largest sector possible of the
neck, so that the arteries are viewed in different angles. For optimization of uptakes, adjust
gain by turning knob marked 2D.
9. Plaque detection: Plaques are defined as an atherosclerotic lesion in the intima with focal
protrusion into the lumen of the artery comprising more than 50% of the adjacent intima
media thickness.
10. Plaques are registered in the following locations:
Far wall of common carotid artery  
Near wall of common carotid artery 
Far wall of bifurcation (bulb) 
Near wall of bifurcation (bulb) 
Far wall of internal carotid artery 
Near wall of internal carotid artery   
To obtain good images, it is important that the segment were the plaque is to be measured 
is     depicted as horizontally oriented in the image as possible. Avoid taking images were the 
artery is bending upwards or downwards at the screen. A plaque image should be obtained 
with a full diameter of the artery. The ideal is that the double contour of the IMT is seen in 
both the near and far wall and as a continuity of the plaque both proximally and distally to 
the plaque.  
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Save images of plaques in every location. If there is more than one plaque in each segment, 
choose the greater one for the image. When good, representative images are depicted on 
the screen, select Freeze. Select the best image by turning the trackball. Name image with 
correct label (i.e. PLAQUE_CCA_FAR_WALL) by selecting HOME at keyboard, hit select 
several times to choose right label. Save image by selecting IMG store. Select Freeze once 
more to remove freeze of cine loop. 
Plaque images should be used for detection of plaque thickness, plaque area and plaque 
echogenicity (GSM). As a main rule, one representative image from each location should be 
used for both size and echogenicity measurements. If you think that the most 
representative thickness and/or area is best shown in one projection, and the echogenicity 
in another projection, capture and freeze two images of the same plaque. Label plaque to 
show localization and purpose of measurement, eg: PLAQUE_CCA_FAR_WALL AREA for area 
measurement, PLAQUE_CCA_FAR_WALL ECHO for echogenicity measurements. If there are 
no plaques in in any part of the artery, capture one representative image of the artery and 
label as NO_PLAQUES.   
11. Continue with R-triggered uptakes of the intima-media thickness in the distal part of 
common carotid artery (far wall and near wall) and in the bifurcation (far wall). It is 
important to depict each segment of the artery (CCA, bulb) so that the ultrasound beam is 
perpendicular on the longitudinal axis of the artery. Furthermore, IMT should be measured 
in a full diameter of the artery. Ideally, the artery should be depicted horizontally on the 
screen with visualization of the typical “double line” contour of the intima media complex in 
both near and far wall.  
Start with CCA. Select Physio to activate ECG-function in the display. When a good depiction 
of IMT is obtained, select ECG TRIG. Record a cine-loop of at least 30 images. Select Freeze 
and choose the three most representative images, which should be at least 10 images apart 
and save. Each image is labeled according to location (for instance IMT_CCA_1). The 
transition between the CCA and bifurcation is marked with a + in the lumen of the artery, 
using the trackball and Caliper. The origin of the bifurcation is defined as the beginning of 
divergence of the near and far wall (divergence of parallel walls). It is important to place the 
+ as precisely as possible. To end ECG trigging, select ECG TRIG once more (knob light turns 
off). 
Then do uptakes of the IMT in the bifurcation. IMT in the bifurcation should be measured 
from the beginning of the bifurcation and 1 cm distally. If the sonographer finds the quality 
of the images not good enough for measuring 1 cm, but is of sufficient quality in a shorter 
segment, this segment should be marked by inserting an exclamation mark at the distal 
measuring point (select ! at the keyboard and place with trackball). Uptakes marking of start 
of the bifurcation and labeling follows same procedure as for IMT in CCA. 
If the quality of the IMT-uptakes in CCA and/or bifurcation is of low quality and not suitable 
for measurements, the images should be labeled IMT_CCA_MISSING and/or 
IMT_BULB_MISSING. 
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12. Participants who fulfill one of the following criteria should be referred to the Department of 
Neurology’s outpatient clinic: 
a. Plaque in the CCA, bifurcation or ICA with s possible or definite maximum 
thickness of ≥50% of the original lumen diameter (stenosis). 
b. Possible or definite occlusion of the CCA, bifurcation or ICA. 
c. Technical difficulties which arises any doubt as to whether the above mentioned 
criteria are fulfilled.   
The participant should be informed about the referral to outpatient clinic before he/she 
leaves the examination, with correct information about the reason for referral. Emphasis 
should be placed on non-dramatization of the condition. The referral will for most persons 
act as a safety precaution, ensuring that preventive measures can be installed. 
Save an uptake that shows the reason why you want to refer the participant, label it correctly 
(REFERRED_STENOSIS, REFERRED_OCCLUSION, REFERRED_TECHNICAL). Fill in referral papers, 
and deliver to mail administrators at the end of the day.  
13. When the uptake of one participant is ended, select Archive, then END EXAM in the Patient 
information sheet. You will be asked to select save all images (Save all), select images for 
saving (Select) or not to save images (None). Normally select Save All, or Select if there are 
images that can be deleted. 
14. Clean probe with soft tissue paper after examination. 
15. Next participant is registered by selecting New exam. 
16. At the end of the day: Turn off VIVID 7. Clean keyboard and probe with moist tissue paper. 
Dry off with tissue paper. 
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